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SUM M ARY
In the preparation of acellular pertussis vaccines (usually containing pertussis toxin 
(PT), filamentous haemagglutinin (FHA) and agglutinogens (AGGs), inactivation of 
the toxic PT component is necessary.
This investigation stems from the work of Christodoulides et a i ,  (Vaccine , S, 
199-207, 1987), who observed that toxoiding of a mixed antigen preparation from B. 
pertussis  consisting of PT and FHA in a 1:1 ratio with a commercial conjugation 
reagent l-ethyl-3-(3-dim ethyIam inopropyl)carbodiim ide (EDAC), resulted in an 
enhanced immunogenic response to these antigens. The objectives of the present 
study were to determine if this effect could be confirmed and whether the enhanced 
response was still elicited after immunization of PT or FHA treated separately with 
EDAC. Also, by using other antigens namely ovalbumin (OA) and lysozyme (LZ), 
the possible restriction of this toxoiding/adjuvanting effect to the antigens o f B. 
pertussis was examined. As controls, the antibody responses after immunization with 
fomraldehyde and glutaraldehyde treatments were also explored.
The work started with two model antigens, ovalbumin and lysozyme, to test 
the specificity of the adjiivanting effect of EDAC. These proteins were treated with 
ED A C under conditions described for toxin inactivation and at several other 
concentrations. On SDS polyacrylamide gels, an extra band (thought to be a dimer) 
was observed for LZ but not with OA. Immunization of mice followed by ELISA on 
the sera gave anti-OA and anti-LZ titres. Two independent experiments showed that 
whilst EDAC treatment resulted in enhanced anti-LZ titres, it actually depressed anti- 
OA titres. Another experiment where EDAC concentration was varied during OA 
treatment showed this repressive response was apparent only when OA was treated 
with 11 and 21 mM EDAC. Treatm ent with 55, 110 and 220mM EDAC did not 
decrease nor increase the antibody response after immunization.
Using loss of bacteriolytic activity to monitor the extent of modification, LZ 
was treated with EDAC, formaldehyde and glutaraldehyde. These agents caused a
IV
respective loss in activity of 30 to 40% for EDAC and >99.9 for formaldehyde and 
glutaraldehyde. W ith all three agents, gel profiles showed higher MW bands 
indicating polymerization. ELISA results on antisera from experiments comparing 
antibody responses obtained by in jecting treated preparations showed that 
formaldehyde and glutaraldehyde had no adjuvanting effects; however two out of the 
three LZ preparations treated with 21 mM EDAC gave a significant enhanced 
antibody response. Treatment with 800 mM EDAC depressed the response.
From B. pertussis transposon-mutant strains, preparations of PT and FHA free 
from each other were made. Some PT preparations were tested for their ability to 
cause the clustering of Chinese hamster ovary cells. These preparations were toxoided 
and post-fixed with the letters E, F or G for treatment with EDAC, formaldehyde and 
glutaraldehyde respectively.
The haemagglutinating activity of FHA was used as an indicator of the extent 
of modification of this protein. Formaldehyde and glutaraldehyde treatment destroyed 
all detectable activity but the effect of EDAC on HA activity (between 51 to 75% loss 
in HA) was less. Gel profiles showed high m olecular w eight bands after 
glutaraldehyde and formaldehyde and a similar but with a slightly lesser degree of 
polymerization after EDAC treatment. Immunization experiments with preparations 
o f FHA also gave variable results. In one experiment, all treated FHA samples 
induced lower responses compared with FHA alone. However, in a repeat experiment 
with independently treated samples, FHA-E showed a similar response but FHA-F 
and FHA-G elicited significantly higher responses compared with FHA alone.
For experiments with PT, histamine-sensitizing activity was used to assess 
inactivation of the toxin. PT-F preparations were invariably >99.9 % inactivated. 
Inactivation levels for PT-G and PT-E were 6 6  and 96% respectively. Anti-PT serum 
titres were best after immunisation with PT-E. The PT-G and PT-F showed equivocal 
responses to untreated PT. Four PT/FHA preparations assessed by SDS-PAGE and 
ELISA methods for their relative concentrations, were toxoided with the three agents.
As with PT only, form aldehyde consistently inactivated the PT com ponent in the 
mixtures to the limits o f detection (>99.9%). Immunisation with these preparations for 
anti-PT showed that PT/FHA-E preparations responded best followed by PT/FHA-G. 
PT/FHA-F responded poorly with titres sometimes falling below the untreated control 
preparation. For anti-FHA, formaldehyde treatment depressed the antibody response 
significantly, whilst EDAC or glutaraldehyde treatment did not appreciably affect 
responses.
In conclusion, the enhancing effect of EDAC does not seem to be specific to 
PT and FHA mixtures alone. It is variable with the antigen used and in some cases 
can actually depress the response. W ith respect to the antigens of B. pertussis  
adjuvanting by EDAC was obtained with PT and a PT/FHA mixture. Immunisation 
with FHA-E alone did not elicit an increased response. Conditions for the treatment 
with EDAC would have to be investigated further to ensure reliable inactivation o f 
PT. However, with respect to antibody response, EDAC-treated PT was superior to 
formaldehyde or glutaraldehyde PT.
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IB O R D E T E L L A  P E R T U S S IS  AND W H O O P IN G  C O U G H
T he O rg an ism
D iscovery  a n d  c la ss ifica tio n
The respiratory tract pathogen that causes whooping cough was first cultured by 
Bordet and Gengou (1906) from secretions coughed up by a five-year-old child which 
were also examined microscopically. As well as noting large numbers o f leucocytes, 
the presence o f "small ovoid bacteria resembling micrococci" was observed. These 
bacteria were identified as. Gram negative and their pleom orphic nature was also 
recorded.
The whooping cough bacillus was reclassified from the H aem ophilus genus 
into the new genus of Bordetella as Bordetella pertussis (Moreno-Lopez, 1952). Other 
members assigned to the bordetellae are B. parapertussis, which causes a similar but 
m ilder form  o f whooping cough; B. bronchiseptica, responsible for broncho­
pneum onia in pigs, dogs and other mammals and B. avium, the causative agent of 
turkey coryza and bordetellosis in other species of birds. The pathogenic mechanisms 
and the virulence factors produced by these organisms were reviewed by W ardlaw 
(1988) and Parton (1996). Since the present work started, two other bordetellae have 
been recognized, B. hinzii isolated from the respiratory tracts of poultry (Vandamme et 
aL, 1995) and B. holmesii isolated from blood cultures of patients (Weyant et aL,
1995).
.a
G ro w th
B. pertussis  was first grown by Bordet and Gengou (1906) on an agar medium 
containing^glycerinated potato extract and blood which is still used today and known by 
their names (BG medium). Subsequently, a wide variety of liquid and solid media were 
developed to support growth of B. pertussis (reviewed by Stainer, 1988). The growth
!
"If:
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of this organism is easily inhibited by peptone, sulphur, peroxide and fatty-acids; 
however, the toxic effects can be overidden by adding blood, charcoal or starch to the 
medium.
A particularly notable development was the defined liquid medium of Stainer 
and Scholte (1970) containing glutamate as the main carbon and energy source. This 
medium was further developed by Imaizumi et aL (1983), who added B-methylated 
cyclodextrin. This additive not only enhanced growth of B. pertussis  but also 
increased yields of pertussis toxin (PT) and allowed growth from small inocula.
In 1931, Leslie and Gardner found by repeated subculture from a single colony 
that B. pertussis underwent phase variation. Phase I and II produced smooth colony 
forms that were toxic to guinea-pigs, whereas phases III and IV had rough colony 
morphologies and were a virulent. Many decades later, it was found that this alteration 
coincided with loss o f several virulence factors as discussed below (Coote and 
Brownlie, 1988).
A similar process leading to the loss of virulence components was identified by 
Lacey (I960). Certain environmental conditions induce growth in X-mode or C-mode. 
Fully virulent X-mode organisms arose from growth at 37 in the presence of NaCl. 
C-mode organisms were produced by growth at lower temperatures (28 ^C) or by high 
concentrations of MgSOq or nicotinic acid. With the advent o f genetic techniques, 
W eiss and Falkow (1984), reported the expression o f these virulence factors was 
controlled by the vir gene now known as hvg for Bordetella virulence gene (Arico et 
at., 1989). Phase I, II or X-mode organisms result when the bvg gene is functional. 
When bvg is switched off through environmental changes or mutation, the organisms 
became avirulent. These authors suggest that this phenomenon occurs either to facilitate 
transmission or to allow avirulent organisms to exist in the host in an inoffensive carrier 
state.
T he D isease 
O ccu rren ce
The earliest report of a whooping cough epidemic was in Paris in 1578 and reported by 
Guillame de Baillou (cited by Mortimer, 1988). In more recent times, the disease has 
occured worldwide in 3-4 year epidemics, with 60 million cases reported annually 
(M uller et al., 1986). Figure 1 presents epidemiological data on the incidence of 
pertussis in England and Wales, Finland, Japan, Sweden and the United States. As 
many as 0.5 to 1.0 million deaths per annum are attributable to whooping cough, with 
the highest incidence found in developing countries. Review s on pertussis 
epidemiology include those of Muller et al. (1986); Cherry et al. (1988) and Hodder 
and Mortimer (1992).
Stocks (1933) noted that most cases of pertussis in the period 1919 to 1931 
occured in children between birth and 8 years old with the incidence and the mortality 
rates being higher in girls. Later, Gordon and Hood (1951) examined cases of 
whooping cough in M assachusetts from 1918 to 1949. Again, they found that 47 to 
55% of cases were in children < 5 years of age. Socio-economic conditions such as 
low education of parents and crowding were correlated strongly with mortality rates. 
Attack rates for pertussis occuring in children of White, Negroid, Chinese or Indian 
extraction were similar, therefore race was not an important factor in susceptibility to 
the disease. It is accepted that control of whooping cough has been largely achieved 
through a combination of vaccination and improved socio-economic conditions (Cherry 
et al., 1988).
Mink et at. (1992) isolated B. pertussis from 26% of university students who 
exhibited a persistent cough of 6 or more days duration. Farizo et al. (1992) also 
reported a large increase of pertussis in adolescents and adults. In a study conducted by 
Nelson (1978), 12 out of 14 infants were found to have contracted the disease from an
F ig u re  1: A n n u al p e rtu ss is  n o tifica tio n s  betw een 1950 a n d  1986 fo r th e  
U n ited  s ta te s , F in la n d , E n g la n d  a n d  W ales, Sw eden  a n d  J a p a n . T h e
pattern is one of epidemics with a cycle of three to four years in each country despite 
major changes in pertussis incidence. (Reproduced with permission from the Reviews 
o f Infectious Diseases , University of Chicago Press; Thomas, 1989)
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infected adult. Such occurrences suggest that these older groups may provide a 
reservoir of infection for susceptible infants and children.
Transmission of B. pertussis occurs through direct respiratory contact with 
organisms shed from an infected person through coughing. In 1968, Linnemann et al. 
attempted to identify the carrier state by isolation of B. pertussis from nasopharyngeal 
swabs from children in an epidemic year. These swabs were plated on BG plates 
containing penicillin or analyzed for the presence of the organism by fluorescent 
antibody staining. However, from a total of 1102 asymptomatic children only 5 were 
positive, suggesting that the carrier state was rare if it exists at all.
C lin ica l aspects
Typically, a case o f whooping cough exhibits four phases: the incubation, catarrhal, 
paroxysmal and convalescent. Details of the disease symptoms have been described in 
the reviews by Mortimer, (1988); Walker, (1988) and Cherry, (1988).
Infection with B. pertussis  begins with the incubation phase which is o f 
between 7 and 14 days duration. The catarrhal phase (7-10 days) follows. In these 
early stages, the infected individual exhibits symptoms similar to the common cold with 
rhinorrhea, sneezing and a mild cough. Sometimes, a slight fever occurs but usually is 
not perpetuated throughout the disease. Treatment with antibiotics at this stage are of 
the most benefit in reducing the length and the severity of the disease (Linnemann et al., 
1975). Also, at this time, B. pertussis can be isolated at a greater frequency from 
nasopharyngeal cultures. The patient is most infectious at this stage.
After this period, the mild cough becomes more severe and the individual enters 
into the paroxysmal stage which can last for many weeks. Paroxysmal coughing is 
described as a series of short violent coughs without inspiration which ends in a final 
cough clearing the air passage of mucus and often accompanied by vomiting. The 
inspiration of air against a narrowed glottis produces the characterisitic ‘whoop’. 
Paroxyms can be induced by feeding, crying, examination of the pharynx or excitement
and seem to occur more frequently at night. As the paroxysms become milder and less 
frequent, the patient begins to recover slowly but with a persistent cough. This is the 
convalescent phase and may last from 1-6 months. Other respiratory infections cause 
the recurrence of paroxysms. During this phase, the patient is not infectious and the 
organism cannot be isolated.
C o m p lic a tio n s
The force o f the expiratory cough during paroxysms som etim es causes minor 
com plications in infants and children (M ortimor, 1988). Oedema of the face and 
ulceration of the tongue caused by its protrusion during paroxysms has been noted.
Venous congestion induces subconjuctival haem orrhages. Fever is not usually 
associated with pertussis, however, its occurrence is usually indicative of secondary 
bacterial infection. Another feature o f secondary infection is otitis media, caused by 
Haemophilus influenzae, S. pneumoniae, S. pyogenes, or Staphylococcus aureus.
Respiratory problem s and encephalitic com plications have more serious 
consequences. The obstruction of blood flow by raised intrathoracic and intra- 
abdominal pressures may lead to cyanosis with subsequent im pairm ent of normal 
respiratory function. A noxia is associated with convulsions and brain damage.
Persistent seizures or a loss of consciousness (particularly in infants ) have been noted.
Diagnosis
An important clinical sign in pertussis is lymphocytosis, noted as early as 1897 by 
Frolich (cited Wardlaw and Parton, 1983) and later by Bordet and Gengou (1906). 
Confirmation o f B. pertussis requires its isolation from a nasopharyngeal swab plated 
on BG or other media. Such medium may be supplemented with penicillin or other 
antibiotics to reduce the growth of contaminants. However, even under favourable 
conditions, the isolation rate may not exceed 60% (Kwantes et al., 1983). Serological 
evidence of infection may be obtained by ELISA. For example, Viljanen et al. (1982),
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developed an ELISA test for anti-pertussis IgM and IgA. B. pertussis has also been 
effectively detected from nasopharyngeal swabs by molecular biological techniques 
such as the polymerase chain reaction (Lichtinghagen and Glaubitz, 1995).
V IR U L E N C E  FA C T O R S AND P A T H O G E N E S IS
Survey  o f V iru lence  F ac to rs
B. pertussis produces a variety of virulence factors which are summarized in Table 1. 
Numerous reviews have been published detailing the purification, structure, activities 
and possible functions of the virulence factors produced by this organism. These 
com ponents will be discussed briefly with particular em phasis on filam entous 
haemagglutinin (FHA) and pertussis toxin (PT). Further information may be obtained 
from the reviews by Munoz and Bergman (1977); Wardlaw and Parton (1983); Pittman
(1984); Weiss and Hewlett (1986); Wardlaw (1988) and Wardlaw and Parton (1988).
Infection occurs through inhalation of the organisms followed by attachment to 
the ciliated epithelium in the pulmonary airways (Figure 2). Thereafter the organisms 
multiply and release a variety of components which act as aggressins and toxins. The 
role of most virulence factors in the pathogenesis of the disease is not clearly defined, 
although in some cases a function has been attributed.
A d h e s in s
The virulence factors believed to be involved in the colonization of B. pertussis to the 
respiratory epithelium are: pertactin (Leininger et a l ,  1990), the agglutinogens (AGG), 
filamentous haem agglutinin (FHA) and pertussis toxin (PT), (W eiss and Hewlett, 
1986).
T ab le  1 : V iru lence  F ac to rs  o f B .p e r tu s s is  .
Vhulence Factor Role in pathogenesis Reference to initial discovery
T o x in s :
Heat-labile toxin local tissue damage Bordet and Gengou (1909)
Pertussis toxin (PT) 
identified for histamine- 
sensitizingactivity
bacterial attachment, 
systemic toxicity
Parfentjev and Goodline 
(1948)
Lipopolysaccharide (LPS) systemic toxicity MacLennan (1960)
HLY-ACT 
Haemolysin (HLY) 
Adenylate cyclase (ACT)
local damage 
evades host defences
Lautrop (1960)
W olff and Cook (1973)
Tracheal cytotoxin (TCT) local damage Goldman et al., (1982)
E n v e lo p e  p ro te in s :
Agglutinogens bacterial attachment? Leslie and Gardner, (1931)
Filamentous 
haemagglutinin (FHA)
bacterial attachment Arai and Sato, (1976)
Kawai haemagglutinin bacterial attachment? Kawai et al., (1982)
Pertactin (69-KDa 
non-fimbrial agglutinogen)
bacterial attachment? Brennan e ta l., (1988)
Brk A bacterial adhesion? Fernandez and Weiss (1994)
Tracheal colonization factor bacterial adhesion? Finn and Stevens (1995)
Based on the reviews of Weiss and Hewlett, (1986) and W ardlaw and Parton, (1988).
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Figure 2: Left: Scanning electron micrograph showing B . p e r t u s s i s  
infiltration of the ciliary layer. Right: Transmission electron micrograph 
of a ciliated epithelial cell infected with B .per tuss is  for 24 h. Note the 
close apposition between the bacterium and host cell membrane. 
Magnification is x 16,500 (Reproduced with permission from Muse et al., 1978)
«
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The agglutinogens were recognized by Andersen (1953) and Eldering (1957). 
O f the 14 A G G ’s described, six of these were unique to B. pertussis. AGG l i s  
common to all B. pertussis strains. AGG 1, 2 and 3 are major antigens and AGG 4, 5 
and 6 are minor antigens. Three of these surface proteins were later identified as 
fimbriae. These were AGG 2 by Carter and Preston (1984), AGG 3 by Ashworth et al.
(1985), and AGG 6 by Cowell et al. (1987). An alternative scheme for serotyping B. 
pertussis strains was proposed by Robinson et al. (1989), where AGG 2 was referred 
to as fim 2 (F 2) and AGG 3 as fim 3 (F 3). The AGG 6 identified as fimbriae by 
Cowell et al. (1987), was thought to be identical to AGG 3 and therefore also termed 
fim 3.
The role of agglutinogens in adhesion is unclear. Some studies have shown that 
fimbriated B. pertussis can adhere to non-ciliated cell-lines and that anti-fimbriae 
monoclonal antibodies blocked their adherence (Sato eta l., 1979; Gorringe et al., 1985; 
Redhead et al., 1985). However, Urisu et al. (1985), reported that a transposon Tn5 
mutant deficient in fim 2 still adhered well to WiDr cells indicating that this protein was 
not im portant in adhesion. Robinson et al., 1990, confirm ed that m utant strains 
deficient in fim 2 and fim 3 still adhered well to mammalian cells but the same study 
also showed that antisera raised against these antigens could prevent bacterial 
adherence. Thus, a minor role has been implicated for fimbriae in the process of 
attachment.
The first evidence for the protectivity of agglutinogens came from the results of 
the MRC trials (MRC, 1959). Protective efficacies of whole cell vaccines in children 
correlated well with agglutinin content. Studies by Robinson et al., (1985) and Zhang 
et al. (1985) dem onstrated protection in animal models o f infection following 
immunization with purified fimbriae.
Novotny et al. (1985), isolated an adenylate cyclase (AC) related protein which 
could protect mice against atrophic rhinitis. Later, Brennan eta l. (1988) identified this 
protein of 69 KDa as present on the surface o f all virulent B. pertussis  strains.
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Leininger et al. (1990) initiated studies into the function o f this protein and found 
monoclonal antibody against it could block the adherence of B, pertussis to CHO cells 
by 33%. This protein was named 'pertactin' and was thought to be im portant for 
mediating cell-attachment. This protein was therefore another candidate for inclusion in 
new acellular vaccine preparations.
Studies by Shahin et al. (1990) and Capiau et al. (1990), analyzed the capacity 
o f the 69 KDa OM P to protect mice from respiratory challenge with virulent B. 
pertussis. The former workers showed that glutaraldehyde-treated pertactin could still 
induce 92% survival o f challenged neonatal mice. Passive administration of an anti- 
pertactin monoclonal induced 90% survival. Furthermore, these workers demonstrated 
the immunogenicity of pertactin in humans. The sera from four humans vaccinated with 
the Takeda type Japanese acellular vaccine showed the presence of anti-69 KDa IgG. 
Capiau eta l. (1990) protected mice by immunization with pertactin upon i.n. challenge 
(particularly potent when combined with FHA and PT) but not after i.e. challenge.
The production of P.69 has been achieved in high yields by Romanos et al.
(1991) through use of the industrial yeast Pichia pastoris as an expression vector. 
These workers observed that the addition of native or recombinant P.69 enhanced the 
i.e. protective activity of pertussis toxoid. Roberts et al. (1992) showed immunization 
with recom binant pertactin was just as effective as the native protein in clearing 
organisms from the upper respiratory tract and inhibition of growth in the lungs.
Filamentous haemagglutinin (FHA) and PT were respectively identified as 
adhesins by Sato et al. (1981a) and Tuomanen and Weiss (1985). In the former case, 
inhibition of B. pertussis attachment to mammalian cells could occur by preincubation 
with anti-FHA. Tuom anen and W eiss (1985) carried out adhesion assays with 
transposon mutant strains deficient in the production of PT or FHA. These strains did 
not adhere, therefore these workers concluded that these proteins were important for 
adhesion. Redhead (1985) also showed that anti-sera against X-mode organism s, 
agglutinogens 1, 2 and 3 or purified FHA could block binding. Further evidence for the
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role o f FHA in attachm ent was provided by Urisu et al. (1985). These workers 
demonstrated inhibition of binding with anti-FHA preincubated organisms to W iDr 
cells. Also, mutant strains deficient in the production of FHA adhered less well than the 
parent strain.
When the organism is secured to the ciliated epithelium, it begins to multiply 
and accquires nutritional factors for growth. Redhead (1987) showed that B. pertussis 
unlike other bacteria did not procure iron with siderophores. The analysis of outer- 
membrane protein preparations suggested that B. pertussis obtained iron directly from 
host iron-binding proteins.
Aggressins and toxins
As the organism multiplies, a range of toxins are produced which enable the evasion of 
host defences, dam age to surrounding tissue in the respiratory  tract and the 
m anifestation o f systemic disease. Heat-labile toxin (HLT); pertussis toxin (PT); 
lipopolysaccharide (LPS); tracheal toxin (TCT) and adenylate-cyclase/haemolysin toxin 
(ACT-HLY), are proposed to be involved (Table 1).
To survive, the organism must evade the host defences. Two toxins of B. 
pertussis  ACT and PT are shown to inhibit the function of immune effector cells. 
Confer and Eaton (1982) demonstrated the inhibition of chemotaxis, phagocytosis, 
superoxide generation and microbial killing by polymorphonuclear leucocytes through 
exposure to ACT. The contribution o f ACT and LILY to the disease process was 
evaluated by Weiss et al. (1986), where a Tn5 mutant deficient in the production of 
both ACT and HLY was unable to cause a lethal infection of infant mice even after very 
high doses. PT was shown to inhibit macrophage migration in-vitro  (Meade et al., 
1984a) and in a further study, in-vivo (Meade et al., 1984b). The oxidative response of 
neutrophils was also inhibited (Bokoch eta l., 1984).
Local tissue pathology may occur through the concerted effects of TCT, HLT 
and ACT-HLY. Goldman et al. (1982) first identified a fragment of peptidoglycan as
. : .
14
TCT and showed that exposure o f a partially purified fraction containing this 
component to organ cultures o f hamster tracheal rings, inhibited ciliary activity. A 
cytopathology similar to that seen with B, pertussis infection was also exhibited. The 
inti'acellularly located HLT (Cowell et al., 1979) caused oedematous lesions in rabbits 
and haemorrhagic necrotic lesions in guinea-pigs and mice (Munoz, 1971; and Cowell 
et al., 1979). The pathogenic role of HLT was to damage tissues of the respiratory tract 
and thought to occur through vasoconstriction and rapid cytopathic changes in the 
peripheral blood vessels of vascular smooth muscle from guinea-pig and suckling 
mouse skin (N aka se and Endoh, 1988)
In the review by Pittman (1984) PT and LPS were the factors responsible for 
the manifestation of systemic disease. The most notable effect of PT is the enhanced 
leukocytosis commonly associated with pertussis cases (Morse and Morse, 1976). 
O ther biological effects such as hyperinsulinaem ia and hypoglycaem ia can be 
reproduced in laboratory animals.
PT appears to be the major protective antigen and its protective activity will be 
discussed in the section below. Aside from PT, the protective activity of the other B. 
p er tu ss is  toxins is not known. Guiso et al. (1989) reported passive or active 
im m unization with anti-ACT or ACT respectively protected m ice against lethal 
respiratory challenge with B. pertussis or B. parapertussis. LPS was found to be non- 
protective by Robinson et a i ,  (1985). Protection studies for TCT and HLT have not 
been done. Their role as protective antigens remains to be determined.
P e rtu ss is  T oxin  
Isolation and purification
In 1948, Parfentjev and Goodline observed that mice injected with whole-cell pertussis 
vaccine became more susceptible to histamine. In order to produce a less reactogenic
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product, research was conducted into the segregation of the many activities o f the 
vaccine (reviewed by Munoz and Bergman, 1977).
Since PT has many biological activities, a number of preparations possessing at 
least one of the activities now known to be caused by this molecule were purified and 
given various names. The procedure for preparing saline extracts from acetone-dried 
cells was reviewed in detail by Munoz (1963). Although many of the cells antigens 
could be separated by starch-block electrophoresis, the mouse protective antigen 
activity (MPA) could not be separated from the histamine-sensitizing activity.
Morse and Bray (1969) detected leukocytosis and lymphocytosis activity in late 
cultures of B. pertussis . They extracted this activity through a caesium chloride density 
gradient centrifugation technique. Subsequently, Sato and Arai (1972), purified the 
lymphocytosis promoting factor (LPF) from solid cultures noting its insolubility in low 
salt buffers. Further work by these workers (Arai and Sato, 1976) purified LPF and 
reported their preparation to have two distinct types of haemagglutinarion activity which 
were separable by molecular sieving through a 6% agarose column. These preparations 
were termed LPF-HA and fimbrial- haemagglutinin (FHA).
Irons and M aclennan (1979b) identified haptoglobin as having receptor 
affinities for LPF-HA. They purified this preparation (Irons and Maclennan, 1979a) 
with human haptoglobin linked to Sepharose-4B as an affinity chromatography 
medium. Arai and Munoz (1981) constructed another affinity medium which consisted 
o f purified 'antipertussigen' antibodies free of anti-FHA antibodies conjugated to 
Sephai*ose-4B. Sato et al. (1983), separated LPF from HA by the particulate material 
hydroxylapatite which bound FFIA but allowed LPF to pass through. The purification 
of PT utilizing a two step purification procedure with two different affinity media was 
done by Sekura et al., (1983). PT was firstly adsorbed onto Affi-gel blue (which 
contained an NAD substrate analogue) and eluted with a buffer containing 1.0 M NaCl 
then passed through a fetuin-sepharose column made according to A skelof et al..
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(1982). This m ethod yielded a preparation w hich was pure and retained 
haemagglutinating and lymphocytosis-promoting activity.
Yajima et al. (1978), purified a protein from B. pertussis culture su pern ate s 
which increased the secretion of insulin by Beta cells o f the pancreas. This preparation 
was termed islets-activating protein (lAP). Pittman (1979) suggested that these many 
preparations MPA, LPF, LPF-HA, H SF and lAP were activities of the same substance 
and suggested the name of pertussis toxin.
S tru c tu re
Morphology of the LPF-HA preparation was investigated by Arai and Sato (1976), 
using electron microscopy and negative staining techniques. Molecules of 'PT’ showed 
up as spherical structures o f approxim ately 6nm diameter. Tam ura et al. (1982), 
showed that PT possessed the A-B subunit structure similar to some other bacterial 
toxins. Figure 3 shows the assembly o f the subunits and their breakdown with 
increasing concentrations of urea. An SDS-PAGE profile is also shown in the insert. 
Tamura et al. (1982) determined that the PT molecule was comprised o f six subunits, 
five of which were dissimilai' by SDS-PAGE and densitometry analysis . These five 
subunits were termed S I, S2, S3, S4 and S5 and were found in the relative ratios of 
1:1:1:2:1. The SI subunit could be isolated by urea treatment under mild dissociating 
conditions followed by haptoglobin-Sepharose chromatography. The B-oligomer of PT 
was composed of two dimers, S2-S4 and S3-S4 connected by the S5 subunit. The 
assembly o f the toxin was investigated by Montecucco et al. (1986) by studying the 
interaction of the toxin molecule with membrane-lipids The SI subunit or A-protomer 
was positioned on top of the five radially distributed subunits constituting the B- 
oligomer. The genes coding for pertussis toxin were cloned and their nucleotide 
sequences elucidated by Nicosia et al., (1986) and Locht and Keith, (1986).
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Figure 3: Structure and properties of pertussis toxin. The insert shows 
the sodium do decyl sulphate polyacrylamide gel electrophoresis of  
purified pertussis toxin under reducing (A) or non-reducing conditions 
(B). Reproduced with permission from Rappuoli and Silvestri (1987).
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Biological activities
The many activities of pertussis toxin are summarized in Table 2. A number o f these 
activities were reported initially as biological activities of whole-cell pertussis vaccine 
before PT was recognized.
Lym phocytosis-promoting activity In 1897, Frolich (cited by W ardlaw and Parton,
1983), was the first to report an increase in the number of white blood cells from 
whooping cough patients. M unoz and Bergman (1977) reported levels o f up to 
175,000 cells/mm^ compared with normal levels of between 7,000 to 11,000. The 
studies of Morse and Riester (1967a and 1967b) showed that there was a migration of 
circulating cells in mice injected with pertussis vaccine. The increased number o f 
lymphocytes arose from a transfer of cells from the spleen, thymus, and lymph nodes 
rather than a multiplication of cells. Later, Morse and Morse (1976), reported that the 
majority of lymphocytes were T-cells with a smaller but more notable rise in B-ceils. 
Monocytes and polymorphonucleocytes were also increased.
Isles activation: PT has a marked effect on the metabolic functions of the infected host. 
Blood-glucose levels were reported as being lower than noimal in infants with pertussis 
by Regan and Tolstoouhov, 1936. Hyperinsulinaemia and changes in blood-glucose 
levels were also reported to occur in mice and rats injected with pertussis vaccine by 
G ulbenkian et al. (1968). Y ajim a et al. (1978), showed that highly purified 
preparations of islets-activating protein also exhibited similar changes in rats. The 
increase in insulin levels occurred by a block in the inhibitory effect of the alpha- 
adrenoceptors in pertussis infected animals resulting in continuous stimulation by beta- 
adrenoceptors of insulin release by pancreatic islet Beta-cells (Katada and Ui, 1981). 
M ouse protective actvity : Kendrick et al. (1947) devised a method for assaying the 
mouse protective antigen content of whole-cell pertussis vaccines. Purification of the 
MPA from HSF actvity was not obtained (Munoz and Bergman, 1977). However, 
Pillemer et al. (1954) purified the stromata protective antigen which was later shown to 
contain MPA with most workers concluding that the MPA was identical to the HSF and
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Table 2: Biological activities of pertussis toxin.
Activity First described by:
Leukocytosis promotion Frolich (1897, cited by Wardlaw and
Parton, 1983)
Islets activation Regan and Tolstoouhov (1936)
Mouse protective antigen (MPA) Kendrick et a/.,(1947)
Histamine sensitization Parfentjev and Goodline (1948)
Adjuvant activity Levine and Pieroni (1966)
Haemagglutination Keogh et ah, (1947)
Mitogen Kong and Morse (1977a)
ADP-ribosyltransferase Katada and Ui (1982a)
'II
t:
t :
I
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an activity of the same protein (Too and Putszai, 1960; Levine and Pieroni, 1966; Irons 
and Maclennan, 1979a; M u n o z e ta l ,  1981a).
Immunization with inactivated PT has been shown by several workers to protect 
mice against intracerebral {i.e.) challenge (Munoz et al. 1981a; Sato et al., 1981a; 
Robinson and Irons 1983; Oda et al., 1984). Passively administered goat anti-PT or 
mouse anti-PT monoclonal also protected mice after aerosol challenge (Oda et al.,
1984). Munoz et al. (1981a) and later Gupta et al. (1990), found that immunization of 
mice with sub-lethal doses o f native PT alone did not protect mice against i.e. 
challenge. The latter workers reported however that mice immunized with FHA as well 
as a small amount of native PT protected 60% of mice. Burstyn et al. (1983) reported 
an IgG and IgM response to PT after vaccination of children. Similarly, Thomas et al. 
(1989), also detected an IgG response to PT in children after vaccination and the 
disease.
Histamine-sensitizing activity : Pertussis-vaccine injected mice were shown to become 
sensitized to a subsequent injection of histamine (Parfentjev and Goodline, 1948). 
Maitland et al. (1955), termed this factor the histamine-sensitzing factor (HSF). Munoz 
and Bergman (1968) found that mice and rats were highly resistant to histamine 
whereas guinea-pigs and rabbits were highly susceptible to the lethal effects of 
histamine. Thus, injection of HSF would show a greater sensitizing effect in an animal 
normally resistant to histamine therefore mice are routinely used. Female mice were 
more sensitive than male mice to histamine after pertussis vaccine injection (Maitland et 
al., 1955). Bergman and M unoz (1964) reported older mice (>7 weeks) were more 
responsive to histamine after HSF than younger mice (3 to 7 weeks old). The intra- 
peritoneal {i.p.) route of injection of HSF or pertussis vaccine is commonly used in the 
assay however, administration via the intra-venous route (i.v.) appeared to elicit the 
best responses (Munoz and Bergman, 1966).
Adjuvant activity : Pertussis toxin has a number of adjuvant effects however, it was 
not until 1966 when Levine and Pieroni showed that this activity was attributed
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specifically to PT and not all as due to LPS. Pertussis vaccine containing PT could 
enhance antibody titres to antigens injected simultaneously (Munoz and Bergman, 
1977). Munoz (1964) noted that antitoxin to diphtheria and tetanus toxoids was raised 
when injected with pertussis vaccine. Also, M unoz et al. (1981a), observed that i.v. 
injection o f PT increased the IgG l and IgE response to mice immunized with OA. 
Increase of IgE was first noted by Mota (1958), described then as 'mast-cell sensitizing 
antibody'.
The autoimmunity condition hyperacute experimental allergic encephalomyelitis 
was induced or accelerated in rats by whole-cell pertussis vaccine (Levine et al., 1966). 
Other types of hypersensitivity reactions (immediate and delayed type) are also affected 
by pertussis toxin (reviewed by Munoz, 1988),
Haemagglutinating actvity : The haemagglutinating activity although first described by 
Keogh et al. (1947) in B. pertussis culture supernates was not attributed to PT until 
1976, when Arai and Sato purified the LPF-HA and found it to haemagglutinate goose 
erythrocytes.
Mitogenic activity : Kong and Morse (1977a, 1977b) found purified PT preparations 
had a mitogenic effect on T-lymphocytes which was only slightly lower in potency than 
the lectin concanavalin A. This activity was a function of the B-oligomer (Nogimori et 
al., 1984a).
ADP-ribosyltransferase activity : The ADP-ribosylating activity o f the SI subunit of 
PT was identified by Katada and Ui (1982a, 1982b). These workers found that PT 
catalyzed the ADP-ribosylation o f GTP-binding regulatory proteins (G-proteins) of 
eukaryotic cells. PT mediates the transfer o f the ADP-ribose moiety of NAD to the G- 
protein substrate, Casey and Gillman (1988) demonstrated that PT ADP-ribosylated a 
family of GTP proteins including Gi, Go and Gt. These proteins are involved in signal 
transfer to effector molecules within the cell. Gi (identified as the MW 41,000 protein 
substrate of Katada and Ui, 1982a, 1982b), regulates adenylate cyclase activity. Thus,
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when Gi is ADP-ribosylated by PT, an increase in cAMP levels is observed since the 
adenylate cyclase is no longer inhibited.
The results of PT causing interference o f these cell-signalling systems are 
numerous, e.g. in vitro  effects o f PT activity are: increased release o f insulin by 
pancreatic rat islet Beta cells (Katada and Ui, 1980); enhanced cAMP production due to 
adenylate cyclase activity in rat C6 glioma cells (Katada and Ui, 1982b) and clustered 
growth of Chinese hamster ovary cells (Hewlett et al., 1983).
Pertussis toxin has many diverse biological activities both in vitro and in vivo. 
Since the discovery of its A-B structure by Tamura et al. (1982), its mode of action was 
investigated by Tamura et al. (1983) who proposed that the B-oligomer mediated the 
binding of the holotoxin to the eukaryotic cell membrane and translocated the SI 
subunit across into the cytoplasm of the cell. Nogimori et al. (1984a) acetaminidated the 
epsilon groups of lysine residues on the lAP molecule and then assayed the in-vitro and 
in-vivo biological actvities of PT. Comparison of lAP and its acetaminidated derivative 
revealed that certain activities (ADP-ribosylation of membrane proteins, stimulation of 
insulin release and haemagglutination) were not affected by chemical modification 
whereas activities such as the mitogenic activity, lymphocytosis promotion, histamine- 
sensitization and adjuvant activity were. These workers concluded that the activities not 
affected by lysine modification were due to the A-protomer which entered the cell 
through action o f the B-oligomer, Neither of these functions was altered by lysine 
modification. However, activities associated with the B-oligomer which were affected, 
indicated that the lysine modification interfered with correct binding of the B-oligomer 
to the cell membrane.
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Filamentous Haemagglutinin 
Isolation and purification
A haemagglutinin (HA) activity for chicken ei'ythrocytes was found in cells from young 
cultures or in the supernate of older cultures o f B. pertussis (Keogh et al., 1947). HA 
was extracted by M asry (1952), by incubating cells in 2M NaCl or by methanol 
precipitation. The latter preparation yielded purer preparations which were toxic. 
However, it was later found that HA activity was not related to toxic activity (Munoz 
and Bergman, 1977). These workers stated in their review that these early preparations 
were crude and contaminated with many other components of the B. pertussis cell.
In 1976, Arai and Sato purified filamentous haemagglutinin (FHA) although at 
that time it was termed fimbrial haemagglutinin. These workers found two distinct 
peaks with HA activity upon separation through gel filtration. One peak had a high HA 
activity w hereas the second peak had low HA activity but possessed high 
lymphocytosis-promoting and histamine-sensitizing activities. Irons and Maclennan 
(1979b) investigated the receptor specificity of FHA and determined that it bound to 
cholesterol. An affinity chrom atography m edium  was prepared and FHA was 
subsequently purified. Static growth of B. pertussis was superior to shaken cultures 
for the production of FHA (Arai and Munoz, 1979). Askelof et al. (1982) described the 
purification by preparing sodium acetate exti’acts according to Masry (1952) followed 
by chromatography on Sephacryl S-300 gel.
FHA purified by Arai and Sato (1976) and Arai and M unoz (1981) were 
contaminated with PT, since FHA made by their methods could sensitize mice to 
histamine (Munoz et al., 1981a). Subsequently, Sato et al. (1983) purified FHA which 
contained <0.002% active PT as assayed by histamine-sensitization.
FHA is highly susceptible to breakdown (Arai and Munoz, 1979). The foimer 
workers noted that all HA activity was lost upon shaking a solution of FHA at 37 oC 
overnight. Sato et al. (1983) reported FFIA could be stored at -70 oC for at least one
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year without any loss in HA. Also, FHA is not specifically produced only by B. 
pertussis but also by B. parapertussis and B. bronchiseptica. (Blom et a l ,  1983).
Structure and Biological activity
Electron microscopy studies on FHA by Arai and Sato (1976), revealed that the protein 
appeared as filamentous structures of approximately 2 nm width x 40 nm length. 
Further studies on FHA morphology by Blom et a l  (1983) showed FHA as a mixture 
o f small thin filaments, 3 nm wide and 40 to 100 nm long and long fimbriae (3 nm 
wide and up to several nm long). These fim briae also showed a tendency to form 
bundles. The highest HA titres however, coiresponded to an increased number of 
shorter filaments.
The approximate MW of FHA was judged by SDS-PAGE was 126,000 (Arai 
and Sato, 1976). Irons and Maclennan (1979b) estimated the MW of the FHA bands at 
127 KDa and 95 KDa by the SDS-PAGE. In a further study, Irons et a l  (1983) 
analyzed the heterogeneity of FHA by western blotting with monoclonal antibodies. 
Bands o f 220 , 127, 95, 76 and 58 KDa were obtained. These were assumed to be 
degradation products of FHA and all derived from the 220 KDa band. Domenighini et 
a l  (1990) also examined the SDS-PAGE profile of FHA. FHA was initially seen as 
one band of 220 KDa, but after storage, it was accompanied by breakdown products of 
140, 125 98, 75 and 58 KDa bands with a concurrent loss in the intensity of the 220 
KDa band.
The gene encoding FHA has been sequenced (Domenighini et a l ,  1990) and 
found to code for a basic protein (pK, 9.65). Alanine and glycine are the two most 
commonly occurring amino-acids making up 21% of the total residues. An arginine- 
glycine-aspartic acid (RGD) sequence occurred twice in the primary structure. Reiman 
e t a l  (1989), provided evidence that this sequence was involved in FHA-receptor 
binding.
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The haem agglutinating activity of FHA has already been described. It 
haemagglutinates sheep, chicken and goose cells (Aral and Sato, 1976; Irons and 
Maclennan, 1979b). FHA has also been described as an important adhesin and binds to 
a number of cell types including rabbit-ciliated cells (Tuomanenef al., 1985) WiDr cells 
-an epithelial-like cell line from a human intestinal carcinoma (Urisu et ah, 1986) and 
Chinese hamster ovary cells (Reiman et al., 1989).
Protective activity in the mouse
Tuomanen and Weiss (1985) showed FHA played an important role in adhesion. A 
transposon mutant strain deficient in the production of FHA did not adhere well to 
human ciliated epithelial cells but this could be overcome by the addition of exogenous 
FHA.
The inclusion o f FHA in acellular vaccine preparations could theoretically 
provide antibodies which block binding of the organism to the cells in the respiratory 
tract thereby preventing infection. A number of studies therefore were undertaken to 
evaluate the protective potency of FHA. Protection of mice immunized with FHA and 
challenged by the aerosol infection model was obtained by Oda et al. (1984). However, 
FHA alone was not protective when mice were challenged i.e. (Munoz et al., 1981b; 
Sato and Sato, 1984; Oda et al., 1984) unless containing pertussis toxoid (Munoz et 
a i ,  1981b; Sato and Sato, 1984). Passive immunization studies in mice receiving 
murine anti-FHA and goat IgG to FHA were protective against aerosol challenge as 
reported by Sato et al. (1981a) and Sato and Sato (1984). Conversely, Oda et al. 
(1984) found passive administration of murine monoclonal antibody or affinity-purified 
goat anti-FHA gave little protection from disease after respiratory challenge. Ashworth 
et al. (1982) showed rabbits im m unized with FHA cleared B. pertussis  more 
effectively from the nasopharynx relative to control animals.
The protective activity of FHA was investigated further by Kimura et al. (1990) 
using the mouse respiratory infection model. These workers reported that immunization
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with FHA resulted in reduced numbers of bacteria recovered from the lungs and caused 
less colonisation o f the trachea. Passive immunization with goat and rat anti-FHA 
resulted in a marked reduction in colonization of lungs and trachea after challenge.
The serological response to FHA in humans after vaccination and the disease 
was examined by Burstyn eta l. (1983) and Thomas eta l. (1989). Both studies reported 
high IgG titles to FHA in both convalescents and vaccinees. IgA was found only in the 
former group. Since these high IgA titres were found in convalescents, Shahin et al.
(1992) proposed long-lived  im m unity m ight be obtained through m ucosal 
immunization. These workers immunized BALB/c mice i.n. and intra-duodenally (i.d.) 
andeanalysed antibody isotypes in sera, nasal washes and bronchoalveolar lavage fliud. 
IgA and IgG was detected in lung lavage fluid of both i.d. and i.n. immunized mice. 
Increased numbers o f FHA specific B lymphocytes were also noted in the lungs. More 
recently, Roberts et al. (1993) demonstrated a mucosal memory response to FHA in 
immunized mice that were boosted nine months later.
IM M U N IT Y  TO  PE R T U SSIS  
N a tu ra lly  A ccqu ired  Im m u n ity
Linneman (1979) reported that immunity to pertussis after the disease was of a longer- 
lasting nature compared with that induced by vaccination. Following infection, IgA, 
IgG and IgM antibodies were detected against B. pertussis by ELISA in sera from 
suspected cases of whooping cough (Viljanen et al., 1982). Comparatively, Ruuskanen 
et al. (1980) reported that IgM and IgG responses were very low in sera from DTP 
vaccinees. An anti-pertussis IgA response was also found in nasopharyngeal secretions 
after natural infection but not after parenteral vaccination by Goodman et al. (1981).
Infection produces higher levels of IgG, IgA and IgM isotypes compared with
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vaccination (Nagel et a l ,  1985). The antibody response to B. pertussis was followed 
by Finger and W irsing von Koenig (1985). These workers found that an antibody 
response was stimulated one to two weeks after the beginning of the clinical symptoms 
o f the disease. IgM and IgA appeared first followed by IgG with a subsequent decrease 
in IgM  and IgA titres for most cases within two to five months.
Antibody responses against the various virulence factors of B. pertussis were 
examined in a number o f studies. The most important antibody for long-term protection 
from the disease is anti-PT. Viljanen et al. (1985) reported the production of an IgM, 
IgA and IgG response to PT during infection. The anti-PT IgG titre increased 
progessively with the paroxysmal cough whilst the IgM titre declined (Wisnes et al.,
1985).
An anti-FHA response was not detected by Nagel et al. (1985) in sera from 
suspected pertussis cases although Winsnes eta l. (1985) found both anti-FHA IgG and 
IgM in convalescent and in vacinee's sera. Granstrom et al. (1982b) measured anti- 
FHA responses in human sera during natural infection. The data showed a significant 
rise in IgG, IgM and IgA levels. Antibodies to LPS were thought to be o f little 
protective value (Pittman, 1984). The heat-labile toxin (HLT) induced low titres of 
antibody if they could be detected at all (Evans and Maitland, 1939).
Whole-Ceil Pertussis Vaccines
Preparation and testing of whole-cell pertussis vaccines.
According to WHO specifications (1979), pertussis vaccines are prepared usually from 
a mixture of several strains of B. pertussis to ensure the presence o f agglutinogens 
types 1, 2 and 3. In the review of Ward law and Parton (1983), the preparation and 
testing of WCPV is described in detail.
Well characterized strains of B. pertussis are grown in bulk culture either on 
solid or in liqiud m edia under conditions which vary considerably between
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manufacturers. The suspension is killed by treatment with formaldehyde, thiomersal, 
long-term  storage at 2-8 °C, or by heating at 56 for 30 min. Thiom ersal (as 
preservative) and mineral adjuvants aluminium hydroxide, aluminium phosphate or 
calcium  phosphate (if required in the final vaccine) are added at this stage. After 
undergoing rigorous tests for pH, sterility, toxicity, potency and stability, the product 
is aliquoted into sterile vials.
Lapin (1943) reviewed the preparation and protective efficacy of early pertussis 
vaccines. These mixtures contained B. pertussis with other upper respiratory tract flora 
(e.g. staphylococci and streptococci); and precipitated with alum. These vaccine strains 
were grown on Bordet-Gengou medium containing horse, human or sheep blood. 
Methods of killing included heating or chemical treatment with formalin, phenol or 
thiomersal (Pittman et al., 1952). When Leslie and Gardner (1931) discovered that B, 
pertussis underwent phase changes, subsequent pertussis vaccines were purposely 
prepared from virulent phase I strains. Since the report by Hewlett et al. (1977) that 
formalin-treated W CPV contains active PT and LPS, other detoxifying agents have 
been tested. Relyveld (1973) first treated the organisms with glutaraldehyde as an 
alternative inactivating agent to yield vaccine preparations. Later, Gupta et al (1987a) 
reinvestigated the effects o f different inactivating agents on potency, toxicity and 
stability of whole-cell pertussis vaccine. Formaldehyde and glutaraldehyde inactivation 
showed similar potencies to heat inactivation, although heat-inactivated vaccines were 
less effective in the mouse weight-gain test. Glutaraldehyde was a better agent for 
reducing the histamine-sensitizing activity of PT (Gupta et al., 1987b, Gupta et al., 
1988). U nder optim al conditions of inactivation (0.05% glutaraldehyde at room 
temperature for 10 min) produced a vaccine which was as potent but less toxic than if 
heat-inactivated.
Safety testing of vaccines utilise the mouse weight gain test (MWGT). Toxicity
.in this test is indicative of the presence of active LPS, PT or HLT. Groups of mice are 
injected i.p. with the test preparation with at least half a human dose and then weighed
a
I
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daily. Loss of weight after 24 h is due to LPS. Slow weight gain or later death is 
attributed to bioactive PT.
A laboratory test designed to assess the protective capacity or potency of 
vaccine preparations was developed by Kendrick et al. (1947) and termed the in tra -  
cerebral mouse protection test (ICMPT). Essentially, graded doses of test and standard 
vaccines are injected i.p. into groups of mice. After 14-17 days the animals are 
challenged by intracerebral {i.e.) injection with 0.03 ml of B. pertussis W 18-323 (a 
highly virulent strain following i.e. injection). The number of survivors are counted 
after 14 days and the potency of the test vaccine is estimated relative to a reference 
preparation. This reference is the Second International Standard for Pertussis Vaccine 
and each ampoule of freeze-dried material contains 46 International Units (lU) of 
protective potency. Test vaccines must have at least 4 lU lower limit 2 lU per human 
dose immunized.
Protective Efficacy
Protection afforded by im m unisation with some early pertussis vaccines was 
demonstrated by clinical field trials in children from the 1920's and onwards.
Madsen (1933) used a form aldehyde-killed suspension o f B. pertussis  to 
vaccinate a total of 3,926 children (combined figures from two trials) with 1,073 
children in the unvaccinated group. The percentage fatalities were less (only 0.15%) in 
the vaccinated group compared with unvaccinated children (2.4%). Sauer (1937) 
immunised 1,122 children. Only six of 128 children subsequently exposed to pertussis 
developed the disease. In the study of Kendrick and Eldering (1939) 4,212 children 
were vaccinated. After home exposure, 89.4% of unvaccinated children contracted 
whooping cough compared with 34.9% of vaccinated individuals.
Not all clinical trials reported successful results however. Me Earl an et al. 
(1945) tested two vaccines produced by the Wellcome laboratories in Britain. Children 
from day nurseries, welfare clinics in Oxford and from residential nurseries were
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immunised Based on clinical diagnosis, no beneficial effect of vaccination against 
whooping cough was apparent.
To ascertain definitively whether pertussis vaccines were effective in protecting 
children from the disease, the MRC conducted a number of trials during the 1950's. In 
the first of these, (MRC, 1951), plain or alum precipitated vaccines manufactured either 
in the U.K. or U.S.A. were adm inistered in three injections to 3,801 children. A 
similar number o f children (3757) were included in the control group. Upon home 
exposure, 87.3% of unvaccinated children compared with only 18.2% of vaccinated 
children becam e infected. Figures for exposure outside the home were 38.0% 
unvàccinated and 8.3% vaccinated. The infection was also noted to be m ilder in 
vaccinated children. Immunised children (44.3%) had a cough of shorter duration (<6 
weeks) com pared with 14.4% in the unvaccinated group. The vaccines varied 
considerably in their protective effect.
Trials to compare the efficacy of 14 pertussis vaccine preparations in 28,799 
immunised children were completed in 1956 (MRC, 1956). Nine of the test vaccines 
used in the first trial were poor whereas the five in the second trial gave better 
protection. The third series of MRC trials, (MRC, 1959) reported protective capacity of 
a number of test vaccines which had been assessed by two laboratory tests - ICMPT 
and agglutinin-production. One of the aims o f these clinical trials was to establish 
which laboratory test gave the best conelation with protective efficacy in children. 
Comparisons were made between vaccines prepared from fluid medium and solid 
medium and of pertussis vaccine alone or mixed with diphtheria toxoid. An antigenic 
fraction of B. pertussis prepared by Pillem er et al. (1954) consisting of a sonic 
disintegrate treated with autoclaved human red cell stromata was also included. It was 
shown that the two vaccines prepared from solid and liquid medium did not differ 
significantly in their protective capacity, however, the third prepared from liquid 
medium  was m ore effective. Protection rates afforded with pertussis vaccine 
administered alone, or as a mixture with diphtheria toxoid, were similar. Although the
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Pillem er vaccine was more effective than W CPV, it also induced more adverse 
reactions. Both ICMPT and agglutinin-production tests correlated well with protective 
efficacy with the exception of the Pillemer vaccine. It was highly potent in protection of 
mice by the ICM PT but produced a poor agglutinin-response (Evans and Perkins, 
1955). Thus, the ICMPT was selected as the laboratory test for assessing the protective
potency of pertussis vaccines. The potency of these vaccines were compared to the first 
British Standard Vaccine.
In a report by the Public Health Laboratory Service (PHLS, 1973), the efficacy 
o f whooping cough vaccines was thought to have decreased. Perkins (1969) amended 
the potency of the British Reference vaccine from 2.1 lU to 4 lU. Altered serotypes of 
infective pertussis strains to explain the drop in effectiveness were also suggested. 
Prevailing serotypes were of 1, 2 or 1, 2, 3 but by 1963-1964 during a pertussis
epidem ic, they changed to predom inantly  1,3 types. This led to the W HO 
recommendation (WHO, 1979) to include strains of all three types in future pertussis 
vaccine preparations.
Since as evidenced in the MRC field trials, pertussis vaccines provided good 
protection, it was considered unethical to withhold vaccination from susceptible 
children. As a result indirect methods of evaluating the efficacy of pertussis vaccines by
:careful surveillance and documentation of pertussis cases were developed. In a recent 
study by Onorato et al. (1992), a vaccine efficacy rate of 96% was estimated for home 
exposure infection in preschool children. Thus pertussis vaccines today offer good 
protection from the disease.
Toxicity
It has long been demonstrated that pertussis vaccine shows toxicity. In the early study 
of Madsen (1933) two children were reported to have died within hours of their second 
pertussis vaccination. Reactions to pertussis vaccines are classified by Mortimer (1988) 
as mild, worrisome or severe. Local reactions include swelling, redness and pain at the
?
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site of injection. Systemic reactions are fever, vomiting, im tability and anorexia. These 
minor or mild adverse reactions occur 12-24 h after immunisation and are normally of a 
transient nature. Reactions o f a m ore worrisome sort are excessive sleepiness, 
persistent crying, an uncommon shock-like state termed an hypotonic-hyporesponsive
episode and fever-related seizures. The most serious reaction to pertussis vaccination is 
acute encephalopathy, however, since this reaction occurs so rarely it has been difficult Ito attribute it without reservation to WCPV.
In 1974 two deaths were reported in Japan following pertussis vaccination.
Further vaccination of children in this country was discontinued. In Sweden, an article 
by Strom (1960) suggested as many as 1 in 6000 children were left brain-damaged after 
immunisation. However this was corrected to 1 in 50,000 after recalculation o f the 
data. K ulenkam pff et al, (1974) published the results of a study where 36 children 
exhibiting neurological illness had been followed over a period o f 1 1  years after 
recieving DTP. The results showed a clustering of neurological complications in the 
first 24 h after immunisation and because of this, it was concluded that DPT vaccine
:had a 'causal' rather than a 'coincidental' effect and vaccination of ill children should be ■
withheld. Adverse media coverage of this article claiming that pertussis vaccine was 
unsafe, resulted in reduced vaccine acceptance rates in Great Britain.
Since the vaccine was thought to cause neurological complications, the need for 
mass immunisation against whooping cough was further questioned by Bassili and 
Stewart (1976). They reported a strong correlation between socioeconomic conditions 
and attack rates, whereas attack rates and vaccine-acceptance rates correlated weakly.
The authors suggested the decline of the incidence of pertussis was not vaccine related 
and found from an outbreak of pertussis in Glasgow, a third of the notified cases were 
in fully-immunised individuals. In 1977, Stewart estimated the incidence o f vaccine- 
associated encephalopathy to occur at a frequency of 1 in 1 0 , 0 0 0  to 1 in 60,000 
children. He stated the risk of developing neurological complications after vaccination 
surpassed the injury caused by the disease. However, Grist (1977) recom mended
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continuing with vaccination arguing that the decline in whooping cough was due to a 
combination of improved socioeconomic factors and vaccine use. He estimated the rate 
of developing neurological complications at 1 in 135,000 children. Pollard (1980) also 
favoured continuing with vaccination. He found a direct relation between the increase in 
notification rates of pertussis and the decrease in vaccine acceptance in England and 
Wales.
be proved.
The reactogenicity of WCPV was assessed by Barkin and Pichichero (1979). I
DTP vaccine was administered to 1232 children. A postal questionnaire was completed 
by parents and on this basis, 72% were found to have local reactions. Cody et al.
(1981) reported reactions occurring within 48 h of vaccination in 784 DT and 15,752 
DTP immunizations. Mild adverse reactions occurred significantly more frequently in 
DTP compared with DT-immunized individuals. Later, B lumber g et al. (1993), carried 
out a detailed study of sixty children experiencing severe reactions within 48 h of DTP 
immunisation. They attributed persistent crying to painful local reactions and vaccine 
endotoxin as the cause of fever. Lymphocyte counts, insulin and glucose levels in these 
children were investigated and acute serum samples examined for active PT. No active
'
PT was found in immunised chidren therefore there was no evidence that PT played a 
role in severe vaccine reactions.
To settle the question of whether pertussis vaccine was responsible for acute 
neurological illness in vaccinees and to provide an estimate of the frequency o f its 
occun’ence, the National Childhood Encephalopathy Study was set up. During 3 years,
1,167 children with certain neurological illnesses from hospitals in Scotland, England 
and W ales were notified in a case-control design method with two matched controls for s
each case. The risk estimate was 1 in 330,000 doses with a 95% confidence interval of 
1 in 50,000 to 1 in 18,000,000. This study concluded that DTP was responsible for
acute neurological illness in some children. However, despite many epidemiological
'surveys, the link between pertussis vaccination and permanent brain damage could not
VI
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A num ber o f reviews surveying the inform ation on adverse reactions to 
pertussis vaccines have been published. These include M iller et al. (1982); Wardlaw 
and Parton (1983); M ortim er (1988); W entz and Marcuse (1991); Robinson (1981); 
Fine and Chen (1992); Hodder and Mortimer (1992).
Acellular Pertussis Vaccines (ACPV)
Developm ent o f acellular pertussis vaccines was undertaken with the purpose of 
producing a less reactogenic more efficacious product which conferred longer lasting 
immunity. Fears over the safety of WCPV led to greatly reduced vaccine acceptance 
rates causing a subsequent rise in the number of pertussis cases in unprotected 
individuals (Pollard, 1980).
A number of experimental vaccine preparations have been constructed and are 
composed of protective antigens identified from animal models of infection. These 
acellular prepar ations differ in their composition and in the method of detoxification.
Origins
Early "component" whooping cough vaccine preparations include the strom ata 
protective antigen of Pillemer et al. (1954) and the "Tri-Solgen" vaccine of Weihl et al. 
(1963). These vaccine preparations did not consist of purified defined antigens but the 
protective antigen component was obtained from supernates o f sonicated cells or 
through removal by chemical extraction from culture supernates. Both vaccines were 
tested by the ICMPT. Further information on earlier vaccine preparations made from 
cell extracts can be obtained from the review by Wardlaw (1992).
In 1972, Sato and Arai were successful in purifying the lym phocytosis- 
promoting factor from the culture supernate of B. pertussis strain Tohama. These cells 
had been grown on solid medium. This preparation had leukocytosis-prom oting.
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histamine-sensitizing and haemagglutinating activities (Sato et a i ,  1973) and was toxic 
but had protective activity. After a mild formalin treatment (0.2% foimalin at 25 for 
7 to 11 days) this preparation could be made atoxic and passed testing by both the 
active and passive ICM PT assays. This discovery was an im portant finding in the 
formulation of acellular pertussis vaccines (ACPV). Arai and Sato (1976) discovered 
that this LPF preparation consisted of two types of haemagglutinin, LPF-HA and FHA 
which were co-purified by their extraction procedures. Then, PT was identified as a 
major protective antigen both in active and passive i.e. and i.n. challenge mouse models 
(M unoz et al., 1981a; Sato et al., 1981a; Robinson and Irons, 1983 and Oda et al., 
1984). FHA was not protective by i.e. challenge but was after i.n. challenge (Munoz et 
al., 1981b; Sato and Sato, 1984; Oda et al., 1984; Sato et al., 1981b) therefore it also 
was included.
By 1981, a pertussis component vaccine containing formalin-detoxified PT and 
FHA was being used for mass immunization in Japan (Sato et al., 1984). This vaccine 
was a preparation of FHA and PT. Culture supernates obtained from scraping the 
growth off solid medium were the starting material for the purification o f these 
antigens. Extraction was by ammonium precipitation, and LPS was removed from this 
crude extract by ultracentrifugation followed by detoxification with formalin. The final 
vaccine mixture contained : FHA (5 to lOpg protein nitrogen/ml (PN/ml)); PT (0.5 to 
5.0|ig PN/ml); diphtheria toxoid (30 to 40 flocculating units (Lf/ml); tetanus toxoid (3 
to 8  Lf/ml); formalin <0.01%; m erthiolate <0.01% and aluminium hydroxide <0.2 
mg/ml as adjuvant.
In Japan, there are six different vaccine manufacturers of acellular vaccines, 
producing basically two types of preparations. The Biken type (B-type) which contains 
inactivated PT and FHA in approx equal amounts and the Takeda type (T-type) which 
is comprised mostly of FHA, PT and agglutinogen 2 (Noble et al., 1987). Figure 4 
shows the com position of the various ACPV preparations available in Japan. 
Preparations of A CPV ’s that vary in antigenic composition and the method of PT
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detoxification were formulated in America, England, France and Italy (Table 3) were 
evaluated by clinical trials.
Iwasi et al. (1985) reported that formaldehyde-detoxified PT could revert in 
vivo by showing mice were sensitized to histamine when challenged on day 1 2  instead 
of the normal third day. Also, formaldehyde reacts primarily with the epsilon-amino 
group of lysine residues and when Nicosia et al. (1986) cloned and sequenced the PT 
gene it was found that the im munodominant SI subunit did not contain any lysine 
residues for reaction with the detoxification agent.
At the Sclavo research centre in Italy, the PT m olecule was genetically 
detoxified in order to produce a less toxic immunogenic vaccine (reviewed by Rappuoli 
et al,, 1991). Pizza et al. (1988), identified the am ino-acids im portant for the 
ribosyltransferase activity of the S 1 subunit in the PT molecule. Thereafter, using DNA 
recombination techniques, the mutated genes were inserted into the chromosomes of B. 
pertussis. The resulting mutant producing a defective SI subunit and even though this 
protein was 1 0  to 1 0 0 0  times less toxic than wild type, it was still too toxic for use in 
vaccines (Pizza et al., 1989). Double mutants containing amino-acid substitutions were 
constructed and the mutant PT molecules tested for toxicity, ADP-ribosyl-transferase 
activity, antibody recognition and T-cell recognition. A mutant PT molecule obtained by 
substituting Arg^ with lysine and Glu^^^ with glycine was stabilized with formaldehyde 
(Nencioni et al., 1991) and tested in adult volunteers (Podda et al., 1991). Two 
vaccines were constructed. A monocomponent vaccine containing 15 pg  of the mutant 
PT-9K/129G and the other containing 7.5 pg  of this double mutant PT, 10 pg of FHA 
and 10 pg of the 69 KDa protein. Vaccinated individuals showed good antibody 
responses to each antigen with only mild local reactions obtained both in the vaccinees 
and placebo. The results of recent phase III clinical trials are shown in the discussion 
section.
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Figure 4 : Composition of Japanese acellular pertussis vaccines.
(Reproduced with permission from Kimura 1988)
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Table 3 : Formulations of acellular pertussis vaccines
Antigen
composition
Method of PT 
inactivation
Manufacturer Reference
PT, FHA, pili formaldehyde Centre for Rutter et a /.,1987 
Applied Microbiological 
Research
PT / hydrogen peroxide National Institute 
of Child Health and 
Human Development
Sek\xx2L et a l ,  1988
PT,FHA (1:1) glutaraldehyde Institute Meiieux Edwards et a l ,  1989
PT
PT, FHA, 69 KDa
genetic
detoxification
Sclavo Research 
Centre
Podda gf al,199Q
Based on Rappuoli et a l ,  1991
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Laboratory characterization
The i.e. mouse protection test of Kendrick et al. (1947) is recom mended by WHO 
guidelines (WHO, 1979) for potency testing of WCPV. Acellular preparations are also 
evaluated by this same method (Sato et al., 1984). Tiru et al. (1990) tested ten 
cand idate  acellu lar vaccine p reparations w ith the E D 5 0  for the Japanese 
monocomponent vaccine (JNIH-7) as reference. Four were comparable to JNIH-7, two 
preparations were one third as effective and four were of very low potency. This test 
has been suggested also as a way of following the consistency o f prepai'ations during 
production.
/  In the past, Preston and Stanbridge (1976), have questioned the relevance of 
infecting the brain of mice to test preparations made to prevent respiratory infection in 
children. Respiratory infection models may be more relevent to the testing of ACPV. In 
this case, vaccine potency is judged by its ability to protect colonization of the lungs 
after i.n. or aerosol challenge. This test was described by Sato et al. (1980). It requires 
large numbers of mice and i.n. infection can lead to variable results (Robinson and 
Funnel, 1992).
Other tests for monitoring the toxicity of ACPV preparations are the MWGT for 
LPS content and CHO cell clustering for active PT (Hewlett et al., 1983). Japanese 
acellular vaccines are much reduced in endotoxin content and biological activities of PT 
compared with WCPV (Sato et al., 1984).
Protective efficacy
The acellular vaccine produced by Pillemer et al. (1954) underwent testing in children 
in the MRC clinical trial reported in 1959 (MRC, 1959). Although the product protected 
against whooping cough, it was too toxic for further use. The T risolgen ' vaccine 
produced by Weihl et al. (1963) was licensed for use in the United States. It produced 
less local reactivity and showed less pyrogenicity than WCPV; however, the product 
did not come into general use.
d.- . , T'.
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In Japan, the death of two infants in 1974, 24 h after recieving DTP, caused 
much public concern (Sato et al., 1984). The DTP vaccine was reassesssed, resulting 
in the ages of administration increasing from 3 months to 2 years in an effort to avoid 
adverse events. Small scale field trials were conducted with newly formulated Japanese 
acellular vaccines (described above) to test for side-effects and protective efficacy. 
From 1978 to 1981, 5,000 children aged under 48 months were tested in total (Sato et 
al., 1984). with both ACPV and W CPV being adm inistered. A ttack rates after 
household exposure to pertussis were 82.8% in unvaccinated children, 14.3% in 
WCPV recipients and 11.1% in ACPV recipients. Adverse reactions were considerably 
lowér for ACPV compared with WCPV. Since 1981, acellular vaccines have been used 
for routine immunizations in Japan in two year old children
In 1985, a group of public health service scientists travelled to Japan to monitor 
the development, production and use of these vaccines. Noble et al. (1987) reported 
since the introduction of ACPV’s the incidence of pertussis was showing a downward 
trend in the country. These authors summarized the results o f three Japanese studies 
with the Takeda-type vaccine administered under a four-dose shedule. When the results 
o f the three studies were combined, efficacy was 87%.
Vaccination with WCPV was discontinued in Sweden in 1979, due to poor 
protection and fears about its safety (Fine and Clarkson, 1987). Two ACPVs 
formulated in Japan were investigated in a phase II clincal trial. One contained 7.5 pg 
protein nitrogen/ml each of PT and FHA (JNIH-6 ) and the other (especially formulated 
for the trial) was a monocomponent vaccine containing 1 2 . 0  pg protein nitrogen/ml of 
form alin-detoxified pertussis toxin. A double-blind random ized field trial was 
designed, involving a total of 3801 children of 5-11 months age. The placebo (vaccine 
solvent) was given to 954 children, 1419 received JNIH-6 , 1428 received JNIH-7. 
Point estimates of vaccine efficacy against culture-confirmed pertussis with cough was 
69% and 54% for JNIH - 6  and JNIH-7 respectively. These workers also reported that 
antibodies to PT and FHA were similar in vaccinated children whether or not they
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subsequently had pertussis. Thus, protection against w hooping cough was not 
correlated with antibody levels. Fewer adverse reactions were reported in comparison 
with reported rates for WCPV. During the 17 to 19 months of follow up, five children 
died. Three children given JNIH - 6  and the other two children were given JNIH-7. 
Causes of deaths were: Haemophilus influenzae type B meningitis, heroin intoxication 
with concomitant pneumonia, Neisseria meningitidis group B septicaemia, suspected 
pneumococcal septicaemia and a brain tumour. The results o f the follow-up study 
(Storsaeter and Olin, 1992) indicated that the two-component vaccine containing 
pertussis toxoid and filamentous haemagglutinin provided better long-term protection 
against pertussis than monocomponent pertussis toxoid vaccine.
TREATMENT OF PROTEINS WITH TOXOIDING REAGENTS 
Toxoiding of Bacterial Toxins
General
M any agents exist which have been used for the toxoiding o f bacterial toxins, none 
however, appear to have been used as extensively as formaldehyde and glutaraldehyde. 
This section therefore focuses on these two agents with some inform ation on
3
li'j-y
carbodiimides which are of particular interest in this project.
The conversion of bacterial toxins to non-toxic products by detoxifying agents
has been known since the late 19^  ^ century. Much of the early work was on the !-
detoxification of diphtheria (DT) and tetanus toxins (TT). Behring and Kitasato,1890,
(cited Parish, 1958) used iodine trichloride to reduce the toxicity of TT before the 
immunization of rabbits. Then subsequently in 1898, Salowski described toxoiding
I■:.3;
TT with form aldehyde was further investigated to prepare toxoids for human
with formalin (cited by Parish, 1958). During the 1920’s, the detoxification of DT and
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immunization (Glenny etaL , 1923; Ramon, 1923). Widespread immunization with the 
first toxoids led to greatly decreased incidences of diphtheria and tetanus.
Glutaraldehyde was used as a toxoiding agent by Relyveld, 1978, although 
previously, it had been used widely for sterilization and disinfection purposes. In their 
review, Relyveld and Ben-Efraim (1983) reported that glutaraldehyde detoxification 
resulted in a more stable product than formaldehyde-detoxified proteins.
A large body of infoimation exists for the wide variety of conditions employed 
in the treatment o f bacterial toxins. Conditions differ for each toxin to be treated. 
Important variables of the toxoiding ti'eatment are: length of exposure to the reagent, 
temjf)erature, pH, concentrations of toxin and toxoiding agent and, with formaldehyde 
and glutaraldehyde, the addition of certain amino-acids usually lysine.
Effect o f pH  : French and Edsall (1945) reported the importance of pH during chemical 
reactions with formaldehyde. Detoxification of bacterial toxins is generally done at 
neutral or alkaline pH with both fomnaldehyde and glutaraldehyde. The effect o f pH on 
the rate of inactivation and the effect on antigenicity was studied with diphtheria toxin 
(Eaton, 1937), shiga toxin (Dubos and Geiger, 1946), staphyloccocal enterotoxin B 
(W arren et al., 1973), Staphylococcus aureus enterotoxins A and C l (Warren et al., 
1975) and cholera toxin (Rapapport et al., 1974). These workers found that highly 
alkaline pH reduced toxicity to the greatest extent however, this was also accompanied 
by the greatest loss of antigenicity. Warren et al. (1973), and in a later study (Warren et 
al. 1975) analysed form aldehyde-treated staphyloccocal enterotoxins by SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) reporting that treatment at acidic or 
neutral pH caused the formation of high MW polymers which could not penetrate the 
gel, indicating interm olecular cross-linking; whereas, treatment at alkaline pH 9.5 
caused the formation of a heterogeneous group of monomeric derivatives indicating 
intra-molecular cross-linking. During the toxoiding reaction, Rappaport et al. (1974) 
and Pollack and Prescott (1982) observed no major fluctuations o f pH in the reaction 
mixture.
i
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Effect o f  concentration  : The ratio of formaldehyde or glutaraldehyde to protein 
concentrations are critical to the end products obtained. Too high a concentration of the 
toxoiding agent caused damage to the toxin and a loss or com plete alteration of 
antigenicity (Eaton , 1937; Wadsworth e ta l ,  1938; Rappaport e ta l ,  1974; Relyveld et 
al., 1978). Murphy et al. (1967) showed that treatment o f TT with formaldehyde 
resulted in a shift from a mixture of monomers, dimers and polymers to the formation 
of large polymers. An increase in polymerization also occurred with increasing protein 
concentration when the formaldehyde was kept constant. Rappaport et al. (1974) 
reported that a high ratio of cholera toxin to glutaraldehyde gave insoluble products.
/  Dawson and M auritzen (1969) exam ined the incorporation o f radioactive 
form aldehyde during modification o f TT. The rate of binding of form aldehyde 
increased with increasing concentrations resulting in an immediate loss of lethality 
(80%) of the toxin. Following this, slower detoxification was noted with binding of the 
agent becoming more gradual. In the classic study by Pittman et al. (1952), the effects 
of different agents on the detoxification of B. pertussis cells for vaccine production 
were evaluated. The subjection of cells to physical factors (heat, UV radiation) or 
chemical agents (phenol, merthiolate or formalin) were examined. Detoxification was 
monitored by the newly developed i.e. mouse protection test (ICM PT) for the 
evaluation of the protective potency of vaccines (Kendrick et al., 1947). Heating to 56 
°C for 30 min and then preservation o f the bacteria with merthiolate yielded the best 
preparation due to stabilised potency. Formalin treatment reduced the toxicity but also 
caused some loss in potency. Clumping of bacteria was also noted. Kendrick et al. 
(1955) however, observed no loss of potency upon formaldehyde treatment.
Effect o f  temperature and time : H igher temperatures of 30-39 °C appear to reduce 
toxicity  rapidly, w hereas treatm ent at room  tem perature resu lted  in slow er 
detoxification. However, antigenicity was better retained at lower temperatures. For 
example, this was shown by Wadsworth et al. (1938) with DT and formalin, and much 
later by Pollack and Prestcott (1982) for detoxification of Pseudomonas aeruginosa
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exotoxin A with formaldehyde. The conversion of poorly immunogenic heat-labile 
toxin to an immunogenic toxoid by formaldehyde treatment in rabbits was reported by 
Livey and Wardlaw (1984). HLT underwent a rapid loss of toxicity at 37 and a 
slower loss at 4 <^ C.
The incubation period of preparations detoxified with glutaraldehyde were 
much shorter than with formaldehyde and varied according to the type of toxin used. 
Relyveld (1973), inactivated B. pertussis with glutaraldehyde at 0.0131 M the bacteria 
being completely killed after only one min exposure. Relyveld (1978), detoxified TT 
for 10 min whereas DT required 3 h before it became atoxic under the same conditions. 
Dubos and Geiger (1946), found Shiga toxin very difficult to detoxify even after 
several months incubation with formaldehyde. Light did not appear to be an important 
factor in the detoxification reaction since their's was the only study where the reaction 
was stated to have been carried out in the dark (Pollack and Prestcott, 1982).
Stability  : Toxins inactivated by formaldehyde were noted to show a reversal to 
toxicity upon removal of the toxoiding agent by dialysis or after storage. The instability 
of formaldehyde-treated bacterial toxins was reported by W adsworth et aL, 1938; 
Linggood et al. (1963) and Relyveld et al. (1978) for DT; by Relyveld et al. (1978) for 
TT; in vivo reversion o f cholera toxin by Northrup and Chisari (1972); PT (Sato et al., 
1974); and Pseudomonas exotoxin A (Cryz et al., 1981). Also, Relyveld et al. (1978), 
reported that detoxification o f D T and TT with glutaraldehyde, instead o f 
formaldehyde, resulted in a stable product which showed no reversal upon storage, yet 
retained antigenicity.
Hewlett et al. (1977), reported that B. pertussis whole-cell vaccines contained 
pertussis toxin (PT) and lipopolysaccharide (LPS) which had not been inactivated by 
the formaldehyde treatment used to kill the cells. Work by Gupta e ta l. (1987a), Gupta 
et al. (1987b), liada and H oriuchi (1987); and Gupta et al. (1988) investigated 
glutaraldehyde as a detoxifying agent for B. pertussis cells which would result in a
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more stable, completely inactivated product. lida and Horiuchi (1987) found treatment 
with 10 mM glutaraldehyde at 37 for 30 min was sufficient to produce a marked 
drop in toxicity with virtually no loss in potency. Arya et al. (1989) however, urged 
caution when using glutaraldehyde as a detoxifying agent for this purpose since 
impurities in the glutaraldehyde solution were noted to give different reactions with 
am ino-acids. Furtherm ore, they reported that detoxification o f PT occurred but 
glutaraldehyde did not detoxify the LPS component.
Bunney (1931), added amino-acids, peptones or proteins to the detoxification 
mixture, stating that they were essential to prevent damage to the toxoid during the long 
periods of incubation required. Eaton (1937) suggested the addition of peptones may 
have had a protective effect on the antigenic properties of the toxin. Linggood et al.
(1963) reported that lysine stabilised form aldehyde-treated proteins and helped 
retention o f antigenicity. Relyveld (1978), found that addition o f lysine neutralised 
excess glutaraldehyde and stopped its further interaction with DT and TT.
Immunogenicity : Glutaraldehyde-toxoided preparations were reported to elicit higher 
antibody titres than formaldehyde toxoids (Relyveld, 1978; Rappaport e ta l., 1974).
Relyveld (1978) observed DT alone was more immunogenic than a formalin toxoid of
.DT adsorbed to A 1(0 H )3 , In contrast, Pavlovskis et al. (1981) reported that a 
glutaraldehyde toxoid of P. aeruginosa  exotoxin A was not as immunogenic as the 
form aldehyde toxoid. The im m unogenicity o f this toxin after treatm ent with 
formaldehyde was low anyway according to Cryz et al. (1981) and Cryz and Iglewski
(1983). Porro et al. (1980) found diphtheria toxoid and a non-toxic mutant of DT 
(crm l97) had equivalent im m unogenicity after form alin treatm ent. Enhanced 
immunogenicity was not always due to polymerization of the toxin molecule. Relyveld 
(1978) noted the dimeric fraction of glutaraldehyde-treated DT was a better immunogen 
than the monomeric or the polymeric fraction. Steame and Birkbeck (1980) found the 
non-immunogenic delta haemolysin of S. aureus to become highly immunogenic after 
formaldehyde treatment but no polymerization was observed.
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T h e  d e t o x i f i c a t i o n  o f  b a c t e r i a l  t o x i n s  w i t h  1 - e t h y l ~3 - ( 3 -  
d im ethylam inopropyl)carbodiim ide (EDAC) has been reported  only in the 
detoxification o f CT by Lonnroth and Holmgren (1975) and for Escherichia coli heat- 
labile enterotoxin by Klipstein et al. (1982), aside from the studies of Christodoulides 
et al. (1987, 1989) with PT. For CT, there was no loss in toxicity or compromized 
antigenicity with EDAC treatment whereas, in comparison, glutaraldehyde-treatment 
decreased toxicity and affected antibody-binding capacity. E. coli enterotoxin exhibited 
rapid loss of activity and retained antigenicity. A mixture of PT and FHA not only lost 
toxicity, but also showed enhancement of immunogenicity after toxoiding with EDAC 
(Christodoulides e t a l . , 1987).
Pertussis toxin
Matsui and Kuwajima (1959), reported treatment of HSF with formalin led to complete 
detoxification, as monitored by loss of histamine-sensitizing activity. Mice immunized 
with this toxoid were protected from sensitization with B. pertussis culture supernate. 
In 1966, Munoz and Hestekin detoxified soluble extracts of B. pertussis  containing 
histamine- sensitizing and protective activity. These workers reported protective activity 
as more resistant to inactivation by formaldehyde than the HSF activity, and suggested 
that formaldehyde treatm ent altered the molecule in such a way as to destroy HSF 
activity but retain protective activity. Sato eta l. (1974) and later, Sato et al. (1984) and 
Sato and Sato (1984), reported detoxification of PT with form aldehyde for the 
production o f acellular vaccines. Sato et al. (1974) carried out O uchterlony gel 
diffusion of toxoided PT and found a line of complete identity to native PT. Sato and 
Sato (1984) showed that formaldehyde-treated pertussis toxin had lost lymphocytosis- 
promoting activity in the mouse at 10 pg/mouse. Antigenicity was not impaired, as 
shown by the ability o f the pertussis toxoid to bind to its receptor haptoglobin in 
ELISA.
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Glutaraldehyde treatment of PT was used by Munoz et al, (1981a), M unoz et 
at. (1981b), Robinson and Plawkins (1983), Robinson and Irons (1983) and Oda e ta l.
I
"3(1984), for investigating the protective activity of inactivated PT. Munoz et al. (1981a,
1981b) found the histamine-sensitizing and haemagglutinating activities of treated PT 
were reduced markedly (25% and 4% of the original values respectively). Also, 
glutaraldehyde-treated pertussigen did not lose its antigenicity, as it actively precipitated 
with antibody. Toxicity was much reduced since 10 pg/m ouse was atoxic from the 
previously toxic 2 pg/mouse of native P T .
Detoxification of PT has also been carried out with hydrogen peroxide (Sekura 
et (M., 1986), with EDAC (Christodoulides et al., 1987), and tetranitrom ethane 
(Winberry eta l., 1988). Trinitrobenzenesulphonic acid (TNBS), potassium iodide and 
chlorane were used by Fish et al. (1984). While elucidating mechanisms of PT action, 
a number o f agents which modified lysine residues were used by Nogimori et al.
(1984a, 1984b). Genetic modification of two amino acids (Arg^ and Glu^^^) resulted 
in an enzymatically-inactivated PT molecule (Pizza et al., 1989 and Nencioni et al.,
1990).
Inform ation on the alteration o f protein m olecules by form aldehyde, 
glutaraldehyde and carbodiimides must begin with a discussion on the chemical groups 
of proteins which are susceptible to attack by these agents. A short account of their 
interactions with proteins follows.
■;$
Reactions of Proteins with Formaldehyde
The reactions of formaldehyde with proteins are numerous and complex as reviewed 
by French and Edsall, 1945; Fraenkel-Conrat and Olcott, 1948a, 1948b; Fraenkel-
■ ■
Conrat and M echam, 1949. Formaldehyde (HCHO) is com mercially available as 
formalin, a solution which contains 37% (w/v) formaldehyde and small amounts of 
methanol, in water. The methanol is added as a stabilizer to inhibit the formation o f
I
a
48
polym ers. In aqueous solutions more than 99.9% of form aldehyde exists in its 
hydrated form as CH2 (OH)2 . Formaldehyde adds to compounds containing an active 
hydrogen atom resulting in the formation of hydroxymethyl compounds (Equation 1).
Equation 1 : \
R -H  +  CH2 O - .............\  R -C H 2(0H )
If the hydrated form of formaldehyde is present, then the hydroxymethyl compound is 
produced by a condensation reaction, with the liberation of water (Equation 2)
Equation 2 :
R -H  + C H 2(0H )2 ■ -  ■ ^  R -C H 2(0H ) + H 2 O
hydroxymethyl compound
The amino groups of proteins react rapidly and reversibly with two moles of 
formaldehyde in neutral or alkaline solutions to give methylol amines (Equation 3).
Equation 3 :
R -N H 2 + H C H O  ■ .> i ,R -N H eH 2 0 H  + H C H O ^ = ^ R - N ( C H 2 ( O H ) 2
methylol amines
Form aldehyde reacts with adjacent amino-acid side chains through electrophilic 
immonium cations (Equation 4) such as tyrosine, tiyptophan, histidine, asparagine and 
cysteine residues (French and Edsall, 1945) resulting in additional rings being formed. 
Equation 4 :
H CH2OH - H 2 O H CH2  +CH2
+ H2 O
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W hen steric relationships are favourable, formaldehyde can react with two groups to 
form methylene bridges (Equation 5)
Equation 5 :
R-CH2(0H) + H -R ’^ = = ^ R - C H 2 -R ’ + H2 O
Numerous groups found in amino-acids, peptides and proteins are capable of 
undergoing addition and condensation reactions with formaldehyde. The epsilon amino 
group o f lysine residues have a much stronger tendency to associate with 
formaldehyde. This rapid primary reaction of formaldehyde with lysine residues results 
in the formation of Schiff bases (Equation 6 ) which can then undergo methylene bridge 
fomfîâtion with a variety of groups.
Equation 6  :
R-NH 2  + HCHO R-NHCH2 OH + H+ ^  ^  R-NH+= CH2  + H2O
lysine Schiff base
Figure 5 shows the reaction of formaldehyde-mediated methylene bridge formation 
with some of the functional groups found in amino-acids. The reaction of thiols is 
much more rapid than its reaction with amines, since the sulfhydryl group is a better 
nucleophile. Only one molecule o f formaldehyde, however, can react with one 
sulfhydryl.
Fraenkel-Conrat and Mecham (1949), showed by means of molecular weight 
analysis and osmotic pressure measurements that methylene bridges were indeed being 
formed between two or more protein molecules. Thus, bond formation can take place 
intra-molecularly, forming ring stinctures, or intermolecularly with the formation of 
molecular aggregates. Polyoxymethylene chains and bridges could also result when 
more formaldehyde molecules entered the reaction.
During the detoxification of bacterial toxins the cross-linking reaction led to 
polymerization of toxin molecules, and was regarded unfavourably, as reversal to
50
Figure 5 : Modification of amino-acids by formaldehyde
The imino group e.g. arginine
R-NH2 + HCHO + R'=NH ^ ---- ^  R-NH-CH2- N=R' + H2O
The amide group e.g. aspai'agine, glutamine
R -N H 2 + H C H O  + N H 2C O R ' ^ = ^ R -N H -C H 2 "  N H C O R ' + H 2O  
The guanidyl group
II II
R -N H 2  + H C H O  + N H 2 - C  R -N H -C H 2 -N H  -C  + H 2 O
N H « . NWQ,
The hydroxyl group e.g. serine
R -N H 2 + H C H O  +  R '-O H  v = ^ R - N H - C H 2 -0 -R ' + H 2 O  
The sulfhydryl group e.g. cysteine
R -N H 2  + H C H O  + R ’-S H  ^ = = ^ R - N H - C H 2 - S - R ' +  H 2 O
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toxicity could occur (M urphy, 1967). Low concentrations of form aldehyde gave 
incomplete toxoiding, therefore Linggood et al. (1963) examined the effects o f the 
addition of vaiious amino-acids. They found the best preparation was obtained by the 
addition of a small amount of lysine. They suggested instead of taking the reaction to 
the point o f methylene bridge formation between toxin molecules, the addition of lysine 
disrupted polymerization by the production of highly stable antigenic side chains. 
(Equation 7).
Equation 7 :
Toxm-H + HCHO + H 2 N.CH.(COOH).(CH 2 )4 .NH2
/ ]
V
Toxin.CH 2 NH.CH.(COOH).(CH 2 )4 .NH2  + H 2 O 
toxin-lysine side chains
Formaldehyde seems to have a stabilising effect on proteins. As far back as 
1896, Blum (cited French and Edsall, 1945) noticed that treatment o f egg-albumin with 
formaldehyde rendered the egg-albumin resistant to coagulation. Collagen and casein 
also became more resistant to the action of trypsin and other proteolytic enzymes. 
Habeeb (1969) showed increased resistance of formal!nized BSA to unfolding with
urea, indicating the formation o f intra-m olecular bonds. Form aldehyde-m ediated 
modification of proteins was found to be dependent on a number of important factors 
such as temperature, pH and the concentration of the agent utilised during the reaction.
The chemical nature of the protein itself contributes to the reaction products obtained.
'."f:iî%
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Reactions of Proteins with Glutaraldehyde
Glutaraldehyde is a bifunctional aldehyde. Its chemical formula is CHO(CH2 )3 CHO. 
The mechanism of cross-link formation is analogous to formaldehyde. Richard and 
Knowles (1968) suggested that the reactive species present in aqueous solutions of 
glutaraldehyde was a condensation polymer. However, Korn et al. (1972) repeated the 
analysis o f glutaraldehyde in w ater and found solutions to consist o f free 
glutaraldehyde, the cyclic hemiacetal o f its hydrate, and oligomers of this. These 
workers also reported that glutaraldehyde reacted with the epsilon amino gi’oups of 
lysine residues in the ratio of four moles of glutaraldehyde per mole lysine. Cheung 
and Nimni (1982) elucidated that glutaraldehyde underwent a number of condensation 
polymerization reactions with the epsilon groups of lysine residues to form, like 
formaldehyde, Schiff-based derived products.
Habeeb and Hiraraoto (1968) investigated the reaction of glutaraldehyde with 
amino-acids and peptides. They found modification of the N-terminal group of some 
peptides, the sulfhydryl group o f cysteine residues and partial reactivity with the 
phenolic and the imidazole of tyrosine and histidine residues. Habeeb (1969) studied 
glutaraldehyde-treated bovine serum albumin (BSA). This protein was found to have 
undergone more extensive modification o f free amino groups with the formation o f 
molecular cross-links. The conformation of the molecule was altered, as shown by 
increased reduction of disulphide linkages compared to native BSA. Antigenicity of the 
molecule was also affected. New antigenic determinants created by glutaraldehyde 
ti'eatment of the protein were apparent. Treatment with glutaraldehyde gave a product 
which was irreversibly modified and resistant to breakdown with urea, semicarbazide, 
wide ranges of pH and ionic strength and temperature (Richard and Knowles, 1968).
53
Reactions of l"ethyl-3-(3-dimethyIaminopropyï)carbodiimide ( E D A C )
Carbodiimides are one of the several classes of un saturated compounds belonging to 
the heterocumulenes family. This family contains compounds based on an allene 
structure and are characterized as such because of the presence o f twinned double 
bonds.
I I—c=c =c —
T hrgenera l formula of carbodiimides is denoted by RN = C = NR' where R and R' 
may be either aliphatic or aromatic groups. A commonly used carbodiimide is the water 
soluble l-ethyl-3-(3-dim ethylaminopropyl)carbodiimide (EDAC) and its formula is 
shown below.
CH3CH2-N=C=N-CH2CH2 CH2 N(CH3) 2
Carbodiimide chemistry has been reviewed in detail by Khorana (1953), Kurzer and 
Douraghi-Zadeh (1967) and Williams and Ibrahim (1981).
Being unsaturated com pounds, carbodiim ides undergo addition reactions 
readily. Primarily addition of a carbodiimide to a protein results in carboxyl group 
modification (Figure 6 ). Reactivity of carboxyl groups increases with increasing acidity 
(Williams and Ibrahim, 1981). The reaction begins with the attachment of a proton to 
the carbodiimide. This is followed by attack of the carboxyl group to form the O- 
acylisourea. This can rearrange to form the N-acylurea. Alternatively, attachment of a 
second molecule results in cation formation. The subsequent attack of an acid anion 
forms a N,N'- disubstituted urea and the acid anhydride. Undesirable side reactions 
can also take place via the rearrangement of the 0 -acylisourea, being quite apart from 
the major side product of the N-acylurea. These include imide formation (Riehm and
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Scherega, 1966), formation of acid anhydride cross-links between adjacent carboxyl 
groups and addition of the carbodiimide on the protein carboxyl group as a substituted 
amide with isocyanate formation (W illiams and Ibrahim, 1981). Addition o f an 
exogenous nucleophile has been used to suppress the rate of side reactions during the 
analysis of carboxyl group content of enzymes (Carraway and Koshland, 1972).
Reactions of carbodiimides may occur with a number of functional groups. 
M odification of the phenolic groups o f tyrosine (Carraway and Koshland, 1968); 
sulfhydryl groups o f cysteine residues, (Carraway and Triplett, 1970); hydroxyl 
groups of serine residues (Banks, Blossey and Shafer, 1969) and imidazole groups 
(Williams and Ibrahim, 1981) have been shown. Carraway and Triplett (1970), found 
the rate of modification of sulfhydryl groups by ethyldim ethylcarbodiim ide and 
carboxyl groups to be equivalent, whereas tyrosine m odification was slower. 
Regeneration o f tyrosine residues was possible using hydroxy lamine (Carraway and 
Koshland, 1968); however regeneration of sulfhydryl groups was not obtained under 
conditions which would preserve protein conformation (Carraway and Triplett, 1970). 
Carraway and Koshland (1972), reported protein amino groups were not reactive at the 
lower pH values used in cardodiimide-nucleophile reactions.
Modification with l-ethyl-3-(3-morpholinopropyl)carbodiimide was reported to 
give inter-molecularly linked thermostable lysozyme and alpha-chymotrypsin (Hattori, 
1970). Pedemonte and Kaplan (1985) found intramolecular bond formation occurred 
through reaction with a carboxyl group and a side chain am ine (acting as an 
endogenous nucleophile), to inhibit the activity of Na^-K+ATP-ase from dog kidney.
In 1955, Sheehan and Hess discovered peptide bond form ation could be 
affected by condensation reactions with dicyclohexylcarbodiimide (DCCD). This 
procedure involved the addition of the carbodiimide to a solution of N-protected amino- 
acids or peptides. The mechanism of peptide bond formation with carbodiimide is 
shown in Figure 7. After protonation of the carbodiimide, reaction with a carboxylate 
anion yields the 0-acylisourea. This can rearrange to form the N-acylurea, react with
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an amino-acid ester to form peptide linkage or react with another carboxylate anion to 
produce urea and acid anhydride. The latter participates in further peptide formation. In 
the review by Rich and Singh, (1979), the formation o f side products during peptide 
synthesis were described. Racemization of am ino-acid esters resulted in 5(4H)- 
oxazolone production, activation of glutamine or asparaginyl carboxyl groups led to 
nitrile formation and the N-acylurea gave decreased yields. Again, addition o f 
nucleophiles reduced the rate of side reactions. Nucleotide synthesis has also been 
reported but will not be described here (see reviews for further information).
A p p lica tio n s  o f ca rb o d iim id es
M ost studies using carbodiimides to modify proteins, have used an added nucleophile '#
to trap the activated carboxyl groups and to suppress the formation of side reactions.
■The use of a nucleophile with a dénaturant allows quantitative evaluation of the amount 
o f carboxyl groups in a protein. The number of free carboxyl groups may be 
determined by the difference in the amount of nucleophile present in the reacted protein 
and the unreacted protein. A common nucleophile is glycine (reviewed by Carraway 
and Koshland, 1971). This method was applied to a number o f proteins including 
ribonuclease, by Riehm and Scherega (1966) and to lysozym e (Carraway and 
Koshland, 1972).
'Buried' carboxyl groups may also be determined using a modification o f the 
above procedure. Reaction of the carbodiimide and the nucleophile without the addition 
of a dénaturent results in incorporation of the nucleophile. After amino-acid analysis, 
the dénaturent is added with radioactive nucleophile and more carbodiimide. In this 
way, any buried residues appearing after unfolding and exposure, are radioactively 
labelled. This method was applied to alpha-chymotrypsin with the identification of two 
buried carboxyl groups (A be to et a l ,  1969).
Studies of carboxyl group modification and correlated loss of enzyme activity, 
have also been made in attempts to assess the importance of carboxyls in binding and
' 5
3
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Figure 6 : Protein carboxyl group modification by carbodiimide.
H+X-N=C=N-Y
carbodiimide
H ^
X-N C=N-Y 
O
0 -acylisourea
H+
H H+
X-N-C-N-Y 
©  — C o\
© -
\ c
V
H H 
I I
X-N-C-N-YII
O
N,N'-disubstituted
urea
+
0-
Q ) — c
O
protein carboxyl group
X-N=CIIo
isocyanate
O
//o
,9 -©
H
X -A -C -N -Y
O
N-acylurea /
O
H
N-Y
O
substituted amide
acid anhydride 
e.g. cross linking of adjacent glutamates
57
Figure 7 : Mechanism of carbodiimide-mediated peptide bond formation 
(from Kurzer and Douraghi-Zadeh, 1967)
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catalytic groups (Toner-W ebb et aL, 1987; Yoshida et al., 1982; Parsonage et al., 
1988).
In the review by Bauminger and Wilchek (1980), carbodiimides were stated to 
be the agents o f choice for the preparation o f im m unizing conjugates. W eakly 
immunogenic or non-immunogenic compounds were linked to larger carrier proteins to 
enhance their antibody-evoking potential. The conjugation required two groups - an 
amino group and a carboxyl g?oup. Carboxyl groups were, in the majority o f cases, 
contributed by the hapten, whereas the amino groups were supplied from the lysyl or 
alanyl residues of the protein carrier. Various proteins ranging from hormones to 
pepride fragments have been conjugated by this method (Arnon and Sela, 1969; Koch 
et al., 1973). Table 5 however lists a selection of references which used EDAC in the 
preparation of conjugates for bacterial vaccines.
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Table 5 : Conjugates prepared for bacterial vaccines with l-ethyl-3-(3- 
dim ethylam inopropyl)carbodiim ide (EDAC)
Hapten Protein carrier Refercnce
E. coli heat-stahjlle 
enterotoxin
porcine IgG Klipstein et aL, 1981
Neisseria meningitidis 
group C polysaccharide
tetanus toxoid Beuvery et a l ,  1983
E. coli ST enterotoxin non-toxic native B- 
subunit of 
labile-toxin
Klipstein et al., 1985
Synthetic cholera toxin 
B-subunit peptide squences
tetanus toxoid Jacob et a l ,  1986
Synthetic shiga toxin B- 
chain peptide sequences
tetanus toxoid or 
a synthetic carrier
Harrari ef a/., 1988
E. coli polysaccharide cholera toxin or 
P. aeruginosa toxin A
Cryz et al., 1990
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O B JE C T  O F R E SE A R C H
This study stems from the report of Christodoulides et a l  (1987), who investigated the 
toxoiding of antigens o f B. pertussis to produce an acellular pertussis vaccine. These 
investigations found that a mixture of pertussis toxin and filamentous haemagglutinin 
was not only detoxified by treatment with a water-soluble carbodiimide, EDAC, but 
also that this preparation had enhanced immunogenicity. The purpose of the present 
study was:
1. to confirm or refute the adjuvanting effect of EDAC on B. pertussis antigens, both 
as PT:FHA mixtures and with the two antigens purified independently;
2. to investigate the specificity of this EDAC-adjuvant effect by treatment of two model 
antigens, ovalbumin and lysozyme, with EDAC;
3. to com pare E D A C -treated antigens with other toxoiding agents, nam ely 
formaldehyde and glutaraldehyde for immunogenicity.
6 1
M A T E R I A L S  A N D  M E T H O D S
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Bacterial Culture 
Strains
The four strains of B. pertussis used in this study were from the departmental culture 
collection. Strains 353 and 357 were obtained from Dr, A.A. W eiss, University o f 
V irginia School of M edicine, Charlottesville, Virginia, USA, and were transposon 
mutants lacking respectively FHA and PT. Strain 77 /1 8319 was a phase I isolate 
supplied by Dr. R. Fallon, Ruchill Hospital, Glasgow. Strain 18323 was a phase I 
organism highly virulent in the ICM PT and provided by Dr. F. Sheffield o f the 
N ational Institute for B iological Standards and Control (N IBSC), Holly H ill, 
Hampstead, London.
The strains were stored either as freeze-dried cultures in vacuum-sealed glass 
ampoules kept at room temperature, or at -70 ^C in 1% (w/v) casamino acids and 
glycerol (Appendix 1).
Culture media
Stock cultures : With strain 77/18319, stock cultures were started from freeze-diied or 
frozen material by plating on to Bordet-Gengou agar (BG) prepared as described in 
Appendix 1 . With strain 353 and 357, kanamycin (50 pg/ ml) from Sigma Chemical 
Co., Fancy Rd., Poole, Dorset, was added to the medium. This was to maintain the 
mutant status of these strains.
Batch cultures : A modification of the CL liquid medium of Imaizumi et. al. (1983) was 
used for large-scale culture of all three strains of B. pertussis. This medium contained 
heptakis (2,6-0-dimethyl)-6-cyclodextrin (MeBCD) which was obtained from Teijin 
Ltd., Chiyoda-ku Tokyo, Japan. The formula of this medium is given in Appendix 1.
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Growth from stock cultures
Frozen cultures w ere thawed at RT for 10-15 min; freeze-dried cultures were 
resuspended in a 1% (w/v) solution of casamino acids (Appendix 1) and kept at RT for 
20 min before plating. One or two loopfuls of suspension were streaked on four BG 
plates and incubated in a humidified box for 48 h at 37 so as to yield single 
colonies.
Confirmation o f culture purity was obtained by visual inspection and Gram 
staining. Loopfuls o f the growth from these plates were used to restreak fresh BG 
plates and again incubated for a further 48 h at 37 °C in a humidified box to provide the 
inoculum for batch cultures.
Growth of batch cultures
Large loopfuls of growth from BG plates were used to inoculate 1 L portions of CL 
medium in 2 L dimpled Ehrlenmeyer flasks. Cultures were incubated for 48 h at 37 ®C 
and aerated by shaking at 150 rpm  on a rotary shaker (L.H Engineering Co. Ltd., 
Stoke Poges, Bucks., England).
At the end of the incubation, culture purity was checked by Gram staining, after 
which the bacterial cells were removed by centrifugation in a Sorvall RC-5B centrifuge 
at 9000 rpm for 30 min at 4 °C. The supernate was collected and centrifuged again for 
further clarification prior to the extraction of PT or FHA.
Preparation of sonicated B. pertussis
For some immunization experiments, B. pertussis strain 18323 was prepared as a 
sonicated suspension of heat-killed bacteria.
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Extraction of PT and FHA
A modification of the method of Sekura et al, (1983) was used to extract PT, FHA and 
a mixture of the two proteins from the culture supernates o f appropriate B. pertussis 
strains, viz 353 for PT, 357 for FHA and 77 /18319 for the mixed-antigen preparation 
respectively.
Culture supernates were adjusted to pH  6.0 at RT with 2.5 M H Cl before the 
addition of thiomersal to 0.01% (w/v) final concentration, as preservative, and 1 ml/L 5 
mM  phenylmethyl-sulphonylfluoride (Sigma) as a pro tease inhibitor. To every one L of 
culture, 10 ml Blue Sepharose CL-6 B gel slurry (Pharmacia LKB, Uppsala, Sweden) 
was then added to absorb the PT and/or FHA. The mixture was stirred overnight at 4 
^C  for 24 h, or for 48 h if stim ng had inadvertently been interrupted. The following 
steps were carried out at RT. The mixture was poured into a G1 sintered glass funnel 
(Gallenkam p, Loughborough, Leicestershire) to retain the gel. The filtrate was 
discarded. W ithout delay, the gel was washed with 0.05 M Tris-HCl, pH 8.0, and 
transferred to a 2.6 x 35 cm chromatography column (LKB 2137, Pharmacia LKB, 
Uppsala, Sweden). The gel was allowed to settle and the packed column was washed 
for 2.5 h with 0.05 M Tris-HCl, pH 8.0, applied with a peristaltic pump, to remove 
unbound material. Elution of the bound protein was done with 0.05 M Tris-HCl, pH 
8.0 containing 1.0 M NaCl and 10 ml fractions were collected. The fractions were 
monitored for absorbancy at 280 nm. Fractions with absorbancy S:0.2 were pooled, 
dialysed against PBS, pH 7.3 overnight at 4 filter-sterilized through a 0.45 p.m 
membrane (Gelman Sciences) and stored frozen at -20 ®C until required.
To regenerate the gel at the end of each run, it was washed with 0.1 M Tris- 
HCl, pH 8.0 containing 0.5 M NaCl and 6  M urea to rem ove any strongly bound 
protein. After this, the gel was washed first with 0.1 M Tris-HCl, pH 8.5 containing 
0.5 M NaCl, and next with 0.1 M sodium acetate, pH 4.5 containing 0.5 M NaCl. This 
alternate washing with low and high pH buffers was repeated twice more before a final
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wash with 0.05 M Tris-HCl, pH 8.0 containing 0.01% w/v thiomersal was applied. 
Finally, the gel was removed and stored at 4 for reuse. Appendix 2 details the 
preparation of the buffers used in this procedure.
Toxoiding of Antigens
Treatment with EDAC
Essentially, the method of Christodoulides et a i  (1987), was followed for the use of 1- 
ethyl-3,3-dimethylaminopropyl carbodiimide (EDAC, MW 191.7) to toxoid PT and to 
treat the non-toxic proteins FHA, ovalbumin (OA; Sigma) and lysozyme (LZ; Sigma). 
EDAC solutions were freshly made, typically at 42 mM so that after addition of an 
equal volume of the protein solution, a final concentration of 21 mM was obtained.
Treatment with EDAC was done at 37 ^C with the protein and the EDAC 
dissolved in 20 mM sodium phosphate buffer, pH 5.0 with or without 0.5 M NaCl. PT 
and PT:FHA mixtures were dialysed at 4 °C overnight against the buffer (containing 
NaCl), whereas with FHA alone, the NaCl was omitted. For toxoiding PT or PT:FHA 
mixtures, 0.5 M NaCl was included in the EDAC stock solution, whereas with FHA 
alone it was omitted. For treatment of OA and LZ with EDAC, the crystalline proteins 
were dissolved directly in the phosphate buffer without NaCl, as was the EDAC.
With PT or PT/FHA the toxoiding mixtures contained 50 pg/m l protein and 
EDAC at 21 mM. W ith FHA there was 250 p.g/ml total protein and an EDAC 
concentration ranging from 2.3 to 50 mM. For the treatment of LZ and OA, much 
higher concentrations of protein (4 mg/ml) were used in conjunction with 11 to 800 
mM EDAC. Mixtures o f protein and EDAC were incubated at 37 ^C for 24 h without 
stirring and were then dialysed for three days at 4 °C against daily changes of PBS, pH 
7.3 containing thiomersal at 0.01% (w/v) final concentration.
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Treatment with formaldehyde
The two bacterial proteins and LZ, but not OA, were treated with formaldehyde by a 
combination and modification of the methods of Linggood et al. (1963), Porro et al. 
(1980) and Sato and Sato (1984). In particular, the usage of lysine was according to 
Linggood et al. (1963), the formaldehyde concentrations were taken from Porro et al, 
(1980), while the treatment times and temperatures were as reported by Sato et al, 
(1984). To avoid uncertainty, the concentrations are expressed both as mM 
formaldehyde and as % {vN) formalin  which is a 37% (w/v) solution of formaldehyde 
(Sigma).
Toxoiding of PT or of PT:FHA mixtures at 50 pg/ml final protein concentration 
was done in 20 mM sodium phosphate containing 0.5 M NaCl, pH  7.4. Freshly diluted 
formalin at 0 .8 % (v/v) was added to give a final concentration o f 0 .2 % (v/v) formalin, 
equivalent to 25 mM formaldehyde. L-lysine (Sigma) at 20 mM was also included in 
the mixture unless otherwise stated. The mixture was incubated at 37 ^C for one week, 
after which it was dialysed against PBS, pH 7.3 containing 0.01% (w/v) thiomersal 
(final concentration) for one week, with daily changes o f buffer, to rem ove the 
formaldehyde and the lysine. The final product was stored at 4 °C.
The toxoiding of FHA was done with a range of formaldehyde concentrations 
of between 3.1 to 25 mM (with or without lysine at the corresponding concentration). 
The final concentration of protein in the reaction mixture was 250 fig/ml. The treatment 
was for 24 or 48 h at 4 °C, 22 ®C or 37 °C in buffer without NaCl. Dialysis o f the 
toxoided sample and subsequent storage was as for PT and PT:FHA mixtures.
Several different concentrations of both formaldehyde and lysine were used to 
treat LZ (final concentration 4 mg/ml) in 20 mM sodium phosphate, pH 7.4. Incubation 
was for 1 week at 37 °C followed by dialysis for three days with daily changes of 
buffer.
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Treatment with glutaraldehyde
The two bacterial proteins and LZ, but not OA, were treated with glutaraldehyde under 
the conditions described by Relyveld (1978) and Munoz et al. (1981).
PT and PT/FHA mixtures at 50 pg/m l were dialysed overnight at 4 against 
20 mM  sodium phosphate buffer, pH 7.4 containing 0.5 M NaCl. Glutaraldehyde 
(Fisons) was diluted from 25% (w/v) as purchased to 2.5% (v/v) which was then 
added in appropriate amounts so as to give a concentration of 0.025% (v/v) or 2.5 mM 
glutaraldehyde when mixed with protein. Incubation was for 2 h at 37 °C, after which 
lysine was added to 10 mM with further incubation for 15 min to terminate the reaction. 
This mixture was dialysed against PBS, pH 7.3 containing 0.01% (w/v) thiomersal for 
three days, with daily changes of buffer, to remove the glutaraldehyde and the lysine. 
The final product was stored at 4 ®C.
FHA (250 M-g/ml) was treated exactly as above except that the buffer used 
throughout the procedure did not contain 0.5M NaCl and the time o f incubation varied 
from 15-120 min at 37 °C with or without the addition of lysine at 10 mM.
LZ was treated in a similar manner except that the final concentration of protein 
was 4 mg/ml and the glutaraldehyde varied over the range 0.006 to 0.025% (v/v). This 
range corresponds to 0.6-2.5 mM. The treatment time was 2 h. The effect of lysine was 
explored by adding it in four-fold molar excess over that o f glutaraldehyde. At the end 
of the 37 °C treatment, the mixture was placed in visking tubing and dialysed against 
PBS, pH 7.3 containing 0.01% thimerosal for three days, with daily changes of buffer. 
The final product was stored at 4 °C.
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In Vivo Procedures
M ice
Male and female mice obtained as CD-I (caesarean-derived animals) of the Ham/ICR 
strain, Charles River (UK) Ltd., M ansion Rd., Margate, Kent, were used. They were 
maintained as a randomly-bred colony and were provided with food and water ad lib.
Immunogenicity of proteins
In a typical experim ent, 60 to 100 mice o f ages ranging from  6  to 8  weeks 
(exceptionally, up to 16 weeks) and o f both sexes, were arranged in cages containing 
12 to 16 animals o f the same sex. The allocation of mice to cages was done in a 
randomized block fashion, each cage being taken as a block, with one recipient for 
each dose of each antigen. By having 5 such cages, each dose of each antigen yielded 
five replicate sera. Appendix 3 shows the detailed layout o f a typical experiment in 
which 4 preparations were each tested at 3 doses, therefore requiring 12 mice per cage.
Injections were administered inü’a-peritoneally {i.p.) as a single shot of 0.5 ml 
o f antigen preparation. To do this, for example with three antigens each at four doses, a 
set o f twelve 2.5 ml syringes was loaded with the injection fluids and one 0.5 ml 
injection given from each syringe to the animals captured without preselection. The 
individual animals in each cage were identified by a system of positional markings with 
indelible dyes on the fur.
A period of three weeks was allowed for the expression o f a primary immune 
response before the animals were killed and blood collected. This was done by 
transferring the mice to a closed chamber containing carbon dioxide for asphyxiation. 
The dead animals were pinned out on a board and blood obtained by cardiac puncture 
with a fresh one ml syringe and a 25 gauge 5/8 inch needle for each animal. The blood 
was allowed to clot either at room temparature for 3-4 h, or overnight at 4 ^C, before 
being spun for 30 min at 3000 rpm and 4 in a MSE M istral 6 L centrifuge with a
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swing-out rotor. Serum was collected with a pasteur pipette, taking care not to disturb 
the pelleted red cells, and stored frozen at - 2 0  ®C.
H is ta m in e -se n s itiz in g  ac tiv ity  (H SA )
Procedures very similar to the above as regards allocation o f animals to cages were 
used for assaying the HSA in prepartions of B. pertussis. Thus, groups o f two or four 
mice ( > 6  weeks old) were injected i.p. with 0,5 ml graded doses o f the test samples in 
a randomized block layout. After a period of five days, each mouse was challenged i.p. 
with 3 mg histamine dihydrochloride dissolved in PBS. The mice were observed for 3 
h at which time the number o f deaths were recorded. The 50%-histamine-sensitizing 
dose (HSDgg) was determined approximately by graphical interpolation o f the dose of 
sensitizing material which gave 50% mortality after histamine challenge. This was 
expressed as the number of pg protein per mouse.
T oxicity  o f E D A C -trea ted  lysozym e (LZ-E )
In a single experiment, 15 female 6 -week old mice were each injected i.p. with 10 mg 
doses in 0.5 ml of LZ before and after EDAC treatment. The animals were observed 
closely for changes in their health and were weighed initially and then daily for three 
days after which they were killed by CO2  asphyxiation.
E nzy m e-L in k ed  Im m u n o so rb e n t A ssay (E L ISA )
A ssay of an tib o d ies
Anti-ovalbumin : For ELISA, flat-bottomed 96-well micro titre plates (Nunc Maxisoip 
F, Gibco BRL, Life Technologies Ltd., Renfrew Road, Paisley, Scotland) were coated 
with 350 pi/well of 100 pg/ml of OA. The OA was made up in coating buffer, pH 9.6 
(Appendix 4). After keeping the plate for 1.5 h at RT in a humidified box, it was 
washed in washing buffer (PBS, pH 7.4 containing 0.05% v/v Tween 20 and 0.01%
70
w/v thimerosal) and allowing 3 min per wash. It was then blotted dry and used without 
delay.
BSA (Sigma), at 50 pg/m l (350 pl/well) in incubation buffer (PBS, pH  7,4 
with 0.05% v/v Tween 20) was added to each well to block sites on the plastic not 
already occupied by OA. Blocking was done at RT for 5 min before further washing 
and blotting three times. Ten-fold dilutions of the test sera were made in incubation 
buffer and 300 pi added to each well. The antisera were titrated in duplicate. Incubation 
was for two h at RT whereupon the wells were again washed and blotted.
A 1:1000 dilution of sheep anti-m ouse IgG-HRP (SAPU, Law Hospital, 
Carluke, Lanarkshire, Scotland) was added (250 pi per well) and incubated in a damp 
box overnight (to avoid the wells drying out) at 4 ®C. Next day the plate was washed 
and blotted as before and developed with 200 pi of 0-phenylene diamine (34 mg/ml) as 
substrate (Appendix 2). Developm ent was done in the dark for 30 min at RT after 
which the reaction was stopped by adding 50 pi 12.5% (v/v) H 2 SO 4  per well. The 
absorbancy of the fluid in each well was measured spectophotometrically at A=492nm 
using an Anthos reader 2001, (Anthos Labtech instruments, Austria).
Anti-lysozym e  : The procedure for quantitating anti-LZ was similar to the above, 
except that the wells were coated with 2 pg/ml of LZ and the incubation time during the 
development stage was reduced to 15 min before the reaction was stopped and read 
spectophotometrically.
Anti-pertussis toxin : The general procedure was the same as above except that the 
wells were coated with 1 0 0  pi of a 1 pg/m l solution of fetuin (from fetal calf serum, 
Sigma) in coating buffer and incubated overnight at 4 °C in a humidified box. The 
contents of the wells were dumped out and the plate was washed three times with 
washing buffer. The wells were then blocked with 2% (w/v) BSA in incubating buffer 
for 1 h at 37 °C. The plates were washed again before adding 100 pi 10 pg/ ml PT in 
incubation buffer. The plate was incubated again for 1 h at 37 °C and washed. Three­
fold dilutions ( 1 0 0  pi) o f each test serum was added to the wells for another 1 h
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incubation at 37 °C followed by 3X washing. A 1: 5000 dilution (100 pi) o f sheep 
anti-mouse IgG (SAPU, Carluke, Lanarkshire) was added and incubated again for 1 h 
at 37 ^C. Plates were washed, developed for 30 min with O-phenylene diamine and the 
reaction terminated with 12.5% v/v H 2 SO4  and read as before.
Anti-filamentous haemagglutinin : Purified FHA at 1.0 pg/ml in coating buffer, (FHA: 
courtesy of Dr. A. Robinson, PHLS, Centre for Applied M icrobiological Research, 
Porton Down, Salisbury, W iltshire, England) was used for the coating phase and 
incubated overnight at 4 °C in a humidified box. The volume of reagent added to the 
wells at each step throughout the test was 100 pi except 200 pi for the substrate and 50 
p i for the H2 SO4 , and all incubations were performed for 1 h at 37 °C. The plate was 
washed three times then blocked by incubation with 2% BSA. After washing, three­
fold dilutions o f the test serum were added to the wells. Polyclonal FHA -H RP 
conjugate termed F 3 (PHLS, Centre for Applied M icrobiological Research, Porton 
Down, Salisbury, Wiltshire, England) was added and incubated. The plates were given 
a final three washes before the addition of substrate and incubated in the dark for 30 
min at 37 ^C in a humidified box when the reaction was terminated.
Assay of bacterial antigens
Pertussis toxin : Wells of the same type of microtitre plates were coated with 200 pi of 
20 pg/ml fetuin in carbonate buffer, pH 9.6. The plate was incubated overnight at 4 ^C 
in a humidified box, then washed three times the next day and blocked with 250 pi per 
well of 10% (v/v) foetal calf serum and incubated for 1 h at 37 °C. A PT standard 
preparation (kindly provided by Dr. R. Parton of this department) and test PT samples 
were adjusted to 1 pg/ml protein and five-fold dilutions made. Each well was loaded 
with 200 pi of sample and incubated for 1 h at 37 °C. After washing, 200 pi of a 1 in 
800 dilution o f anti-PT m onoclonal antibody (L io PHLS, Centre for A pplied 
M icrobiological Research, Porton Down, Salisbury, W iltshire) was added and 
incubated for 1 h at 37 °C. Plates were washed and 200 pi of a 1: 3000 dilution o f
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sheep anti-mouse IgG (SAPU) was added per well and again incubated for 1 h at 37 
°C. The plates were given their final three washes, developed for 30 min, and finished 
in the usual way.
Filamentous haemagglutinin : Anti-FHA capture Ab (F2  in ascites fluid, PHLS, Centre 
for Applied Microbiological Research, Porton Down, Salisbury, Wiltshire ) was diluted 
1:16,000 in coating buffer and 200 pi used to coat each well. The plate was incubated 
overnight at 4 °C in a humidified box. After plates had been washed, they were blocked 
with 10% (v/v) foetal calf serum (Gibco) in incubating buffer at 250 pi per well, for 1 h 
at 37 °C. FHA standard (CAMR) and test FHA antigen samples were adjusted to 1 
pg/ml protein from which 5-fold serial dilutions were made. Test samples were titrated 
in duplicate and 200 pi added per well. The test plate was incubated for 1 h at 37 ^C, 
washed and incubated for a further 2 h at 37 ^C with conjugate. To each well 200 pi of 
F 3 IgG anti-FHA HRP (0.5 pg/ml, CAMR) were added. The plate was washed and 
developed as before.
Other In Vitro Procedures
Protein estimation
Protein content was measured either according to the method o f Lowry et al. (1951) 
using the Folin-phenol reagent or by the Micro-BCA protocol of Smith et al. (1985) 
with bi^cinchoninic acid. BSA (Sigma) was used as the standard protein in both 
assays.
Lowry m ethod  : A series o f dilutions o f standard and test samples was prepared in 
duplicate in distilled water (DW). The BSA standard solutions ranged from 0-500 
pg/ml. Each test sample (0.5 ml) was mixed with 0.5ml of IN  NaOH and placed in a 
boiling water bath for 5 min. Immediately before use, a solution consisting of 0.5% 
(w/v) CUSO4 .5 H 2 O (1 ml), 1 % (w/v) sodium potassium tartarate (1 ml) and 5%
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sodium carbonate (50 ml) was prepared and 2.5 ml added to each sample. These were 
held at RT for 10 min then mixed with 0.5 ml of IN  Folin-Ciocalteou phenol reagent 
(Sigma). Test tubes were incubated for a further 30 min at RT to allow full colour 
development. A-y^onm was measured in a SP6-550 UV/VIS spectophotometer (Pye 
Unicam) in 1 cm light path disposable plastic cuvettes. The machine was blanked 
against the 0  pg/ml standard.
Smith method : Dilutions of standard and test samples were prepared in DW. Standard 
solutions ranged from 0-50 pg/ml. These samples were mixed with an equal volume 
(0.5ml) of BCA-working reagent (BCA-WR) prepared as follows: Reagent A (8 % 
Na2'tl0 3 .H2 0 , 1.6% (w/v) NaOH, 1.6% (w/v) Na2 tartarate adjusted to pH 11.25 with 
solid NaHCÜ3 ) was mixed (in equal volumes) with reagent C (0.4g o f BCA.Na2  in a 
plastic universal dissolved in 10 ml of DW with 0.4 ml o f 4% (w/v) CUSO4 .5 H 2 O 
added immediately before use). Samples were incubated in a water bath for 60 min at 
60 and read in a UY/VIS spectophotometer at Ag^^nm- The machine was blanked 
against the 0  pg/ml standard.
SDS-polyacrylam ide gel electrophoresis (SDS-PAGE)
The method of Laemmli (1970) was followed. Two glass plates (15.8 cm x 19 cm) 
were separated with 1.5 mm thick plastic spacers and sealed with yellow tape. To 
ensure the system was leakproof, the sealed glass plates were baked at 80-100 for 
2-3 h. Separating gel, stacking gel and running buffer were prepared as described in 
Appendix 5. Lower gel solution was pipetted into the sealed plates to a level of 
approximately 11 cm, avoiding air bubbles. The solution was overlaid with ethanol so 
that the surface of the gel set evenly. The gel was left to set for 30 min at RT. Before 
pouring the upper gel (stacking gel) solution, the ethanol was removed and the surface 
of the gel washed with DW and a teflon comb inserted. This stacking gel solution was 
allowed another 30 min setting time at RT. The sealing tape was removed from the 
bottom of the gel to allow contact with the electrophoresis buffer. The wells were
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washed with DW and the plate was inserted into a gel tank with the upper and lower 
reservoirs filled with running buffer. W ells were loaded with solubilised samples 
(which contained bromophenol blue as tracking dye, Appendix 5) with a Hamilton 
syringe. The samples were run through the stacking gel and into the separating gel at 18 
mA then the current was turned up to 30 mA. The gel was run for 3-4 h.
W estern blotting
Gels were run as above and were blotted according to the method o f Towbin et al. 
(1984). The gel was overlaid with nitrocellulose membrane (mesh size o f 0.4 pm , 
Amersham), Whatman filter paper (3mm) was laid on both sides o f the gel and finally 
two Scotchbrite pads (Bio-Rad laboratories) were laid on either side. The sandwich 
was held together with plastic binders. This cassette was inserted into a transblot 
appparatus and filled with transfer buffer (Appendix 5). The protein was allowed to 
transfer overnight at 0.08 A at RT, The nitrocellulose was then removed and developed 
as below.
Staining of gels and blots
Proteins contained within polyacrylam ide gels were stained either with Coomassie 
brilliant blue R250 (BDH, M cQuilkin & Co., Laboratory furnishers, 21 Polm adie 
Avenue, Glasgow) or with silver nitrate (Sigma).
Coomassie blue staining : The gel was carefully removed from the glass plates and 
immersed in a fixing/staining solution of Coomassie blue R250 stain (Appendix 5) with 
gentle shaking overnight. The gel was destained the following day with a mixture of 
diluted methanol and acetic acid (Appendix 5). Destaining was carried out at RT for two 
days, with three changes of destain on the first day and one change on the second. 
Finally, the gel was rinsed thoroughly in DW and preserved by heat-sealing in plastic. 
The detection limit of this method was 0.3-1 pg  protein per band.
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Silver staining  : Since this staining procedure is very sensitive to contamination 
(detection limit of 2-5 ng protein/band) the gel was handled with thoroughly-rinsed 
plastic gloves. All incubations were carried out for 30 min at RT with gentle shaking 
unless otherwise stated. First, the gel was prefixed in a mixture containing 30% (v/v) 
methanol and 10% (v/v) acetic acid in DW. This solution was poured off and, without 
rinsing, 10% (v/v) glutaraldehyde was added. Following this step, the gel was washed 
for 10 min in DW five to six times before soaking in a large volume overnight. The gel 
was washed again for 15 min in DW  and incubated in a 5 p-g/ml solution o f DL- 
dithiothreitol (Sigma). W ithout rinsing, 0.1% (w/v) silver nitrate (Sigma) was added. 
The gel was rinsed twice in DW and twice more with 100 ml volumes of developer (3% 
sodium carbonate with 50 p.1 of 37% w/v formaldehyde). The gel was left to soak in a 
measured 100 ml o f developer, this volume being neutralisable by the subsequently 
added 5 ml of 2.3 M citric acid which was poured in when bands were visible. Finally, 
the gel was washed in DW several times then with 0.03% (w/v) sodium carbonate 
before being preseived by heat sealing in a plastic sleeve.
Development o f blots : Nitrocellulose was removed from the transblot apparatus and 
unbound sites were blocked with 2% BSA in TTS (20 mM Tris, 1% Tween 20 in 
saline) and incubated with gentle shaking. Anti-PT monoclonal L io  or polyclonal anti- 
FHA F2  was added at a 1 in 1000 dilution and incubated for 1.5 h. Anti-serum was 
removed by five washes with TTS over 30 min. Sheep anti-mouse IgG-HRP (SAPU) 
was diluted to 1 in 1000 and incubated for a further 1.5 h. The blot was washed twice 
with TBS (20 mM Tris in saline) before the addition of the developer : 60 mg 4-chloro- 
1-naphthol (Bio-Rad Laboratories Ltd., Bio-Rad House, M aylands Avenue, Kernel 
Hempstead, Hertfordshire) in 10 ml of methanol. TBS (90ml) and hydrogen peroxide 
(100 p.1) were added just before use. When the blot had developed satisfactorily, it was 
rinsed several times in DW, air dried and stored at RT in the dark (wrapped in 
aluminium foil).
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Haemagglutination assay
Test samples containing FHA were diluted in two-fold steps in PBS in polystyrene 
round-bottomed 96-well microtitre plates (Nunc-Immunoplate, Gibco-BRL) leaving 50 
|al in each well. A 2% (v/v) suspension of washed horse red cells was added (50 p.1 per 
well) and after gentle mixing the contents were allowed to settle either at RT for 3-4 h 
or overnight at 4 ^C. The HA titre was defined as the reciprocal dilution of the last well 
to show complete agglutination. Horse red cells in PBS and a known FHA standard 
were included as negative and positive controls on each plate.
Chinese hamster ovary cell-clustering assay
CHO cells (courtesy of Dr, E.L. Hewlett, University of Virginia School of Medicine, 
Charlottesville, Virginia, U.S.A.) were treated with 5 ml of trypsin/EDTA solution in 
Puck's saline (Gibco BRL) for 1 min. The solution was poured off and the cells were 
allowed to detach. After 5 min, 10 ml of growth medium (Ham's F I 2 containing 10% 
(v/v) foetal calf serum , Gibco BRL) was added to stop the activity of trypsin. The cells 
were transferred to a sterile universal container, centrifuged at 1000-1500g for 10 min 
and resuspended in Ham's F12 + 1% (v/v) foetal calf serum by gentle aspiration with a 
long-form pasteur pipette to break up clumps. The cell suspension was counted in a 
Neubauer counting chamber and used for replating or for the assay.
The wells of sterile microtitre plates (Nunclon, Gibco BRL) were seeded with 
approximately 10,000 CHO cells in a volume of 200 p.1. The plate was incubated in a 
5% CO2  atmosphere at 37 ^C for 20 h to allow attachment and stabilization. Serial 10- 
fold dilutions were made of test and standard PT samples in sterilized 100 mM 
Na2HP0 4  + 0.5 M NaCl, pH 7.0. Each dilution was assayed in duplicate with 25 pi of 
sample added per well. Cells were exposed to toxin for 24 to 48 h and examined for the 
clustering response by light microscopy after staining. Preparation of Coomassie blue 
stain for staining CHO cells is given in Appendix 5. Cells were fixed with 4% (v/v)
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formalin in PBS for 15 min (200 pi per well) then stained with Coomassie blue R250 
(50 p i per well) for 15 min, rinsed extensively with DW and air dried.
Lysozyme Activity
A modified procedure was followed from the manufacturer product information leaflet 
for LZ (Sigma). A lyophilised preparation of Micrococcus lysodeikticus cells (Sigma) 
was resuspended in PBS and allowed to equilibriate until the suspension was stable at 
A 4 5 0  nm= 1 fh and 2.5 ml of the suspension was delivered into 1 cm light path 
cuvettes. Dilutions of standard LZ and treated LZ preparations were made and tested in 
duplicate. To each cuvette 0.1 ml of test sample was added and thoroughly mixed using 
nescofilm  (Alpha laboratories, Hampshire) to seal the opening. The A450nm was 
m onitored at this point and 30 min later. The % activity of LZ or treated LZ was 
determined from the drop in absorbance relative to a control preparation consisting of 
cells and 0.1 ml of buffer. A dose-response curve of M. luteus lysis by lysozyme is 
shown in Figure 8.
Statistical Procedures
Test for normality
As a preliminary step in the statistical analysis of antibody titres it was necessary to 
determ ine whether they were distributed normally, lognormally, or followed some 
other distribution. For this purpose rankit analysis W ardlaw (1985, p. 69-78) was 
adopted as a convenient procedure.
Briefly, ELISA titres from a group of typically five mice were arranged in rank 
order starting with the highest, and two graphs were plotted, one of rankit value against 
arithmetic titre and the other of rankit value against logio titre. The rankit values were 
obtained from the rankit table. Independently, the mean and SD of both the arithmetic 
titres and the logio titres were calculated and used to provide the theoretical straight 
lines for the two rankit plots (Figure 9). The goodness-of-fit of the theoretical and
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experimental rankit lines was then analysed by the ordinate deviations of the individual 
points. With each antigen preparation, such as a particular batch o f EDAC-treated LZ, 
the rankit deviations were tabulated according to rank number and the mean, SD and 
95% CL calculated for each rank number. Summary graphs were then plotted of rankit 
deviation versus rank number and the decision about the underlying distribution made 
from the goodness-of-fit of the rankit deviations with the horizontal line at zero.
Further statistical analysis
With or without logarithmic transformation, groups of serum titres were subjected to 
analysis o f variance to determ ine prim ary effects and interactions o f the relevant 
experimental variables. They were also analysed as 4-point and 6-point assays for 
quantitative com parisons of im m unogenicity and t-tests for com parison o f group 
means. These procedures were all obtained from Wardlaw (1985).
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F ig u r e  8 : D o se -re sp o n se  c u rv e  o f  M ic r o c o c c u s  lu t e u s  lysis by 
lysozym e. The reaction was carried out at RT and the A^gonm o f the bacterial 
suspension was measured 30 min after the lysozyme was added.
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F ig u re  9: E xam ple o f ra n k it  plots to  de term ine  n o rm ality  o r  logno rm ality  
o f se ru m  ti tre s . T h ese  5 se ra  w ere ra ise d  ag a in s t 1 m g o f L Z -E . T h e
vertical dotted line represents the ordinate deviation of the fourth rank number from the 
theoretical line.
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ELISA TITRES OF ANTISERA
B efore describ ing  the effects o f  toxo id ing  agents on m odel an tigens and  on  the an tigens 
o f  B . pertussis, the  p ro c ed u re s  u sed  fo r th e  d e riv a tio n  an d  an a ly se s  o f  an tise ru m  
E L IS A  titres are p resen ted  first.
Determination of ELISA Titres
A n tib o d y  p ro d u c tio n  in  m ice  w as in v estig a ted  by a s ing le-sho t im m u n iza tio n  p ro to co l 
w ith  the v ario u s  an tig en s, u sin g  g roups o f  five  an im als at each  d o se  lev e l ex cep t o n ce  
w hen  g roups o f  fo u r w ere  taken. A  u n ifo rm  tim e in terva l o f  21 days w as a llo w ed  fo r 
th e 'e x p re s s io n  o f  th e  p rim ary  re sp o n se  b efo re  the  an im als  w e re  b led  an d  th e  se ra  
obtained. T he ind iv idual sera w ere then titrated  by E L IS A  for an tibodies specific fo r the 
re le v an t anti gen (s). E L IS A  titres w ere  ob ta in ed  by  p lo ttin g  the A492 nm against serum  
d ilu tio n  on sem i-lo g arith m ic  graph paper. F ig u re  10 show s an  ex a m p le  o f  a p lo t o f  
ab so rb an ce  at 4 9 2  n m  ag a in s t lo g io  [rec ip ro cal an tiseru m  d ilu tio n ]. E n d p o in ts  w ere  
o b ta in ed  from  th e  in te rsec tio n  o f  th e  A492 nm = 0.5  line  w ith  th e  cu rv e , fo llo w ed  by 
in te rp o la tio n  d o w n  to  the  x -ax is at A492 n m  = 0  . W ith  lo w -titre  sera, en d p o in ts  w ere  
o b ta in ed  by ex tra p o la tio n  up to  th e  lin e  a t A492 nm =  0 .5 . W h e re  ev en  th is  w as n o t 
p ossib le , an arb rita ry  titre  o f  one w as recorded . A lthough  read  o f f  a  lo g arith m ic  scale , 
titres w ere in itially  recorded  as their arithm etic values.
Statistical Analysis of Antiserum Titres
Rankit plots for analysis of the underlying distribution
F o r sta tis tica l ana lysis  o f  E L IS A  titres it w as f irs t necessary  to  d e te rm in e  w h e th e r the 
d a ta  fo llo w ed  a n o rm al o r lo g -n o rm al d istrib u tio n  pattern . T h is  w as d o n e  by use  o f  
ran k it p lo ts, a sam ple o f  w hich  is g iven  in F ig . 11 w hich p resen ts  selected  resu lts from
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Figure 10: Derivation of an ELISA titre. Sample data illustrating interpolation 
of the dose-response curve with the A492  nm = 0.5. The resulting logio tilre is 
approximately 3.9, giving an arithmetic titre of 7900.
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Figure 11: Rankit plots after immunization with OA-E, LZ, FHA and 
AP16-F. The left column shows plots with arithmetically expressed titres, the right 
after logarithmic transformation.
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experiments with various doses of four different antigens, namely EDAC-treated OA 
(OA-E), lysozyme (LZ), FHA and the anti-PT titres of formaldehyde-treated A P I6  
(AP16-F) which was a mixture of PT and FHA. With the sera from each antigen, two 
different rankit plots were made, viz with the arithmetic values o f the ELISA titres (left 
colum n diagram s) and the logarithm ic values o f the same titres (right column 
diagrams). In both types of diagram  the observed titres are plotted with the open 
circles, while the straight line joining the closed circles represent the theoretical rankit 
line based on the mean and standard deviation (SD) of the group.
Visual inspection of the diagrams shows that all those in the left hand column 
exhibit the characteristic inverted L-shape of logarithmically-distributed data which have 
been presented on an arithmetic rankit plot, whereas those in the right hand column 
show a much better fit of theoretical and experimental lines indicative of an underlying 
log-normal distribution, or approximation thereto.
The sample o f eight rankit plots in Fig. 11 were selected from the accumulated 
278 rankit plots and are the results from the 57 groups of mice used in the whole study. 
Inspection of the totality of these results indicated that not all groups of sera benefited 
from logarithmic transformation of the ELISA titres in order to achieve normalization. It 
was therefore necessary to summarize the rankit plots in further diagrams which would 
highlight the differences between the experimental and the theoretical rankit lines to 
allow the appropriate decision on transfoimation.
Further analysis of rankit plots.
A sample of summarized rankit diagrams is provided in Fig. 12 for antisera raised 
against particular doses of four different antigens. In each diagram the deviations of the 
ranked points are presented with their 95% confidence limits. W herever one of the 
confidence limits is outside the theoretical line an arrow has been inserted to highlight 
this feature. Thus it will be noted that in Fig. 12a there are 9 such arrows in the column
8 6
F ig u re  12a: R a n k it-p lo t co n fidence-lim it ana ly sis  o f a n ti-L Z  ti tre s  fro m  
experim ent C. The mean vertical deviation from the theoretical line with 95% CL is 
plotted against rank no. for LZ treated with ED AC, formaldehyde and glutaraldehyde. 
Arithmetic plots are the left column diagrams, logarithmic plots are the right column 
diagrams. Arrows indicate deviations that are significant at the P= 5% level.
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of arithmetic rankit plots of antisera against variously treated samples of LZ, but only 
one in the column of logarithmic plots. It therefore appeared advantageous for the 
ELISA titres o f sera raised against LZ and its derivatives to be transform ed into 
logarithms prior to statistical analysis.
W ith sera raised against OA and its derivatives, Fig. 12b shows that as with 
LZ, it was beneficial to make a logarithmic transformation of the titres although there 
are only four deviation arrows in the five diagrams of the anti-OA arithmetic plots. The 
results with the remainder of the anti-OA and anti-LZ sera are given in Appendix 6 .
With antisera against the two B. pertussis  antigens, PT and its derivatives 
(Fig,. 12c) and FHA and its derivatives (Fig. 12d), the logarithmic transformation had 
less normalizing effect than it did with anti-LZ and anti-OA and their derivatives. 
Nevertheless, in the interests of consistency it was decided to use logarithm ically 
transformed titres for the further analysis of anti-PT and anti-FHA, The results with the 
remainder of the anti-PT and anti-FHA sera are also given in Appendix 6 .
1
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F ig u re  12b: R a n k it-p lo t confidence-lim it ana ly sis  o f an ti-O A  titre s  fro m  
experim ent C. The mean vertical deviation from the theoretical line, with 95% CL is 
plotted against rank no. for OA and OA-E treated to various extents. Arithmetic plots 
pre the left column diagrams, logarithmic plots are the right column diagrams. Arrows 
indicate deviations that are significant at the P= 5% level.
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Figure 12b continued
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Figure 12c: Rankit-plot confidence-lim it analysis of anti-PT titres after 
immunization with PT, PT-E, PT-F and PT-G. The mean vertical deviation 
from the theoretical line, with 95% CL is plotted against rank no. for each preparation. 
Arrows indicate deviations that are significant at the P= 5% level.
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Figure 12d: Rankit-plot confidence-lim it analysis of anti-FHA titres after immunization with FHA, FHA-E, FHA-F and FHA-G. The mean 
vertical deviation from the theoretical line, with 95% CL is plotted against rank no. for 
each preparation. Arrows indicate deviations that are significant at the P= 5% level.
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E F F E C T  O F T O X O ID IN G  A GENTS ON L Y SO Z Y M E  AND
O V A L B U M IN
Before studying the effect of toxoiding agents on the immunogenicity of the antigens of 
B. pertussis, it was considered necessary to explore the effects of these agents on other 
antigens taken as models. In these studies two such antigens, ovalbumin (OA) and 
lysozyme (LZ), were treated with toxoiding agents. Most o f the effort was eventually 
focused on LZ because the course of toxoiding could be monitored by loss o f enzymic 
activity. Thus LZ was treated with EDAC, formaldehyde and glutaraldehyde, whereas 
OA as a non-enzymically active protein was treated with EDAC only.
Additional reasons for choosing LZ were: high NH^-group content and the 
likelihood of greater modification by formaldehyde and glutaraldehyde, rather than 
EDAC; and high immunogenicity, which raised the question of whether toxoiding 
could have any significant enhancing effect on antibody production.
OA was chosen because it is a weak immunogen and is in standard use for 
adjuvant studies (Stewart-Tull, 1989). These features together with the high carboxyl- 
gi'oup content made it suitable for treatment with EDAC which combines principally 
with such groups (and also to a lesser extent with the hydroxyls of serine and tyrosine).
E xp erim en ts  W ith  O valbum in
I
ÏThe concentration of OA taken for treatment with EDAC was chosen so that a top 
immunizing dose of 1 mg per mouse would be contained in a volume of 0.5 ml for 
convenience of i.p. injection. The protein, initially at 8  mg/ml was treated with various 
concentrations of EDAC so as to provide molar ratios with reactive amino-acids ranging 
from approximately 1:1 to 20:1. According to Haurowitz (1963), the molecule of OA !
contains 84 carboxylic groups in glutamate and aspartate residues, 36 hydroxyl groups 
in serine residues, 9 phenolic groups in tyrosine residues and 5 sulfhydryl groups
■■ft
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associated with cysteine/cystine. In calculating the EDAC : protein ratios, it was 
assumed that all of these groups w ould be reactive. OA at 4 mg protein per ml 
corresponds to 11.832 mM  of all the above groups taken together. Thus EDAC at 11, 
21, 55,110  and 220 mM with OA at 4 mg/ml was calculated to provide ratios o f EDAC 
to total reactive groups o f 1:1, 1:2, 1: 5, 1: 10 and 1: 20. The preparations from  these 
were labelled respectively O A -E (ll) , 0A -E (21), OA-E(55), O A -E (llO ) and OA- 
E(220).
It may be noted that the treatment with 21 mM EDAC was the same as used by 
Christodoulides et al. (1987) for toxoiding PT except that the latter was at 50 pg/ml.
Effect of EDAC on SDS-PAGE profiles
The above EDAC-treated samples were heated at a lOO^C in solubilizing buffer and 
then run on a 12.5% SDS-polyacrylamide gel, with the results shown in Fig. 13. The 
major band in each lane is due to OA at 45 KDa or modified OA at an apparently lower 
value of about 40 KDa. There appeared to be both bands in lane 7, while in lane 3, the 
40 KDa band was much thickened. The proportion o f the faster-m igrating material 
increased with the severity of EDAC treatment. At the highest ratio of EDAC to protein 
(lane 3), there was also evidence o f polymeric material at the top o f the lane. It was 
clear that EDAC had had a significant effect on the electrophoretic mobility o f OA.
Anti-OA ELISA
In setting up the ELISA for measuring m ouse anti-OA IgG, it was first necessary to 
determine the appropriate concentration of OA for coating the wells in the microtitre 
plate. Fig. 14 shows the effect of a 125-fold range o f OA coating concentrations on the 
A 4 9 2  values given by 10-fold dilutions of a pool of the 40 anti-OA sera from the 
experiment described below. From this figure, a coating concentration of 100 pg/ml 
was chosen as giving a satisfactory result, i.e the serum endpoint titres increased about
94
F ig u re  13: E ffect o f ED A C on th e  SD S-PA G E pro file  o f ova lb u m in . O A
and various EDAC-treated OA preparations were run on a 12.5% polyacrylamide gel. 
Each lane was loaded with 10 jig of protein. From left to right the lanes contained the 
following:
Lane Sample
1 Sigma standards MW-SDS-70 kit^
2 OA
3 OA-E(220)
4 OA-E(llO)
5 OA-E(55)
6 O A -E (ll)
7 0A-E(21)
8 Sigma standards MW-SDS-200^
 ^Sigma standards M W SDS-70 kit contained a mixture of the following proteins : 
lysozyme (14.3 kDa), beta-lactoglobulin (18.4 kDa), trypsinogen (24 kDa), pepsin 
(34.7 kDa), ovalbumin (45 kDa) and bovine plasma albumin ( 6 6  kDa).
Sigma standards M W -SDS-200 kit contained a mixture of the following proteins : 
carbonic anhydrase (29 kDa), ovalbumin (45 kDa), bovine plasma albumin ( 6 6  kDa), 
phosphorylase B (97.4 kDa), beta-galactosidase (116 kDa) and myosin (205 kDa).
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Figure 14: Effect of OA coating concentration on the A492  nm the 
ELISA on mouse anti-OA. The wells of microtitre plates were coated with OA at 2 
jig/ml 10 |ag/ml (D), 50 |ag/ml (A), 100 jig/ml (o ) and 250 |Lig/ml ( • ) .
I
2 . 0
1 . 0
A492 nm=0.5
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9-fold when the coating concentration was increased from 10 to 100 jig/ml but were 
little improved when 250 jig/ml was used.
Effect of EDAC and AI(OH)3 on immunogenicity
The object of these experiments was to determine whether EDAC treatment of OA had 
an enhancing, depressing or no effect on antibody production. A l(OH )3  was included 
as a further component for possible adjuvanting. OA-E treated with EDAC at 21mM 
only was used in this experiment. Both OA and OA-E(21) were tested as soluble 
antigens and after mixing with an equal weight of Al(OH)3 . In each of two independent 
experiments, experiment A and experiment B, (with separately prepared batches of OA- 
E(21) teiTned O A -E(21,l) and OA-E(21,2) respectively) groups o f 5 mice were given 
either 0.1 or 1.0 mg doses o f these preparations i.p. and bled 21 days later. Table 6  
presents the arithmetic titres of the sera of all 80 mice while Fig. 15 summarize the data 
as bar charts of the group geometric means (g.m.) with 95% CL. Visual inspection of 
this figure suggests that (a) the two experiments gave qualitatively similar results, (b) at 
the 0.1 mg dose, EDA C treatment reduced  the im m unogenicity of OA, and (c) 
A 1(0 H )3  had an adjuvant effect but only in some instances.
In order to investigate further the influence o f each variable on anti-OA 
production, multifactorial analysis o f variance was performed (Table 7). The two 
independent experiments showed that EDAC had a highly significant (**) repressive 
effect on anti-OA formation, while A 1(0 H )3  had a significant adjuvanting effect; 
however, dose was influential in experiment B but not in A. As regards the interaction 
terms, the two experiments differed: experiment B showed no significant interactions 
between the variables, whereas in experiment A there was significant interaction of 
doses X EDAC and Al(OH )3  x EDAC. The highly significant doses x EDAC term in 
experim ent A showed that in these mice, EDAC reversed the negative slope of 
response on dose and also significantly repressed the adjuvanticity o f Al(OH)3 .
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T ab le  6 : E ffect o f ED A C on th e  im m unogen icity  o f O A  in m ice; also the 
effect of immunizing the animals at 0.1 and 1.0 mg, with and without Al(OH ) 3  added 
to the treated or untreated OA. The ELISA titres are from two experiments A and B 
with independently made preparations of EDAC-OA (0A -E(21,1) and OA-E(21,2)^ 
Geometric mean titres are shown in bold.
Anti-OA ELISA titre of individual mice and group g.m. after immunization with (mg):
OA OA-E(21)
plain A1(0H)3 plain A1(0H)3
0 . 1 1 . 0 0 . 1 1 . 0 0 . 1 1 . 0 0 . 1 1 . 0
Expt A 5000 1825 7200 38000 8350 11300 875 19800
4050 9965 9950 6500 1975 2875 1775 6700
3100 12250 24500 2 0 0 0 935 4700 1225 8075
5300 2 0 0 0 38000 18250 345 3850 430 7350
5400 3050 32000 2 0 0 0 4100 1850 1 0 0 0 4600
4 4 7 5 2 6 5 3 1 8 4 4 2 7 0 9 9 1 8 5 4 4 0 5 0 9 6 1 8 1 6 2
Expt B 5500 6950 9500 23500 385 7600 915 6600
8500 1700 5350 9700 1800 70 775 8100
2775 5600 4050 36000 3500 6650 1230 7550
1275 9200 570 2850 50 4050 2250 7100
5800 5700 7900 2 0 0 0 0 55 4450 3000 7800
3 9 4 6 5 1 0 7 3 9 2 3 1 3 6 1 5 3 6 7 2 0 1 9 1 4 2 5 7 4 1 3
 ^ Mice were immunized with a single-shot dose of antigen and bled 21 days later. 
A1(0 H )3  was used at equal weights of antigen, i.e. 0.1 or 1.0 mg/mouse for the 0.1 or 
1 .0  mg/mouse dose .
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Figure 15: Effect of EDAC and Al(OH )3  on the logio anti-OA ELISA  
titres from mice. Each bar represents the geometric mean titre from a group of five 
mice and the vertical line the upper 95% CL. OA (□ ) ,  OA-E (21,1) and OA-E (21,2) 
for experiment A and B respectively (Q), OA with Al(OH)3 (□ ), OA-E(21,l) and OA- 
E (21,2) with A1(0H)3 O ) .
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T ab le  7: A nalysis o f v a ria n ce  on th e  effect of dose, ED A C  an d  A 1(0 H )3  
on th e  p ro d u c tio n  o f an tl-O A  in m ice from  tw o In d ep en d en t exp erim en ts
A and  B. Multifactorial analysis was performed on the log lo anti-OA titres.
Source of variation Mean square 
E xptA  ExptB
F value 
Expt A Expt B
i
Doses &246 2.780 1.76 11.04**
A1(0H)3 0.704 1.554 5.03* 6.17*
EDAC 1.264 2.858 9.03** 11.34**
Doses X A 1(0 H )3 0 . 1 0 1 0 . 1 0 2 0.72 0.41
Doses X EDAC 2.281 0.404 16.3** 1.61
A1(OH)3x EDAC 0.655 0.334 4.68* 1.32
Doses X AI (OH) 3 x EDAC 0.378 0.128 2.70 0.51
Residual 0.140 (X252 - -
Tabulated F value for 1 and 28 degrees of freedom at P = 5% is 4.20 (*) and at the P = 
1% is 7.64(**).
I
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In a follow-up study, experiment C, OA was treated with EDAC at the four 
concentrations listed above. M ice were immunised with 0.01, 0.1 or 1.0 mg/mouse of 
OA, O A -E (ll) , OA-E(55), O A -E (llO ) and OA-E(220) with bleeding on day 21. 
Initially, the sera were titrated from a starting dilution of 1:100. However, the anti-OA 
responses were very low in some sera in that there was no detectable antibody in 19 out 
o f the 75. These sera were therefore retested from a 1:10 starting dilution. ELISA titres 
and group geometric means are given in Table 8  and the results are summarized as bar 
charts w ith 95% CL in Fig. 16. The main conclusions were that (a) the lowest dose, 
0 . 0 1  mg, of each preparation stimulated lower titres of antibody than the two higher 
doses and (b) EDAC treatment had an adjuvanting effect, with the 0.01 mg dose, and a 
repressive effect with the two higher doses.
In an attempt to gain further insights into the results, the titres were analyzed as 
for a 6 -point parallel-line assay which is depicted diagi’amatically in Fig. 17. The output 
of the analysis of variance (Table 9) shows a highly significant effect o f dose (the slope 
term), but complex effects of the other factors. Only O A -E (ll)  significantly reduced 
antibody response when compared with OA alone. In Fig. 16 the diagrams 1 and 2, for 
OA-E(l 1) and OA-E(55) each compared with OA, show lack o f parallelism between the 
2 dose-response lines. Diagrams 2 and 3 show the "simple kinking" which is supported 
by significance for "quadratic curvature" while "difference of quadratics" is illustrated 
by the curves in diagrams 1 and 2 .
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T a b le  8  : E ffec t o f ED A C  on th e  im m u n o g en ic ity  o f OA in m ice 
(experim ent C); EDAC-treated OA preparations O A -E (ll) , OA-E(55), O A -E(llO ), 
OA-E(220) were injected in groups of five m ice and anti-OA ELISA titres were 
obtained.
i
Anti-OA ELISA titres (and group g.m.) after immunisation with 
the following doses of antigen preparation (mg/mouse) 
0.01 0.1 1.0Sample
OA 8 8 3050 337551 1 2 0 0 2950' 34 920 2700
17 675 860
16 505 820
33 1 0 2 8 1 8 0 3
O A-E(ll) 450 415 4350
285 94 630
108 72 480
45 41 195
2 0 la 108
105 41 4 8 8
OA-E(55) 700 860 965
650 315 950
615 215 770
455 1 2 0 620
170 24 565
4 0 5 176 757
OA-E(llO) 845 6200 3900
790 840 2900
43 800 1250
41 705 870
40 435 715
137 1 0 5 0 1 5 4 5
OA-E(220) 1 1 0 0 4700 2125
105 3600 1400
85 440 1350
57 330 710
23 1 2 670
105 4 9 4 1 1 3 8
 ^An arbritary value of 1 was assigned to this serum for purposes of statistical analysis 
since anti-OA levels were similar to normal serum.
i
1 0 2
F ig u re  16: E ffec t o f ED A C  on th e  im m u n o g en ic ity  o f O A . E ach  ba r 
represents the geometric mean anti-OA ELISA titre from a group o f five m ice and the 
vertical lines the 95%  CL. Four EDAC-treated OA preparations were used. OA (O ) ,  
O A -E (ll) (:□), OA-E(55) # ) ,  O A -E(llO ) ( 0 ), OA-E(220) (S ) .
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F ig u re  17; A n tib o d y  resp o n ses  o f m ice to im m u n iz a tio n  w ith  E D A C - 
trea ted  OA. The four diagrams are plots of logio geometric mean titres of untreated 
OA (o) and EDAC-treated OA (•) preparations. Diagrams 1 ,2 , 3, 4 denote responses 
obtained after immunization with OA treated with EDAC at 11, 55, 110 and 220 mM 
respectively.
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T ab le  9: A nalysis of v a r ia n ce  on the effect of ED A C  on th e  p ro d u c tio n  
o f an ti-O A  in m ice (experim en t C). Summary statistics are presented from  6 - 
point parallel line assays.
Source of variation O A -E (ll)
F-values
OA-E(55) OA-E(llO) OA-E(220)
Slope 20.97** 41.12** 53.40** 31.85**
Preparations 4.48* 0 . 0 0 1.40 0 . 0 1
Parallelism 4.41* 25.16** 3.20 2.03
Quadratic curvature 0.03 10.57** 8.80** 3.53
Difference of 
quadratics
8.96** 19.21** 0.60 1 .2 1
Tabulated F value for 1 and 24 degrees of freedom at P = 5% is 4.26 (*) and at the P 
1% is 7.82 (**).
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Experiments With Lysozyme 
Effect of EDAC, formaldehyde and glutaraldehyde
Different considerations were adopted for planning the treatment of LZ with EDAC 
from  those used with OA. In particular, it was decided to use the conditions of 
treatment with EDAC, formaldehyde and glutaraldehyde which had been applied by 
other workers to the detoxification of bacterial protein toxins. Thus, LZ at 4 mg/ml 
(final concentration) in intial experiments was treated with 21 mM EDAC at pH 5.0 for 
24 h at 37°C as used by Christodoulides et al. (1987) for detoxification o f PT which 
was%t 50 p-g/ml. Subsequently, 200, 400 and 800 mM EDAC were also used.
With form aldehyde, LZ (4 mg/ml) was treated for 168 h with 25 mM 
formaldehyde as used by Porro et al. (1980) for diphtheria toxin at 4.36 mg protein/ml 
except that the treatment was performed at 37 °C instead of 2 2  <^ C; in a later experiment, 
12.5 and 6.25 mM formaldehyde were also employed. Similar treatments were done in 
the presence of lysine at concentrations equal to 80% of the molarities of formaldehyde.
W ith glutaraldehyde, LZ (4 mg/ml) was treated for 2 h with 2.5 mM of the 
reagent used by M unoz et al. (1981a) for the detoxification o f PT (final protein 
concentration not stated) except that the treatment was performed at 37 °C instead of 
22 °C. Lower concentrations of 0.625 and 0.312 mM were also employed. All 
mixtures at the end of 2 h were treated with lysine at levels equivalent to 4 times that of 
the glutaraldehyde so as to neutralize it before dialysis.
Enzyme activity : The effects of the above chemical treatments on the enzymic activity 
of LZ was monitored by bacterial lysis tests with Micrococcus lysodeikticus (Table 
10). It is apparent that all three toxoiding agents caused loss of enzymic activity, with 
formaldehyde and glutaraldehyde treatments abolishing it completely, i.e. > 99% loss 
of enzyme activity.
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Table 10: Effect of EDAC, form aldehyde and glutaraldehyde on LZ 
enzyme activity: EDAC, formaldehyde and glutaraldehyde treatments were for 24, 
168 and 2 h at 37°C respectively. Loss of activity was followed by the lysis of M . 
luteus cells spectrophotometrically at A4 95  nm
Treated preparation % loss in activity 
Expt 1 Expt 2 Mean
LZ-E(21,1) 33.3 nt -
LZ-E(21,2) 34.4 43.7 39.1
LZ-E(21,3) 37.0 nt -
LZ-E(200) 49.0 nt -
LZ-E(400) 38.0 nt -
LZ-E(800) 43.0 nt -
LZ-F(25) >99.9 nt -
LZ-F(12.5) >99.9 nt -
LZ-F(6.25) >99.9 >99.9 >99.9
LZ-F(25) Lys(20) >99.9 >99.9 >99.9
LZ-F(12.5) Lys(lO) >99.9 >99.9 >995)
LZ-F(6.25) Lys(5) >99.9 >99.9 >99.9
LZ-G(2.5) >99.9 nt -
LZ-G(1.25) >99.9 nt -
LZ-G(0.625) > 9 9 ^ nt -
LZ-G(2.5) Lys(lO) >99.9 nt -
LZ-G(1.25) Lys(5) >99.9 nt -
LZ-G(0.625) Lys(2.5) >99.9 nt -
LZ-G(2.5) Lys(10)a >99.9 nt -
LZ-G(L25) Lys(5)a >99.9 nt -
LZ-G(0.625) Lys(2.5)a >99.9 nt -
^Lysine was added to the m ixture at the beginning of the reaction and at the end in 
separate preparations which were incubated for a further 15 min before dialysis, 
nt = not tested
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With both formaldehyde and glutaraldehyde this result was independent of whether or 
not lysine was present. EDAC differed from the two aldehydes in leaving between 33 
and 49% of the original activity intact, and with very little regular effect with EDAC 
concentrations over the range 21 to 800 mM.
SDS-PAGE profile  Fig, 18 shows SDS-PAGE profiles for LZ and the four LZ~E 
preparations, and indicates that the EDAC had produced a reduction in mobility of the 
main 14.3 KDa band due to LZ itself, together with dimers in the 24 to 29 KDa range. 
Increasing the EDAC concentration from 21 to 800 mM caused progressive changes in 
SDS-PAGE profile. Thus the lowest level of EDAC produced a small reduction in 
mobility together w ith a very prominent dimer band. As the concentration of EDAC 
was raised, the mobility of the main component decreased and at 800 mM EDAC also 
appeared to be attenuated. Meanwhile the intensity of the dimer bands decreased and 
appeared to have disappeared after treatment with the highest level of EDAC.
The effect of formaldehyde and glutaraldehyde treatments on the SDS-PAGE 
profile of LZ is shown in Fig. 19. Treatment with either formaldehyde, glutaraldehyde 
or EDAC (21 mM) gave consistently a dimer band (between 24-29 KDa). Moreover the 
intensity of this band corresponded to the concentration of the reagent. Thus the dimer 
band is only barely discernible with the 6.25 mM formaldehyde and is very pronounced 
with formaldehyde at 25 mM; the addition of lysine appeared to have little modifying 
effect. In the region above the dimer bands, there was evidence of higher polymers but 
exact molecular weights could not be assigned.
With glutaraldehyde (Fig. 19), the dimer bands were well developed as with 
foraialdehyde, and at the highest concentration of agent there was a strong band just 
below the stacking gel (lanes 11 and 17) corresponding to a high degree of 
polymerization. In these particular lanes, the extra protein at the top o f the gel was 
accompanied by weaker staining of the monomeric LZ band. Addition of lysine to the
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F ig u re  18: E ffect o f ED A C on th e  SD S-PA G E profile of lysozym e: eac h  
lane was loaded with 10 pi o f the preprations described below and run on a 12.5% 
polyacrylam ide gel. From left to right the lanes contain the following:
Lane Sample
1 SDS-70 MW standards^
2 LZ
3 LZ-E(21,3)
4 LZ-E(200)
5 LZ-E(400)
6 LZ-E(800)
7 SDS-200 MW standards^
3 See foootnotes to Figure ; 13 (p 94)
i . î  1 1  î : î   L
2 4 .
18 -4 .
" f^;Xyy
1 4 3 .
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Figure 19: Effect of EDAC, formaldehyde and glutaraldehyde on the 
SDS-PAGE profile of LZ; each sample was loaded into the lanes of a 12.5% 
polyacrylam ide gel as described below:
Lane Sample
1 LZ-F(6.25)
2 LZ-F(12.5)
3 LZ-F(25)
4 LZ-F(6.25) Lys(5)
5 LZ-F(12.5) Lys(lO)
6 LZ-F(25) Lys(20)
7 LZ-E(21,3)
8 SDS-6 H MW standards
9 LZ
1 0 SDS-7 MW standards
11 LZ-G(2.5)
1 2 LZ-G(1.25)
13 LZ-G(0.625)
14 LZ-G(2.5) Lys(lO)
15 LZ-G(L25) Lys(5)
16 LZ-G(0.625) Lys(2.5)
17 LZ-G(2.5) Lys(10)a
18 LZ-G(L25) Lys(5)a
19 LZ-G(0.625) Lys(2.5)a
A fter glutaraldehyde treatment, lysine was added and the i
incubated for a further 15 min before dialysis.
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system at the beginning of the treatment with glutaraldehyde allowed formation of 
dimers but appeared to discourage the development of higher polymers.
There appeared to be little effect of formaldehyde or glutaraldehyde on the 
mobility of the monomeric band and the apparently decreased mobility at the edges is 
attributed to uneven current during electrophoresis.
Im m u n o g e n ic ity
Ejfect o f  EDAC'. In an initial experiment on the effect of EDAC on LZ immunogenicity,
the enzym e was treated with EDAC at 21 mM, The dose-response of mice to
immunization with LZ and LZ-E(21,3) was exam ined in groups of 5 animals which
were injected i.p with 0 .0 0 1 , 0 .0 1 , 0 . 1 , 1 .0  and 1 0  mg/mouse of the two preparations.
Anti-LZ quantitation of the sera by ELISA was done at a starting dilution of 1:100 and
the data tabulated (Table 11) as the arithmetic titres, with g.m. values. Those sera with 
.titres <100 were found by extending and extrapolating the line to the A4 9 2  = 0.5 level. 
It will be noted that LZ-E was toxic at the top dose in that 4 out of the 5 mice died, the 
deaths occurring between 24 and 48 h after inoculation. Inspection of Table 12, which 
summarizes the statistical analysis of these titres, showed that EDAC at 21 mM had no 
m ajo r effect on the im m unogenicity of LZ as shown by the non-significant 
preparations term. However, the single surviving animal after the 10 mg dose of LZ-E 
had a higher titre than any of the five animals with unmodified LZ at 10 mg.
To investigate the toxicity of EDAC-treated LZ, the same preparation as used 
above was retested with and without further extensive dialysis ( 2 x 3  days), in case 
EDAC itself was responsible for the toxicity. Three groups of five m ice were injected 
with 10 mg of LZ or of the two preparations of LZ-E(21,3). The m ice were weighed 
initially and then observed closely for condition and were reweighed (Table 13). Most 
of the m ice showed a small loss in weight after 24 h while at 48 h there were two 
deaths in each of the two groups receiving LZ-E. Moreover, the surviving animals in
:
i
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T ab le  11 : E ffect o f dose on th e  im m unogenicity  o f LZ an d  L Z -E  in m ice 
(p re l im in a ry  ex p e r im en t) . M ice were im m unized with five ten-fold spaced 
dilutions over the range 0 .0 0 1  to 1 0  mg/mouse.
Anti-LZ ELISA titre (with group g.m.) after immunization (mg/mouse) of;
LZ LZ-E(2I,3)
0 . 0 0 1 0 . 0 1 0 . 1 1 . 0 1 0 . 0 0 , 0 0 1 0 . 0 1 0 . 1 1 . 0 1 0 . 0
144 80 4050 6300 6250 1 0 0 2 0 1 0 2 0 0 8300 died
115 1 0 0 1575 2450 2400 1 118 3425 1350 died
128 448 448 690 3800 125 65 238 1375 10625
11 2 1 90 1550 1625 18 50 1 0 0 7300 died
1 2 370 370 680 2150 8 1 0 0 2 0 1675 died
4 9 123 6 2 5 1 6 2 2 2 8 8 3 18 151 2 0 1 4 5 1 7 -
■s
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T able 12: A nalysis of variance ; the effect o f dose on the
im m unogenicity o f LZ and LZ-E (preliminary experim ent). S u m m a ry  
statistics from the 6  point parallel-line assay are given below.
Source of variation Mean square F-value
Slope 7.192 20.63**
Preparations 0 . 0 2 1 0.06
Parallelism 0.031 0.09
Quadratic cuiwature 0.225 0.64
Difference of quadratics 0.725 0.64
Residual 0.349 -
Tabulated F value for 1 and 24 degrees of freedom at P = 5% is 4.26 (*) and at the P 
1% is 7.82 (**).
%
113
T able 13: Toxicity o f L Z -E  ; groups of five m ice were injected with LZ or LZ- 
E(21,3) at a fixed dose of 1 0  mg/mouse. Animals were weighed daily and their health 
observed.
Preparation Weight o f mouse in g (and weight change from day 0)
on day ;
0 1 2
LZ 25 26 (-1 ) 25(0)
25 25 (0) 24 (-1)
23 24 (+1) 23(0)
30 29 (-1) 29 (-1)
24 24 (0) 24(0)
(Av = + 0.2) (Av = -0.4)
LZ-E(21,3) 26 25 (-1)* 26 (0 )**
23 22 (-1)* died
27 26 (-1 )* 28 (+ 1 )**
25 24 (-1)* died
27 25 (-2)* 25 (-2)**
(Av = -1.2) (Av = -0.3)
LZ"E(21,3) twice dialysed 26 24 (-2)* died
26 24 (-2)* 24 (-2)**
26 24 (-2)* 25 (-1)**
2 2 22 (0)* died
26 25 (-1)* 27 (+1)**
(Av = -1.4) (Av -  -0.4)
* sick ; ** moribund, experiment terminated.
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these groups were all moribund and had to be put down, whereas the animals given 
untreated LZ were active and healthy. It seemed clear therefore that EDAC treatment 
definitely made LZ toxic for m ice although a relatively high level (10 mg) had to be 
used to demonstrate it.
Ejfect o f  EDAC and A l(0H )3  : As reported above, AI (OH)] had a significant adjuvant 
effect with OA and it was therefore of interest to determ ine whether there would be a 
similar effect on LZ and LZ-E. For this latter purpose, LZ-E prepared with EDAC at 21 
mM  was used. The two preparations were m ixed with equal weights of Al(OH)] and 
inoculated i.p into groups of 5 m ice at doses of either 0.1 or 1.0 mg per animal in two 
separate experiments involving a total of 80 mice. Anti-LZ titres were obtained by 
ELISA on sera taken at 21 days after inoculation. Table 14 presents the individual titres 
and the g.m. for each group. Fig. 20 is a bar chart plot of these data with 95% CL and 
shows that (a) both EDAC and Al(OH)] had an appreciable adjuvant effect and (b) the 
two doses gave similar high titres.
These two conclusions were confirmed by analysis of variance (Table 15) in 
which only AI(OH)] and EDAC were consistently significant variables (P<1%, P<5%, 
respectively) and the doses term was not significant. None of the interaction terms was 
significant except doses x Al(OH)] in one experiment.
Effect o f  ED AC, form aldehyde and glutaraldehyde : In order to compare the effect of 
the three different toxoiding agents on the immunogenicity of LZ, experiment C was 
conducted where some of the same preparations exam ined above in SDS-PAGE and for 
enzymic activity were injected into mice. Four preparations of LZ-E , two of LZ-F, and 
two of LZ-G were compared with untreated LZ at doses of 0.1 and 1 mg in groups of 
five m ice. The particular form aldehyde and glutaraldehyde samples chosen were 
selected because they showed high levels of inactivation of enzyme activity compared
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T a b le  14 : E ffec t o f ED A C  on th e  im m u n o g en ic ity  o f L Z  in  m ice 
(experim ent A an d  B); also the effect of immunizing the animals w ith and without 
A 1(0 H ) 3  added to the trea ted or untrea ted LZ. The ELISA  titres are from  two 
experiments A and B with independently made preparations of EDAC-LZ^ > LZ-E(21,1) 
and LZ-E(21,2) respectively..
Anti-LZ ELISA titre of individual mice and group g.m. after immunization with (mg) :
LZ LZ-E(21)
plain A1(0H)3 plain A1(0H)3
0 . 1 1 . 0 0 . 1 1 . 0 0 . 1 1 . 0 0 . 1 1 . 0
ExptA 2500 2371b 285 1900 5100 6350 1750 5200
1950 1 1 0 0 480 1500 1400 4400 3500 5950
625 4400 490 11500 2500 6050 2025 8750
4400 2150 738 3400 1800 2700 1900 950
1750 1700 325 4300 3400 9000 315 5300
1 8 7 9 2 1 1 9 4 3 8 3 4 3 7 2 5 5 7 1 4 9 3 5 2 8 2 4 2 3 6
Expt B 738 275 7750 18000 13000 430 6400 33000
430 628 1 1 0 0 0 14750 1 2 0 0 4200 1 0 0 0 0 7750
7000 26500 180 17000 3350 30500 57500 19000
3000 425 300 14750 3900 2450 2 0 0 0 0 43000
95 2950 29000 32500 9500 7550 4900 47000
9 1 3 1 4 1 8 2 6 6 0 1 8 4 9 3 4 5 4 4 3 9 9 6 1 2 9 2 4 2 5 0 2 6
 ^ M ice were immunized with a single-shot dose of antigen and bled 21 days later. 
A 1(0 H )3  was used at equal weights of antigen, i.e. 0.1 or 1.0 mg/mouse for the 0.1 or 
1.0 mg/mouse dose b The missing titre was calculated as outlined in Wardlaw, (1985)
;1
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Figure 20: Effect o f EDAC and AI(OH)3  on the logic anti-LZ ELISA  
titres from mice; each bar represents the geometric mean titre from a group of five 
mice and the vertical line the upper 95% CL. LZ (□ ), LZ-E (21,1) and LZ-E (21,2) for 
experiment A and B respectively (Q ), LZ with Al(OH)3 ( [ ] ) ,  LZ-E(21.1) and LZ-E 
(21,2) with A1(0H)3 (H ).
Experiment A
I
3 -
2  -
1 ’
A
0 . 1
X
i 1 -
Experiment B
I
0 . 1
o
THtSDO
2  -
X
0.1
4 -
1 -
Dose (mg/mouse) 0,1
X . 1
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T ab le  15: A nalysis of v a r ian ce  on the effect of dose, ED A C  and  A I(O H ) 3  
on the p ro d u c tio n  o f an ti-L Z  in m ice from  tw o in d e p en d en t ex p er im en ts
A and B. Multifactorial analysis was performed on the log lo anti-LZ titres.
Source of variation Mean square F value
Expt A E xptB ExptA ExptB
Doses 0.354 0 .100 3.93 2.50
A1(0H)3 1.838 5.008 20.42** 12.51**
HDAC 0.832 2.413 9.24** 6.03*
Doses X  A 1(0 H )3 0.602 0.617 6 .6 8 * 1.54
Doses X  EDAC 0.006 0.402 0.06 1.00
A1(0H)3 X  EDAC 0.020 0.068 0 .20 0.17
Doses X  A 1(0 H )3  x  EDAC 0.311 0.059 3.45 0.15
Residual 0.090 0.400 - -
Tabulated F value for 1 and 28 degrees of freedom at P = 5% is 4.20 (*) and at the P 
1% is7 .64(**).
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with the 30 to 40% inactivation produced by EDAC. Double the number of mice, i.e. 
two independent groups bu t w ith the same LZ preparation, w ere used for the 
immunizations with LZ alone. This was done because the sera from these groups were 
destined to serve as comparators for the sera raised against the various treated LZ 
preparations. Despite using the same preparation in this way, there were appreciable 
differences in the medians and the g.m.s from the two plain-LZ groups (Table 16, rows 
1 and 2 at 0.1 mg/mouse and rows 11 and 12 at 1.0 mg/mouse). Figure 21 summarizes 
the results as bar charts with 95% CL for all the groups except LZ-B where the results 
were suspect.
Statistical analysis of the data was done by assembling them as a series of 4- 
point parallel-line assays in which each of the treated LZ preparations was compared in 
turn with both LZ-A and LZ-B. Table 17 shows that substantially different results were 
obtained depending upon which of the two plain LZ results was taken as standard. 
Thus w ith LZ-A, none of the chem ical treatments had any significant effect on 
immunogenicity since the " preparation" terms in the analysis o f variance were non­
significant. In contrast when LZ-B was taken as standard, all of the chem ical treatments 
had an adjuvanting effect. The table also shows that the chem ical treatments had veiy 
little effect on the "slope" and "parallelism" terms in the analysis of variance.
The overall conclusion from this experiment was that the chem ical treatments, 
some of which caused more than 99% inactivation of enzymic activity, certainly did not 
diminish the immunogenicity of LZ but it is difficult to say exactly by how much they 
may have enhanced it.
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T ab le  16: E ffec t o f E D A C , fo rm a ld e h y d e  a n d  g lu ta ra ld e h y d e  on th e  
im m unogen ic ity  o f L Z  in m ice (exp er im en t C); groups of five m ice were 
immunized with 0.1 and 1.0 mg/mouse of untreated LZ and certain preparations o f 
EDAC-treated LZ, formaldehyde-treated LZ and glutaraldehyde-treated LZ.
Preparation 
and dose
Anti-LZ ELISA titre (and group g.m.)
0 . 1  m g /m ou se
LZ-A 2 2 0 0 5650 158 510 4100 1 3 2 7
LZ-B 1 0 2 50 410 1 0 640 106
LZ-E(21,3) 2 0 0 0 525 910 845 790 1 4 4 9
LZ-E(200) 3050 500 300 950 435 7 1 7
LZ-E(400) 1250 190 565 338 510 47 1
LZ-E(800) 670 6 8 545 24 1275 2 3 8
LZ-F(6.25) 1700 153 2975 920 740 8 8 0
LZ-F(6.25)Lys(5) 7850 330 5600 820 245 1 2 3 9
LZ-G(2.5) 4350 3650 1400 2750. 910 2 2 3 4
LZ-G(2.5)Lys(10) 1650 3125 1150 1950 850 1 5 8 0
1 . 0  m g /m ou se
LZrA 230 1400 1115 80 830 7 9 3
LZ-B 575 130 230 160 590 2 6 9
LZ-E(21,3) 2525 560 3100 6300 2025 2 2 3 5
LZ-E(200) 890 270 375 325 7050 7 3 0
LZ-E(400) 3600 2800 285 130 780 7 8 1
LZ-E(800) 2525 790 225 5600 1900 1 367
LZ-F(6.25) 655 1150 760 8150 2350 1 6 1 4
LZ-F(6.25)Lys(5) 1145 850 455 8900 6100 1 8 8 8
LZ-G(2.5) 2950 445 540 815 4200 1193
LZ-G(2.5)Lys(10) 2180 1720 1975 490 6350 1874
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Figure 21: Effect of EDAC, formaldehyde and glutaraldehyde on the 
immunogenicity of LZ in mice (experiment C); each bar represents the 
geometric mean titre from a group of five mice and the vertical line the upper 95% CL. 
LZ-E(21,3) (B ), LZ-E(200) (ES), LZ-E(400) (B ) , LZ-E(800) (S ) ,  LZ-F(6.25) (Q ), 
LZ-F(6.25)Lys(5) (B ), LZ-G(2.5) (Q ) and LZ-G(2.5)Lys(10) ( a )  LZ (□ )
C /3 0
2  -
3 -
0
0 . 1
0.1 Dose (mg/mottse) ^
Figure 21 continued
4 “1
3 -
IIÏI
1 "
0 . 1 0 , 1
3 "
1 -
JL
2  -
1 -
i
0. 1 Dose (mg/moose) 0.1
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Table 17: Analysis of variance; effect of EDAC, form aldehyde and 
glutaraldehyde on the immunogenicity of LZ (experiment C). F o r each 
preparation , replicate ELISA titt’es from groups of five mice were analysed against two 
untreated LZ samples, LZ-A and LZ-B by the 6  point parallel-line assay. F-values and 
the level of significance is given below.
Source of variation :
Sample Preparation Slope Parallelism
LZ-A LZ-B LZ-A LZ-B LZ-A LZ-B
LZ-E(21,3) 0.31 24.97** 0.31 4.77* 2.34 0 . 0 0
LZ-E(200) 0.03 9.78** 0.90 1.13 0.97 1.05
LZ-E(400) 0.31 7.77* 0.30 2.61 2.56 &25
LZ-E(800) 0.27 4.89* 0.33 6 .2 0 * 4.87* 0.53
LZ-F(6.25) 0.44 13.90** 0 . 1 2 2.27 1.77 0 . 1 2
LZ-F(6.25)Lys(5) 0 . 8 6 1 2 .2 2 ** 0.18 1 . 2 2 1.05 0.19
LZ-G((2.5) 2.14 24.70** 2.81 0.13 0.17 3.06
LZ-G(2.5)Lys(10) T . 2 2 30.80** 0.99 1.85 1.93 0.90
Tabulated F value for 1 and 12 degrees of freedom at P = 5% is 4.75 (*) and at the P 
1% is 9.33 ( M .
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EFFECT OF TOXOIDING AGENTS ON B. P E R T U S S IS  ANTIGENS
Extraction and Characterization of PT and FHA
Pertussis toxin (PT), FHA and PT;FHA m ixed antigen preparations were extracted 
respectively from B. pertussis  353, B, pertussis 357 and B. pertussis 77/18319. 
Strains 353 and 357 were Weiss Tn5 mutants of B. pertussis 338 (Weiss et a i ,  1983). 
These strains were selected as they allowed the purification o f PT and FHA 
preparations free from each other.
An affinity-chrom atography method using B lue-Sepharose CL-6 B which 
contains the dye Cibacron blue (a stiaictural analogue of NAD) was chosen as it had
affinity for both PT and FHA (Sekura et al., 1983). Thus extraction of both antigens '■
was possible with the same batch of chromatography medium regenerated between 
separate runs.
Fractions were monitored for absorption at 280 nm, pooled, dialysed then 
tested for protein content. Table 18 lists the protein yields obtained from twelve FHA 
extractions, five PT extractions and four PTiFHA mixed-antigen preparations. Protein 
yields were usually higher after extraction of FHA from B. pertussis 357 (a.m.= 2.33 
mg/L) than PT (a.m .- 1.26 mg/L) or PT:FHA (a.m.= 1.05 mg/L) preparations.
Samples were run on SDS-containing polyacrylam ide gels to confirm the
I
presence of bands corresponding to the known MWs for PT and FHA. Figure 22 '■
shows the SDS-PAGE profiles of FHA-containing extracts from culture supernates of 
B, pertussis 357 obtained after staining of the gel with Coomassie blue. Intense bands 
corresponding in MW to the 205 KDa myosin marker are visible and are consistent
with the 200 KDa of undegraded FHA. The ladderlike patterns below the high MW 
bands appear to be degradation products of FHA. As seen from Figure 22, FHA-l had
...
fewer contaminating bands than FHA - 6  and FHA-7. Contamination with bands in the
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T ab le  18 : P ro te in  y ields fro m  e x tra c ts  of c u ltu re  s u p e rn a te s  of B .  
p e r tu s s is  p re p a re d  by gel-a ffin ity  c h ro m a to g ra p h y ; arithm e tic means are 
given in bold with SEM in parentheses.
Batch no. Strain Volume of 
culture (L)
Protein 
yield (mg/L)
FHA-1 B.p. 357 6 3.7
FHA-2 t t 4 1.3
FHA-3 1 I 4 1 . 8
FHA - 6 1 t 6 1.7
FHA-7 1 1 6 1.4
FHA - 8 t 1 6 2 . 1
FHA-9 1 1 1 0 3.4
FH A -10 t f 1 0 3.0
FH A -11 1 0 3.3
FH A -13 1 0 3.3
FH A -14 9 0 . 8
FH A -15 9 2.2
2 . 3 3
(0 .2 8 )
PT-1 B.p, 353 6 1.4
PT-2 6 1 . 8
PT-3 6 1 . 0
PT-4 9 0 . 6
PT - 6 1 0 1.5
1 .2 6
( 0 , 2 1 )
PT:FHA-1 B.p. 77/18319 6 1.3
PT:FHA-2 8 0.9
PT:FHA-3 1 0 1 . 0
PT:FHA-4 1 0 1 . 0
1 .0 5
(0 .0 9 )
î-i-
f
Î
:
!
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Figure 22 : SDS-PAGE profile of FHA preparations extracted from B .
pertussis  ; lanes were loaded with 20 p i of sample onto a 12.5% polyacrylam ide gel. 
Each lane contains the following :
Lane Sample
1 Sigma marker MW-SDS-70^
2 FHA - 6
3 FHA - 6
4 FHA-7
5 FHA-7
6 Sigma marker MW-SDS-200a
7 FHA-1
8 FHA-1
9 FHA-1
1 0 Sigma markers MW-SDS-70^
a See footnote to Figure 13 (p 94)
1 2 3 4  5I I I Î Î Î Î T
2 0 5 .
116. 
97 4_ S - I t  I
#  ^
s
t
■
I
.66
.45
.24
.18-4
.14-3
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region of 14 to 28 KDa, corresponding to subunits of PT, was undetectable.
F igure 23 shows SDS-PAGE profiles o f PT and PT:FHA m ixed antigen 
preparations after silver staining o f the gel. A number o f independently-purified 
preparations of PT and PT:FHA were obtained and run on the gel for purposes of 
comparison. The bands thought to correspond best with reported sizes for the subunits 
of PT and for FHA are indicated by arrows on the figure. Lanes 2, 4 and 6  contain PT 
preparations extracted from B, pertussis 353. Independently extracted preparations of 
PT can be seen in lanes 5 and 6 . Similarly, lanes 7 and 8  contained PT:FHA-4 and an 
antigen mixture prepaied by the same procedure independently; for comparison, lanes 9 
an d /10 show independently-purified mixtures of PT and FHA. It is clear from the 
picture that the preparations contain many other unidentified contaminating proteins. A 
faint band corresponding to the 205 KDa marker was noted in lanes 2  and 4 even 
though the strain from which the preparation was extracted had a transposon insertion 
mutation disallowing the production o f FHA. As adenylate cyclase (ACT) also is 200- 
210KDa, this band could perhaps have been ACT. These preparations were not further 
purified and samples PT:FHA-4, PT - 6  and AP16 were used for toxoiding and 
immunization of animals.
Western blotting was used to confirm that the extracts did contain PT and FHA, 
Probing of the protein bound to nitrocellulose with an anti-PT monoclonal antibody 
directed against the S i subunit (L iq) and an anti-FHA polyclonal antibody conjugated 
to horse radish peroxidase (Fg- HRP) were used. This process would also indicate 
whether the PT and FHA extracts from mutant strains were free from contamination by 
each other. F igure 24 shows the SDS-PAGE profile of certain PT, FHA and PT;FHA 
preparations of an aery 1 am ide gel stained with Coomassie blue after transfer of the 
proteins onto nitrocellulose. The gel shows prominent bands in lanes 2, 3 and 4 
corresponding to the S l S 2  and S3  subunits of PT. These bands are also faintly
1
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F ig u re  23 : SD S-PA G E profiles of P T  and  m ixed an tig en  p re p a ra t io n s  of 
PT  an d  FH A . The 12.5% polyacrylam ide gel was stained with silver. Each lane 
contains the following :
Lane Sample jag/lane
1 Sigma marker MW-SDS-70^ 5
2 PT-5 2
3 PT-5(a fetuin sepharose extract) 0.5
4 PT - 6  2
5 PT (independently purified reference) 2
6  PT(independently purified from 353) 2
7 PT:FHA-4 2
8  AP16(independently purified PT:FHA sample) 1
9 PT:FHA(independently purified PT:FHA sample) 2
10 PT;FHA(purified from fermentor grown organisms)2
11 Sigma marker MW-SDS-200a 5
 ^See footnote to Figure 13 (p.94)
I
■I'i:
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F ig u r e  24 : S D S -P A G E  p ro f i le  o f  P T , F H A  a n d  P T :F H A  m ix e d  a n t ig e n  
p r e p a r a t i o n s  p u r i f i e d  f r o m  B . p e r t u s s i s  3 5 3 , 3 5 7  a n d  7 7 /1 8 3 1 9  
re s p e c tiv e ly . E ac h  lan e  w as lo ad ed  o n to  a  12.5%  p o ly ac ry lam id e  gel w ith  20  fxg o f  
sam ple as fo llow ing  :
Lane Sam ple
1 S igm a m arker M W -SD S -200a
2 PT -6
3 PT -5
4 PT :FH A -3
5 P T :F H A -2
6 FH A -15
7 F H A -14
8 C A M -R  FH A
9 S igm a m arker M W -SD S-70^
^ S ee  foo tno te to  F ig u re  13 (p 94)
y
-
2 0 5 -
116.
8
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present in lane 5. There were fewer contaminating bands seen on this gel for PT-5 and 
PT - 6  preparations probably due to their transfer onto nitrocellulose. Heavily stained 
bands of 205 KDa are also clearly visible which may be FHA in lanes 4, 6  as they 
correspond to the purified FHA (CAMR) run in lane 8 . This gel was run in duplicate to 
allow samples to be probed with both anti-PT or anti-FHA specific antibody. Each lane 
was loaded with 20 pg of protein. Antigens were transfened at 80 mA in a tank 
containing transfer buffer. Blots were developed with chloronaphthol and shown in 
Figure 25, F igure 25a presents the blot probed with anti-PT L io  and Figure 25b the 
blot probed with polyclonal anti-FHA. It was noticed that both the gel and blots had 
background mottling after staining. By comparing Figure 25a and Figure 25b, PT was 
present in preparations PT-6 , PT-5, PT:FHA-2 and PT:FHA-3. Using this method, no 
PT was detected in FH A -14, FHA-15 or the CAMR FHA. From 25b, FHA was found 
in PT:FHA-3, FHA-15 and the reference CAMR FHA. Surprisingly, no FHA was 
detected in FH A -14 which was extracted from B. pertussis  357. Neither was any 
detected in PT-5, PT - 6  and PTtFHA 2. Nevertheless, there was no cross contamination 
o f PT or FHA extracts from the mutant strains as far as could be determ ined by this 
method.
PT-6 , PT:FHA-3 and PT:FHA-4 were tested for histamine-sensitizing activity 
which reflects the potency of PT present in these preparations. These preparations were 
inoculated into groups of two mice > 6  weeks old at a range of dilutions and challenged 
five days later with three mg/mouse of histamine. Mouse deaths were recorded and the 
H SD 5 0  was estimated. The H SD 5 0  for both PT - 6  and PT;FHA-4 was 250 ng, and 
1000 ng for PT:FHA-3.
A pooled batch of PT preparations 1, 2 and 3 and PT - 6  was tested for its ability 
to induce clustered growth o f Chinese hamster ovary (CHO) cells. Figure 26 shows 
photographs o f control CHO cells and cells treated with PT. Cells exhibited the 
morphology typical after exposure to PT, with clumped growth (Figure 26b) rather 
than the spreading pattern of control cells treated with buffer alone (Figure 26a).
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Figure 25: Western blots of PT, FHA and PT:FHA antigen preparations.
The gel shown in figure 24 was blotted onto nitrocellulose and the proteins transferred. 
Blot (a) was probed with a 1 in 1000 dilution of anti-PT monoclonal Ljo and blot (b) 
with a 1 in 1000 dilution of anti-FHA polyclonal F3 conjugated to HRP.
Blot (a) Blot(b)
Lane Sample Lane Sample
1 PT - 6 1 PT:FHA-3
2 PT-5 2 FHA-15
3 PT:FHA-3 3 CAM-R FHA
4 PT:FHA-2
1 2 3 4
A";
'  ■ I  \ /   ^ '• < 1
/
: C
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Figure 26 : Effect of PT on the morphology of Chinese Hamster Ovary 
(CHO) cells. Cells were exposed to (a) 100 mM Na2HP0 4  + 0.5M NaCl, pH 7.0 
or (b) 12.5 ng a pooled PT preparation of PT-1, PT-2 and PT-3. Magnification xlOO.
(b)
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PTiFHA preparations used for toxoiding and subsequent immunisation of mice 
were assayed for the quantity of each antigen present in the m ixture by ELISA. Using a 
sandwich ELISA method with fetuin as the coating phase, PT was probed with an anti- 
PT monoclonal antibody L iq . Similarly, F 2  IgG anti-FHA capture antibody was the 
coating phase in the sandwich ELISA technique used for the detection o f FHA. 
Standard PT was supplied (from Dr. R. Pai*ton) while the FHA standard came from 
CAMR. All samples were adjusted to 1 |ig/m l, with three fold dilutions of each 
preparation being made in PBS, pH 7.4 + 0.01% Tween 20. A plot of volume (ml) 
added per well of the 1 pg / ml solution against A 4 9 2  was made. The volume o f sample 
required to reach an A 4 9 2  = 1.2 was noted and used to calculate the amount of PT or 
FHA present in these preparations relative to each standard. The following PT : FHA 
ratios were calculated for each sample. PT:FHA-2, 4:1, PT;FHA-3, 2:3 and PT:FHA- 
4, 1:5. It was difficult to judge whether these results agreed with SDS-PAGE gel 
profiles PT:FHA-2 (Figure 24, lane 5), PT:FHA-3 (Figure 24, lane 4) and PT:FHA-4 
(F igure 23, lane 7). PT:FHA-3 and PT:FH A -4 were used fo r toxoiding and 
immunization.
Experiments with FHA
In vitro effects of EDAC, formaldehyde and glutaraldehyde
Ejfect on HA activity : Despite FHA being non-toxic, the treatment with toxoiding 
agents was done under the same conditions which were also em ployed for the 
detoxification o f PT, except that with formaldehyde the time was reduced from one 
week to 48 h. A summary of the standard treatment conditions with the three agents is 
presented in Table 19. However, independently of these standard conditions, the effect 
of varying the concentration, temperature and time was also investigated to provide 
additional infoimation.
132
Table 19 : Summary table of standard treatment conditions for exposure 
of FHA to toxoiding agents,
Toxoiding Concentration of Concentration o f Temperature Time Lysine 
agent FHA (pg/ml) agent (mM) (^C) (h) (mM)
Foimaldehyde 250 25 37 48 2 0
Glutaraldehyde 250 2.5 37 2 1 0
EDACa 250 2 1 37 24 N/A
^ Toxoiding conditions used by Christodoulides et al. (1987) for the detoxification of 
PT.
133
Loss of the HA activity of FHA was used to indicate the extent to which this 
protein had been modified by the various toxoiding treatments. In the case of treatments 
with formaldehyde and glutaraldehyde, the effect of adding lysine to the reaction 
mixtures was also investigated.
With formaldehyde, a modification of published conditions for inactivation of 
diphtheria toxin (Porro et al., 1980) and pertussis toxin (Sato et a i ,  1984) was used 
both as the basis for the standard conditions and for the ancillary investigation. In the 
context of the latter, FH A -13 was adjusted to 250 pg/ml with PBS, and treated for 48 h 
at 37 °C with four concentrations of formaldehyde, 3.12, 6.25, 12.5 and 25 mM. In 
each of these m ixtures a final lysine concentration of 20 mM was included. After the 
treatments, the samples were dialysed against daily changes of 2 L PBS, pH 7.4, for 
one week at 4 ^C.
.The treated preparations were assayed for HA activity with a 2% suspension of 
horse RBCs, and the percent HA loss determ ined by comparison with untreated FHA. 
This latter was a solution of FH A -13, diluted to 250 pg/ml in PBS and stored at -20 °C 
to minimize degradation. The untreated FHA-13 had an HA titre of 14 on a log2  scale 
(Table 20). The lowest concentration of formaldehyde tested, 3.12 mM, was sufficient 
to reduce the HA activity by 87.5%. Thereafter, increasing the concentration to 6.25 
mM and higher caused loss of all detectable activity i.e > 99.9%.
In a separate experiment the formaldehyde was kept constant at 25 mM for 
treatment of another batch of FHA (FHA-3) which was used at 250 pg / ml at three 
different temperatures: 4 °C, RT (22 ^C) and 37 ®C. Samples were removed at 24 and 
48 h, dialysed and assayed for HA activity as before. Untreated FHA-3 had a titre of 
128 from which the percentage inactivation results shown in Table 21 were calculated. 
It was found that approx. 50% loss of HA activity occurred without formalin, i.e. as a 
result of 48 h exposure at 4, 22 and 37 ^C, followed by dialysis. W ith formaldehyde 
the % loss in HA increased upon increasing the time from 24 to 48 h.
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T a b le  20 : E ffec t of fo rm a ld e h y d e  c o n c e n tra tio n  on th e  loss o f HA 
activ ity  o f FHA . F H A -13 (250 pg/m l) was treated with four concentrations of 
foimaldehyde in PBS, pH 7.4, after which lysine was added as a neutralising agent at 
20 mM, for 48 h at 37 a.
Formaldehyde 
(mM) % w/v
% loss in HA activity
3.12 0.009 87.5
6.25 0.019 >99.9
12.5 0.037 >99.9
25.0 0.074 >99.9
a FHA-13 stored at -2Q0 C, was used as a standard on each HA test plate. No drop in 
HA activity was observed after incubating FHA -13 alone or with lysine (20mM) for 48 
h at 37 OC.
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T ab le  21 : E ffect o f te m p e ra tu re  d u r in g  fo rm ald eh y d e  tre a tm e n t on the  
HA activity of FH A . FHA-3 at 250 pg/m l was treated with formaldehyde for 24 h 
or 48 h at 37®C with a fixed concentration of 25 mM formaldehyde in PBS, pH 7.4, 
with or without the addition of lysine (20mM).
FHA-3
treatment
Temperature
(O C )
% loss in HA activity 
24 h 48 h
conti’oia 2 2 0 0
FHA 4 0 50
FHA 2 2 0 50
FHA 37 0 50
Formaldehyde FHA(FHA-F) 4 8 8 8 8
FHA-F 2 2 94 97
FHA-F 37 94 >99
Formaldehyde FHA with
lysine(FHA-F, Lys) 4 75 75
FHA-F, Lys 2 2 75 >99
FHA-F,Lys 37 94 >99
a FHA-3 was stored at -20^C prior to use as a standard on each HA plate. IÎ
Î
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A dding lysine to the system appeared to cause less loss of activity than with 
formaldehyde alone, especially during the first 24 h (Table 21). However at 48 h, the 
difference was only appreciable with the sample treated at 4 ®C.
For the glutaraldehyde treatments, the conditions chosen both for standard and 
exploratory treatments were modifications of those used by Rely veld (1978) with a 
variety of antigens, and by M unoz et al. (1981a) with pertussis toxin. For the 
exploratory treatments of FHA, the following procedure was applied: glutaraldehyde at 
2.5 mM in PBS, with 10 mM lysine, at 37°C, with samples being removed at 15, 30 , 
60 and 120 min. They were then immediately put to dialyse at 4 against 2 L PBS 
for three days with daily changes of buffer. The results in Table 22 show that there was 
complete, or almost complete inactivation o f HA, and with little significant effect of 
adding the lysine. Compared with formaldehyde, glutaraldehyde caused much more 
rap id HA inactivation. For exam ple, w ithin 15 m in, only 2-3 % o f HA activity 
remained. As controls, incubating FHA-7 alone with or w ithout lysine for 2 h a t 37 
showed no detectable loss of HA activity.
The ti'eatment of FHA with EDAC was applied according to Christodoulides et 
al. (1987) for pertussis toxin, except that FHA was used at 250 pg/ml protein instead 
o f 50 |i.g/ml of PT. As with the other two agents, exploratory treatm ents were 
investigated independently of the standard treatment. For the exploratory tieatments, the 
percentage loss in HA activity after treating FHA-7 and FHA-13 with EDAC at various 
concentrations are shown in Table 23a and 23b respectively. All these treatments were 
done in 20mM phosphate buffer, pH 5.0 for 24 h at 37 °C. With FHA-7 (Table 23a), 
the treatments with 0, 2.4, 12.5, 25 and 50 mM EDAC were sampled at 1, 3, 6  and 24 
h and dialysed for 3 days against daily changes of 2 L PBS. As is apparent from Table 
23a, no loss of HA activity was observed in either the 0 mM EDAC control 
preparation, or in any of the reaction mixtures containing EDAC, until 24 h. Increasing 
T ab le  22 : E ffect o f tim e d u r in g  g lu ta ra ld e h y d e  tre a tm e n t on the  
HA activity  of FHA . FHA-7 (250 m g/ml) was treated with glutaraldehyde
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T ab le  22 : E ffect o f tim e d u r in g  g lu ta ra ld e h y d e  tre a tm e n t on the 
HA activ ity  of FH A . FHA-7 (250 mg/m l) was treated with glutaraldehyde 
at a fixed concentration of 2.5 mM  glutaraldehyde in PBS, pH  7.4 w ith or 
w ithout the addition of lysine (10 mM) at 37 ®C.
Time
(min)
% loss of HA activity 
FHA-G FHA-G + lysine
15 97 98
30 98 99
60 >99 >99
1 2 0 >99 >99
FHA-7 was used as a standard on each plate. No drop in HA activity was 
observed after incubating FHA-7 alone or with lysine (lOmM) at 37°C.
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T ab le  23a: E ffect o f ED A C on the HA activ ity  o f FH A ; FHA -7 (250 
(Xg/ml) was treated with EDAC at 4 levels in 0.02M phosphate buffer, pH 5.0 
for 1 , 3, 6  and 24 h at 37 «C
EDAC
(mM) 1
% loss in HA activity at 
3 6 24 h
0 0 0 0 0
2.4 0 0 0 51
12.5 0 0 0 51
25.0 0 0 0 51
50.0 0 0 0 75
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the concentration of EDAC approximately 10 fold, from 2.4 to 25.0 mM appeared to 
cause no additional reduction in activity from 51% although with the 50 mM EDAC, 
inactivation reached 75%. In a second experiment with a different batch of FHA and 
different EDAC concentrations, the results were generally similar (Table 23b) i.e. 
w ithin one two-fold dilution in the HA assays. The maximum percent inactivation of 
HA in this second preparation, FH A -13, was 75% as before.
The FHA preparations used in the immunization experim ents were treated 
according to the conditions summarized in Table 19. The results of these standard 
treatments are presented in Table 24 where three independently-extracted batches of 
FHA were exposed to the three toxoiding agents. Generally, formaldehyde and 
glutaraldehyde treatment resulted in the vast majority of HA activity consistently being 
lost, with only a residual level of 1% activity remaining. For EDAC however, the 
inactivation was much less com plete, lying in the range of 50-75%. W ith control 
preparations containing no toxoiding agents there was little drop in activity after 
incubation for 24 and 48 h at 37 Only a 50% loss in activity was noted for FHA - 8  
after the 48 h period.
r;î
I
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Ejfect on SDS-PAGE profiles : A representative selection of the FHA preparations 
from above was analyzed by SDS-PAGE, with the results shown in Figs. 27. W ith 
untrea ted F H A -13 (stored at -20 ^C ), there was an intense band (lane 12) 
corresponding to the 205 KDa marker in lane 1. The ladder-like patterns below this 
band are presumably degradation products. There seemed to be no difference in the 
profiles of FHA which had been incubated at 37 ^C either for 24 h or 48 h in 20 mM 
phosphate, pH 5.0 (lane 8 ) or PBS, pH 7.4 (lane 2).
Treatm ent with form aldehyde produced major changes in gel profiles. In 
particular, there were (a) bands corresponding to MW >205 KDa suggesting that
'
polymerization had occurred; and (b) losses of the ladder pattern in the region of 98 to 
205 KDa. The faint pattern in lane 6  may reflect an error in loading the gel.
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T ab le  23b: E ffect o f ED A C on the HA activ ity  o f F H A ; F H A - 13 
(250 flg/ml) was trea ted with EDAC at various concentrations in 0.02 M 
phosphate buffer, pH 5.0 for 24 h at 37 °C.
EDAC % loss in HA activity
(mM)
0 0
2.3 75
7.0 75
2 1 . 0 75
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T a b le  24: S u m m a ry  of th re e  e x p e r im e n ts  on th e  e ffec t o f  E D A C , 
fo rm ald eh y d e  an d  g lu ta ra ld e h y d e  on the  HA  ac tiv ity  o f FH A . T re a tm e n t 
conditions were as described in the text. No loss in HA activity was observed with 
FHA alone when incubated for 2, 24 and 48 h at 37 °C. Only FH A - 8  showed a 50% 
loss in activity after 48 h at 37 °C. :
Preparation^ % loss in HA activity
FHA 8 -F 
FHA 9-F 
FHA 13-F
>99
>99
>99
FHA 8 -G 
FH A 9-G  
FHA 13-G
99
99
>99 a:
F H A 8 -E 
FHA 9-E 
FHA 13-E
75
75
50
^ The letters F, G and E refer to the treatments with formaldehyde, glutaraldehyde and 
EDAC respectively.
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F ig u re  27 : SD S-PA G E  p ro file  o f FH A  a n d  th e  e ffect o f ED A C  a n d  
fo rm aldehyde  tre a tm e n ts ; Each lane of the 7.5% polyacrylam ide gel was loaded 
with 6  jig protein. Formaldehyde and EDAC treatments o f FH A -13 were done as 
detailed below.
Lane no. Preparation Concentration of
toxoiding agent (mM)
Conditions of treatment
1 MW-SDS-200 kita - -
2 FHA 0 48 h in PBS and 20 mM lysine
3 FHA-F 25
4 FHA-F 12.5
5 FHA-F 6.25
6 FHA-F 3.12
7 FHA 0 in PBS, kept frozen until use
8 FHA 0 24 h in 20 mM phosphate, pH 5.0
9 FHA-E 2.3
1 0 FHA-E 7.0
11 FHA-E 2 1 . 0
1 2 FHA 0 in 20 mM phosphate, kept frozen until use
13 MW-SDS-70 kita - “
See footnote to Figure 13 (p94)
"Ç
1 2 3 4  5 6 1.0 11 12 13
2 0 5 .
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2 9 .
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F ig u re  28 : SD S -P A G E  p ro file  o f F H A , an d  o f E D A C , fo rm a ld eh y d e  
an d  g lu ta ra ld e h y d e - tre a te d  FH A . Each of the toxoiding trea tm ents was done 
according to the standard condition, with batch FHA9. Lanes of a 7.5% polyacrylam ide 
gel were loaded with 12.5 pg treated or untreated FHA as below:
Lane Sample
1 MW-SDS-2 0 0 kita
2 FHA9
3 FHA9-G
4 FHA9-E
5 FHA9-F
a See footnote to Figure 13 (p94)
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With EDAC, treatment at the two higher concentrations (lanes 10 and 11) there 
w ere strong bands corresponding to MW >205 KDa, again suggesting that 
polymerization had occurred; however the lowest concentration of EDAC (lane 9) 
seemed to have had little effect. Compared with formaldehyde, EDAC produced less 
alteration in the ladder pattern.
The effect o f glutaraldehyde treatment, compared with form aldehyde and 
EDAC, is shown in Fig. 28 which also includes an untrea ted control. The 
glutaraldehyde preparation (FHA-G, lane 3) gave a pattern very similar to that of the 
formaldehyde treated FHA (FHA-F, lane 5) in showing that neither sample had moved 
into the stacking gel indicating a marked degree of polymerization. Correspondingly, 
there was very little material resembling unaltered FHA. The EDAC sample (FHA-E, 
lane 4) was much less altered although still extensively polymerized.
Effect on immunogenicity
To com pare the effect o f the three different toxoiding agents on the 
immunogenicity o f FHA, some of the preparations made with the batches FHA9 and 
FHA 13 (examined above in SDS-PAGE and for HA activity) were injected into mice.
In the first o f the two experim ents, w ith the batch FHA9, the untreated 
preparation was injected i.p. into male m ice of six weeks age and on average weighing 
25 g. Doses were at 0.01, 0.1, 1.0, 10.0 and 100 pg per mouse in groups of four m ice 
for each dose. The treated preparations, namely formaldehyde-treated FHA9 (FHA9- 
F), glutaraldehyde-treated FHA9 (FHA9-G), which both were inactivated for HA 
activity by > 99%, and EDAC-treated FHA9 (FHA9-E), inactivated to only 75%, 
were injected at 0.1, 1.0 or 10 pg per mouse only. Sera were collected in the usual way 
with mice being bled 21 days after immunization. The titres and their geometric means 
for each group of sera are shown in Table 25.
A dose-response curve of the log anti-FHA titres after immunization with the 
various doses of untreated FHA9 is presented in Fig. 29. A low response was obtained
«
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T a b le  25: E ffec t o f E D A C , fo rm a ld e h y d e  an d  g lu ta ra ld e h y d e  on th e  
im m unogen icity  o f FH A  (E x p er im en t A). Serum ELISA  titres of individual 
m ice from experiment A are shown with group geometric means in bold. M ice were 
immunized with various doses of untreated FHA (batch 9) or treated FHA preparations.
ELISA titre (and g.m.) after immunization with dose (pg/mouse) of :
Sample 0 . 0 1 0 . 1 1 . 0 1 0 . 0 1 0 0 . 0
FHA 23 80 510 1600 10800
44 76 450 3250 8150
80 135 235 11500 15350
1 0 195 1925 970 15
3 0 113 5 6 8 2 7 6 0 2 1 2 1
FHA-E nt 29 2 1 2 1 0 0 nt
nt 2 0 1 0 5500 nt
nt 1 0 150 5650 nt
nt 2 0 410 680 nt
19 6 0 2 5 8 1
FHA-F nt 50 1 2 0 660 nt
nt 97 305 860 nt
nt 1 0 480 3225 nt
nt 60 145 300 nt
4 1 2 2 5 8 6 1
FHA-G nt 1 0 25 850 nt
nt 2 0 2 0 1400 nt
nt 1 0 0 1 0 910 nt
nt 140 1 0 3250 nt
4 1 15 1 3 7 0
nt = not tested
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F ig u r e  2 9 : A n t ib o d y  d o s e - re s p o n s e s  o f  m ic e  to  F H A . F H A  (b a tc h  9 ) w a s  
im m u n ized  in to  g roup s o f  fo u r  m ice  a t 0 .0 1 , 0 .1 , 1.0, 10.0 an d  100 p g /m o u se . E ach  
b a r  is rep resen ta tiv e  o f  th e  g.m . o f  each  g roup w ith  its upper 95%  CL.
II
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at 0.01 pg per mouse as evidenced by a g.m. of 30. However, the number of positively 
responding sera began to increase at 0.1 pg/ mouse (g.m. 113). At 1, 10 and 100 pg / 
mouse, m ice responded increasingly strongly with anti-FHA titres reaching up to 
15,350 at the top dose. Exceptionally, one serum from the group injected with the top 
dose responded poorly (15). Maximum titres were obtained within the range of 10-100 
pg / mouse.
The logio serum titres obtained after immunization with the treated preparations 
are summarized in Fig. 30, The main conclusions from this experiment were that (a) 
anti-FHA titres increased with dose for all preparations except glutaraldehyde-treated 
FHA, and (b) responses generally appeared lower for all the three treated preparations 
relative to the untreated FHA. This latter observation was statistically confirmed upon 
analysis of the data by 6 -point parallel-line assays (Table 26). H ighly significant 
differences in responses were found relative to the untreated group (Table 26a) and one 
preparation significantly different with comparison of the treated groups to each other 
(Table 26b).
W ith the other batch of FHA (FHA 13) as the source of the preparations for 
immunization, a similar repeat experim ent was carried out. Formaldehyde-treated 
FHA 13 (FHA13-F), glutaraldehyde-treated FHA (FHA13-G) and EDAC-treated 
FHA 13 (FHA13-E) were inactivated o f HA activity by >99% , >99% and 50% 
respectively. These samples were injected into groups of five m ice i.p. with 0.1, 1.0 or 
10 pg/ mouse and sera collected as before. Anti-FHA arithmetic titres from this 
experiment are given together with geometric means in Table 27 and summarized as bar 
charts in Fig. 31. The figure shows that (a) generally, increased doses stimulated 
increased titres and (b) formaldehyde and glutaraldehyde-treated FHA stimulated higher 
titres than the untreated or the EDAC-treated FHA. Analysis by 6 -point parallel-line 
assays (Table 28a and b) showed FHA13-G and FHA13-F elicited significantly better 
responses than the other two preparations, as indicated by the significant preparations 
terms. Untreated FHA 13 and FHA 13-E were very similar to each other.
"I
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Figure 30: Immunogenicity of FHA after treatment with EDAC, 
formaldehyde and glutaraldehyde (experiment A). FHA (batch 9) was 
immunized into groups of four mice at 0.1,1.0 and 10 pg/mouse. Each bar represents 
the g.m. serum ELISA titre, with the upper 95% CL.
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1
0
FHA FHA-E FHA-F FHA-G
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Table 26a: Analysis of variance of the effect of EDAC, formaldehyde 
and glutaraldehyde on the production of anti-FHA in mice in experiment 
A, with the untreated preparation of FHA used as a comparator. Sum m a ry  
statistics are presented from 6 -point parallel line assays
Source 
of variation EDAC
F-values for toxoided FHA preparations 
with untreated FHA as the comparator
Formaldehyde Glutaraldehyde
Slope 63.46** 52.06** 62.47**
Preparations 10,85** 8.53** 26.46**
Parallelism 2,90 0,04 0,13
Quadratic curvature 2.07 0.06 13.92
Difference of 
quadratics
2,19 0.04 14,29**
Tabulated F value for 1 and 18 degrees of freedom at P = 5% is 4.41(*) and at the P 
1% is 8.29 (**).
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Table 26b: Analysis of variance on the effect of EDAC, formaldehyde, 
and glutaraldehyde on the production of anti-FHA in mice for 
experiment A using the treated preparations as comparators. S u m m a ry  
statistics are presented from 6 -point parallel line assays
Toxoided preparations F-values and source of variation
taken for comparison Slope Prep^ Parall^ Quadratic Difference
curvature of quadratics
FHA-F and FHA-E 58.57** 0.65 3.33 1.53 2.64
FHA-F and FHA-G 56.17** 4.44* 0.29 11.69** 15.06**
FHA-E and FHA-G 67.37** 0.95 1.93 20.67** 2.72
Tabulated F value for 1 and 18 degrees of freedom at P = 5% is 4.41(*) and at the P = 
1 % is 8.29 (**).
^ Prep and Parall denote the 'preparations' and 'parallelism ' terms in the analysis 
respectively.
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T a b le  27 : E ffec t o f E D A C , fo rm a ld eh y d e  an d  g lu ta ra ld e h y d e  on th e  
im m un o g en ic ity  o f FH A  (ex p er im en t B). Serum ELISA titres of individual 
mice from experiment B are shown with group geometric means in bold.
ELISA titre (and g.m.) after immunization with (fig/mouse) of :
Sample 0.1 1.0 10.0
FHA 98 1 2 0 1650
49 90 1600
285 405 2235
60 125 1770
94 205 2 0 0 0
95 1 6 2 1 8 3 6
FHA-E 150 76 1960
130 2 1 0 1500
2 0 0 190 2600
50 190 1900
140 530 1900
1 2 2 1 9 8 1 9 4 2
FHA-F 500 228 4800
180 360 2175
590 2 2 0 4950
165 2 1 0 7200
2 0 0 2 0 0 3600
2 8 1 2 3 8 4 2 2 1
FHA-G 218 770 4850
225 580 5350
1 0 0 515 5300
24 800 4200
190 700 2500
1 1 8 6 6 4 4 2 8 5
I
-A
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F ig u re  31: Im m u n o g e n ic ity  o f  F H A  a f te r  t r e a tm e n t  w ith  E D A C , 
fo rm a ld e h y d e  a n d  g lu ta ra ld e h y d e  (e x p e r im en t B). FHA  (batch 13) was 
im m unized into groups o f five m ice at 0.1, 1.0 and 10.0 |ig/m ouse. Each bar 
represents the g.m. serum ELISA titre w ith the upper 95% CL.
0.1 /<g/mouse
FHA FHA-E FHA-F FHA-G
1.0 /ig/monse
i
1I
5
4
3
2
1
0
FHA FHA-E FHA-F FHA-G
10.0 /<g/moase
5
4
3
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i
0
FHA FHA-E FHA-F FHA-G
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Table 28a: Analysis of variance on the effect of EDAC, formaldehyde 
and glutaraldehyde on the production of anti-FHA in mice for
experim ent B, with the untreated preparation of FHA used as a 
comparator. Summary statistics are presented from 6 -point parallel line assays
Source
F-values for toxoided FHA preparations 
with untreated FHA as comparison
of variation EDAC Formaldehyde Glutaraldehyde
Slope 151.67** 164.87** 171.90**
Prepai’ations 0.80 18.07** 16.24**
Parallelism 0.18 0.33 1.61
Quadratic curvature 20.98** 41.63** 5.46*
Difference of 
quadratics
0 .0 1 2.28 4.12
Tabulated F value for 1 and 24 degrees of freedom at P = 5% is 4.26(*) and at the P 
1% is 7.82 (**).
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Table 28b: Analysis of variance on the effect of EDAC, formaldehyde 
and glutaraldehyde on the production of anti-FHA in mice for 
experiment A, using the treated preparations as comparators. S u m m ary  
statistics are presented from 6 -point parallel line assays
Toxoided preparations 
taken for comparison Slope
F-values and source of variation 
Prep^ Parall^ Quadratic Difference 
curvature of quadratics
FHA-F and FHA-E 160.59** 11.45** 0 . 0 2 41.93** 2.77
FHA-F and FHA-G 180.27** 0 . 1 0 3.58 15.27** 12.83**
FHA-E and FHA-G 167.39** 10.60** 2 . 8 6 5.14* 3.83
Tabulated F value for 1 and 24 degrees of freedom at P = 5% is 4.26(*) and at the P = 
1% is 7.82 (**).
^ Prep and Parall denote the 'preparations’ and 'parallelism ' term s in the analysis 
respectively.
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The overall conclusions from  these experim ents w ere that (a) the 
immunogenicity of the treated preparations varied with the batch of FHA used and (b) 
formaldehyde and glutaraldehyde FHA samples (which were m ore than 99% 
inactivated of HA activity) from the second experiment, were slightly more 
im m unogenic and (c) ED A C trea tm ent o f FHA did not appear to enhance 
immunogenicity.
Experiments with Pertussis Toxin
ïn  vitro effects of EDAC, formaldehyde and glutaraldehyde
Ejfect on histamine-sensitizing activity : A pooled preparation was made from the first 
three batches of FT which had been processed by Blue Sepharose gel affinity 
chromatography, from the mutant B. pertussis  strain (B.p. 353) deficient in FHA 
production. Toxoiding was done under the standard conditions given in Table 29.
The toxoiding trea tm ent with EDAC was done exactly as described by 
Christodoulides et al. (1987) for detoxification of FT. This was with 21 mM EDAC at 
pH 5.0 for 24 h at 37 ^C, followed by dialysis against daily changes of 2L PBS, for 
three days.
For formaldehyde treatment, as with FHA, the standard conditions were based 
on the inactivation of pertussis toxin (Sato et a i ,  1984). The PT preparation was 
adjusted to 50 pg/m l protein with 20 mM phosphate, pH 7.4 containing 0.5 M NaCl. 
Formaldehyde at 25 mM and lysine at 20 mM (final concentrations) were added, and 
the m ixture was incubated for 1 week at 37 °C. After the treatment, the sample was 
dialysed against daily changes of 2L PBS for one week.
W ith glutaraldehyde, PT was treated for 2 h with 2.5 mM of the reagent as used 
by M unoz et a i  (1981a) for the detoxification of this toxin, except that the treatment 
was performed at 37 ®C instead of 22 ®C.
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Table 29: Summary table of standard treatment conditions for exposure 
of PT at 50 pg/ml to toxoiding agents at 37 ^C.
Toxoiding
agent
Concentration of 
agent 
(mM)
Time
(h)
Lysine
(mM)
EDAC 2 1 24 N/A
Formaldehyde 25 168 2 0
Glutaraldehyde 2.5 2 1 0
.
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The extent of inactivation after the toxoiding treatment was assessed by the loss 
of histamine-sensitizing activity. Groups of four m ice (> 6  weeks of age and of mixed 
sex) were immunized i.p. with untreated PT and the three toxoided PT preparations 
each at five doses (0.06, 0.19, 0.56, 1.7 and 5.0 jig/mouse). The same PT preparation 
which was also incubated at 2, 24 and 168 h at 37 °C to determ ine the background loss 
of activity was tested. Mice were challenged with histamine at 3 mg/mouse on the fifth 
day after injection. The number of deaths after challenge were recorded and the HSD 5 0  
estimated (Table 30).
Formaldehyde and EDAC treatment of PT resulted in the greatest loss of HSA, 
with 97% and 96% inactivation respectively. PT exposed to glutaraldehyde however, 
showed only a 6 6 % reduction. Incubation of the untreated control preparation at 37 °C 
showed that half o f the HSA activity was lost after 2 h incubation. Incubation for the 
longer periods of 24 h and 1 week resulted in a successive decrease in activity.
The toxoiding treatment with the three agents was repeated under the standard 
conditions described above in o rder to m ake prepara tions fo r investigating 
immunogenicity. A PT extract (batch-6 ) was used for this puipose and termed PT-6 . 
PT - 6  alone was incubated for 2 h, 24 h and 1 week to assess the residual drop in 
activity due to incubation without any toxoiding agent.
As before, m ice were immunized i.p. with these preparations to determ ine the 
extent of modification. The doses chosen were selected to indicate inactivation to levels 
of 99%, 90% and 50%. Only two mice per dose were injected. Table 31 showed that 
formaldehyde-treated PT (PT6 -F) appeared to be >99% inactivated. The EDAC-treated 
(PT6 -E) and glutaraldehyde-treated PT (PT6 -G) were inactivated only to 50 to 90%. 
The toxoiding process was therefore repeated with these same samples after redialysis 
and reestimation of protein content. These preparations were termed PT 6 -EE and PT6 - 
GG to emphasize the double treatment with the respective toxoiding agents. The HSA 
of the retreated PT toxoids was determ ined but, even after this double treatment the 
HSA was not completely inactivated (Table 31). Thus PT6 -GG from the double
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T a b le  30: E ffec t o f E D A C , fo rm a ld e h y d e  an d  g lu ta ra ld e h y d e  on th e  
h is tam ine -sen s itiz ing  ac tiv ity  of PT , PT (pooled from ex tractions 1, 2 and 3) 
and the three toxoids were injected into groups of 4 mice and challenged with histamine 
(3 mg/mouse) five days later. The number of deaths was recorded and the H SD 5 0  
determ ined. The upper half o f the table shows HSD 5 0  for toxoided preparations 
whereas the lower half shows the progressive reduction in HSF activity of PT w ith 
time.
Sample Dose (ug/mouse)
5.0 1.7 0.56 0.19 0.06 
No. of deaths /  4 mice immunised
H SD 5 0
(Fg)
% inactivation
PT 4 4 4 3 0 0.13 -
PT-E 3 1 0 0 0 3.35 96
PT-G 3 4 4 0 0 0.38 6 6
PT-F 2 0 0 0 0 5.00 97
PT nt 4 4 2 0 0.19 -
PT (2 h) nt 4 3 0 0 0.38 50
PT (24 h) nt 4 0 0 1 1.14 83
PT (1 week) nt 2 1 0 0 1.7 89
i
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T a b le  31; E ffec t o f E D A C , fo rm a ld e h y d e  an d  g lu ta ra ld e h y d e  on th e  
h is tam in e -sen s itiz in g  ac tiv ity  (HSA) o f P T 6 . PT6  was trea ted with EDAC, 
formaldehyde and glutaraldehyde and the toxoids were injected into groups of two mice 
which were challenged with histamine (3 mg/ mouse) 5 days later. The number o f 
deaths were noted and the HSD 50  determined.
Sample Immunisation with dose to test at the inactivation level {%) of ;
99 90 50
No. of deaths out of 2 immunized after % inactivation 
histamine challenge
PT6 2 2 2 0
PT6 -G 2 2 0 > 5 0  < 9 0
PT6 -E 2 1 0 > 50 <90
PT6 -F 0 0 0 > 9 9
PT 6 -GG& 2 2 0 > 50 < 90
PT-EEa 1 0 0 > 90 < 99
^ Due to incomplete inactivation , PT was reU'eated with EDAC and glutaraldehyde as 
above then retested for HSA activity.
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glutaraldehyde treatment still retained 50 to 90% HSA. However, double treatment with 
EDAC, increased the inactivation from 50 to 90% to 90 to 99%.
Effect on immunogenicity
To compare the effect o f the three toxoiding agents on the im munogenicity o f PT, 
EDAC, formaldehyde and glutaraldehyde toxoids prepared above i.e. PT 6 -E (50 to 
90% inactivated), PT6 -F (>99% inactivated) and PT6 -G (50 to 90% inactivated) were 
injected into mice even though some of the preparations were not com pletely 
inactivated. Untreated PT6  was included as a reference preparation. Due to the inherent 
toxicity of PT, untreated PT 6  was injected i.p. at doses of only 1 or 5 pg/m ouse 
whereas the toxoided preparations were given at doses of 1, 5 and 25 |ig/mouse. A 
heat-killed sonicate of B. pertussis 18323 (18323 HKS) whole cells was included for 
purposes of com parison. This preparation was injected at 0.5 ml containing the 
equivalent of 5 opacity units of bacteria and regarded as approx. one-quarter of one 
human dose. M ice were bled on day 21 and the sera were analyzed for anti-PT by 
ELISA.
Arithmetic anti-PT serum ELISA titres and geometric means are given in Table 
32 and the logio  serum titres presented in Figure 32. From this experim ent the 
conclusions were that anti-PT titres increased with dose for all toxoided preparations 
but not for the untreated PT6 , and secondly, that responses appeared higher for all the 
three treated preparations relative to PT. However, this was not confirmed by statistical 
analysis. Four-point parallel-line assays with the untoxoided PT as a comparator (Table 
33) were conducted. W ith untreated PT as the reference (Table 33), the preparations 
term for the EDAC and glutaraldehyde treatments was significant, indicating an 
adjuvant effect, but the formaldehyde treatment was not. Also, the response induced by 
1 and 5 qg/m ouse of PT and its toxoids were similar as demonstrated by the non­
significant s lo p e  terms. F inally, the assays did not show any deviation from 
parallelism. Next, EDAC-treated PT was compared with the other two toxoids by one-
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T a b le  32: E ffec t o f E D A C , fo rm a ld e h y d e  a n d  g lu ta ra ld e h y d e  on th e  
im m unogenicity  of P T , Serum ELISA litres of individual mice are shown with 
group geometric means in bold. Mice were immunized with various doses of untreated 
PT (batch 6 ) or treated PT preparations.
Sample
Anti-PT ELISA titre (and g.m.) after immunization with :
1 5.0 25.0 5 o.u.
(pg/mouse) (0.5 ml/mouse)
PT6 420 350 nt -
540 60 nt —
1 150 nt -
150 1 nt -
40 300 nt -
67 62 nt -
PT6 -E 240 6700 9200
1300 7000 1500 -
2 1 0 2 0 0 0 6000 -
2 0 0 0 1 2 0 0 9000 -
550 55 9000 -
5 9 1 1 4 4 0 5 8 2 4 "
PT 6 -F 450 250 900
450 400 150 -
1 2 0 500 3500 -
30 1 0 4900 -
190 1080 370 -
1 6 9 2 2 2 9 6 9 “
PT 6 -G 1 1 0 1400 1400
300 640 1550 -
400 880 8000 -
1 2 0 2 0 0 3500 -
310 1500 7800 —
2 1 8 7 4 9 3 4 2 8 -
18323 HKS& 45
- - - 820
_ _ 1
- - - 450
- - - 700
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#
^ Strain 18323 heat-killed (56 ^C) and sonicated, 
nt = not tested
1 6 2
F ig u r e  32: Im m u n o g e n ic i ty  o f  P T  a f te r  t r e a tm e n t  w ith  E D A C , 
fo rm aldehyde an d  g lu ta ra ldehyde . PT (batch 6 ) was injected into groups of five 
m ice at 1.0 or 5.0 |ig/m ouse. Toxoided preparations were also immunized at 25.0 
pg/mouse. Each bar represents the g.m. serum ELISA titre w ith the upper 95% CL.
1.0 /<g/mouse5
4
3
2
1
0
PT PT-E PT-F PT-G
II
I
I
5.0 /Ig/mouse
5
4
3
2
1
0
PT PT-E PT-F PT-G
25.0 /Ig/mouse
5
4
3
2
1
0
PT PT-E PT-F PT-G
■i
5
I
Preparation
1
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Table 33a: Analysis of variance of the effect of EDAC, formaldehyde 
and glutaraldehyde on the production of anti-PT in m ice, with the 
untreated preparation of PT (batch 6) as a comparator. Sum m ary statistics 
are presented from 4-point parallel line assays.
Source
F-values for toxoided PT preparations 
with untreated PT as comparison
of variation EDAC Formaldehyde Glutaraldehyde
Slope 0.19 0 . 0 1 0.50
Preparations 8.15* 1.42 5.00*
Parallelism 0.27 0.04 0.64
Tabulated F value for 1 and 16 degrees of freedom at P = 5% is 4.49*) and at the P 
1% is 8.53 (**).
VS;
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T a b le  33b: A nalys is of v a r ia n c e  of the  e ffect o f E D A C , fo rm a ld eh y d e  
a n d  g lu ta ra ld eh y d e  on th e  p ro d u c tio n  o f an ti-P T  in m ice w ith  th e  tre a te d  
p re p a ra t io n s  as c o m p a ra to rs . Summary statistics are presented from  6 -point 
parallel line assays.
Toxoided preparations F-values and source of variation 
Slope Preparations Parallelism Quadratic
curvature
Difference 
of quadratics
PT-F and PT-E 9.97** 9.86** 0.18 0.60 0 . 1 0
PT-F and PT-G 18.00** 4.42* 0.91 0 . 6 6 0.25
PT-E and PT-G 26.31** 3.28 0.23 0 . 2 2 0 . 0 2
Tabulated F value for 1 and 24 degrees of freedom at P = 5% is 4.26(*) and at the 
l% is  7 .82(**).
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tail t-tests for each dose (Table 34). This analysis revealed that (a) ED AC-treated PT 
was more immunogenic than formaldehyde-treated PT at 25 jig/mouse and (b) PT-E 
had similar im munogenicity to PT-G. Thus it was concluded that PT-E and PT-G 
induced the best responses followed by PT-F.
Experiments with PT and FHA Mixtures
In vitro effects of EDAC, formaldehyde and glutaraldehyde
Preparations of PT and FHA were copurified from B, pertussis  77/18319 by Blue 
Sepharose gel-affinity chromatography. Two PT/FHA m ixtures ex tracted by this 
method were designated PF3 and PF4 and used for toxoiding in the following 
experiments. The third mixture was an independently extracted preparation by the same 
procedure and term ed A P I6 , for antigen preparation 16. This was toxoided for 
com parative purposes. The PT:FHA ratio as determ ined by ELISA for A P I6  was 
1:2.25.
The relative amounts of PT and FHA in PF3 and PF4 were determ ined by 
ELISA and SDS-PAGE. However, the results were not consistent as judged by the two 
tests. PF3 had a PT iFHA ratio of 2:3 by ELISA analysis and indeed the gel profile 
(F igure 24, lane 4) appeared to show an excess of FHA. PF4 appeared to show 
equivalent amounts of PT and FHA by SDS-PAGE (Figure 23, lane 7) but this result 
was not confirmed upon ELISA data analysis which indicated that the PT:FHA ratio 
was 1:5. The toxoiding procedure was the same as described for the inactivation of PT 
with EDAC, foimaldehyde and glutaraldehyde where the conditions are summarized in 
Table 29.
Effect on histamine-sensitizlng activity: Toxoided A P I6 , PF3 and PF4 were 
.investigated for histamine-sensitizing activity to assess the extent o f modification of PT
in the antigen mixtures. To begin with, the potency of the PT in the untreated antigen I
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Table 34: Dem onstration of the superior im m unogenicity of EDAC- 
treated PT over other PT toxoids by one-tail t-tests.
Pertussis toxoid 
made with
Statistic Data from one-tail t-tests of superior 
immunogenicity at mouse dose (jig)
1 5 25
EDAC g.m. 591 1440 5824
Form aldehyde g.m. 169 2 2 2 969
t -1.865 -1.556 -2.403
P NS NS $
Glutaraldehyde g.m. 218 749 3428
t -1.919 -0.680 -1.033
P NS NS NS
t = students t-test stastistic
P = probability of significance for t statistic at 8  D.f.
167
mixtures was assessed by injecting two mice per group with 1 ,5  or 25 pg/mouse. All 
m ice challenged on day five w ith 3 mg of histamine died. The endpoint HSD 5 0  was 
therefore below 1 pg/mouse for each preparation. In order to define the HSD 5 0  further,
groups of two mice were immunized with 4, 16, 63, 250 and 1000 ng/mouse. The 
results from this second experiment showed that A PI6  and PF3 had H SD 5 Q of approx.
1 .0  pg / mouse while PF4 had a HSD 5 0  value of approx. 0.25 pg/ mouse.
The effect of EDAC, formaldehyde and glutaraldehyde treatment on HS A is 
shown in Table 35. Formaldehyde treatment o f all three m ixtures destroyed > 98% 
activity in AP16-F and PF3-F and PF4-F showed >99% inactivation. Toxoiding the 
m ixtures with glutaraldehyde and EDAC caused less inactivation of the HSA. Thus, all 
glutaraldehyde-treated preparations showed <50% inactivation. AP16-E and PF3-E had 
>50 but <90% inactivation levels. PF4-E had >90 <99% inactivation.
Although it was subsequently realised that the glutaraldehyde and EDAC
preparations were not fully inactivated for HSA, m ice had already been simultaneously
'
immunized for the raising of antisera. The process with glutaraldehyde and EDAC was
therefore repeated as before on these same samples in an effort to increase the level of 
.inactivation (Table 35). AP16-GG (double toxoiding with glutaraldehyde) and PF3-GG 
were >98% inactivated from the prev ious level of <50%. PF4-GG  was >99% 
inactivated. Similarly, w ith the EDAC re toxoiding, AP16-EE and PF3-EE showed 
Increased inactivation levels of >90<98% inactivation from >50<90%; however PF4- 
EE remained the same,
2
Effect on immunogenicity
PT and FHA antigen mixtures A P I6 , PF3 and PF4 were toxoided with formaldehyde, 
glutaraldehyde and EDAC with HSA activities as detailed above. For each toxoided 
preparation, 5 m ice were immunized with 5 and 25 pg/m ouse. Due to toxicity, the 
doses of untreated PT was restricted to 5 pg/mouse. As before, the experiment was 
term inated on day 21, and sera obtained. Anti-PT and anti-FHA were assayed by
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T a b le  35: E ffec t of E D A C , fo rm a ld e h y d e  a n d  g lu ta r a ld e h y d e  on 
h is tam in e -sen s itiz in g  ac tiv ity  of P T  an d  FH A  an tig en  m ix tu re s . H S D 5 0  
for untreated A PI 6  and PF3 was approx. 1.0 pg/ mouse and 0.25 pg / mouse for PF4.
Sample
2 . 0
No. o f deaths/ 2 injected 
Dose (pg/ mouse) 
1 0 .0 50.0
approx
HSD50
approx 
% inactivation
AP16-F 0 0 0 > 50 .0 > 9 8
AP16-G 2 2 2 > 1 .0  < 2 . 0 < 5 0
AP16-E 0 0 2 > 2 . 0  < 1 0 > 50 < 90
AP16-GG^ 0 0 0 > 50 .0 > 9 8
AP16-EE ^ nt 0 2 > 10 < 50 > 90 < 98
PF3-F 0 0 0 > 5 0 .0 > 9 8
PF3-G 2 2 2 > 1 .0  < 2 . 0 < 5 0
PF3-E 0 2 2 > 2 . 0  < 1 0 > 50 < 90
PF3-GG^ 0 0 0 > 50 .0 > 9 8
PF3-EB ^ nt 0 2 > 10 < 5 0 > 90 < 98
Sample No. of deaths/ 2 injected
Dose (pg/ mouse) approx approx
0.5 2.5 25.0 HSD50 %
inactivation
PF4-F 0 0 0 > 25 .0 > 9 9
PF4-G 1 2 2 0.5 < 5 0
PF4-E 0 0 2 > 2.5 < 25 > 90 < 99
PF4-EE a nt 0 1 25.0 > 90 < 99
PF4-GGa 0 0 0 > 25 .0 > 9 9
“ Due to insufficient inactivation, these preparations were subjected to retoxoiding with 
G or EDAC as before, and HSF activity determined.
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ELISA and are listed in Tables 36 and 37, respectively, with group geometric means.
W ith respect to anti-FHA titres, bar charts (Figure 33) allowed the following 
conclusions to be made (a) that the anti-FHA response increased with increased dose,
(b) there appeared to be differences between preparations i.e. A P I 6  titres were , I
-generally lower than PF3 and PF4 and (c) anti-FHA titres were the highest after
immunization with EDAC-treated preparations. Statistical analysis was commenced by 
1 -way analysis of variance to ascertain whether there were differences between the 
three preparations (A PI6 , PF3 and PF4) after each toxoiding treatment for each dose 
(Table 38). These tests were performed primarily to determ ine whether there were 
significant differences in the antibody response between the untreated and treated 
PT:FHA preparations. The results indicated that the data were heterogeneous for anti- 
FHA titres with the untreated, EDAC-treated and glutaraldehyde-treated PT:FHA 
samples immunized at 5 pg/mouse. Statistical analysis therefore was continued by 
considering each PT:FHA preparation individually. The untreated PT:FHA preparation 
was used as the reference in t-tests for comparing the toxoided samples at the 5pg dose 
for each mixture. Table 39 presents a summary of the results. An adjuvant effect was 
noted for the EDAC and formaldehyde-treated A P I6 . However, formaldehyde-treated 
PF3 and PF4 showed significantly lower responses. The other EDAC-treated and 
glutaraldehyde-treated samples were not significant. In order to judge whether there 
was a difference between the toxoided preparations, 4-point parallel line assays were 
performed on the titres generated by immunization with 5 and 25 pg/mouse (Table 40). 
Formaldehyde-treated PF3 and PF4 were significantly lower than EDAC-treated PF3 
and PF4. There were no differences between the three toxoiding treatments with the 
AP16 preparation despite the adjuvanting effects obtained at the 5 pg/mouse dose. The 
main conclusion from this experiment was that EDAC-treatment of PT:FHA gave the 
highest anti-FHA titres compared with the other toxoiding treatments, although a ■
consistent adjuvant effect against the untreated prepai'ation could not be demonstrated.
V
i
Î
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T ab le  36: E ffect o f ED A C, fo rm aldehyde  an d  g lu ta ra ld e h y d e  on th e  an ti- 
FH A  respon se  a f te r  im m unization  w ith  P T :F H A  an tigen  m ix tu res . G roups 
of five m ice were immunized with 5 and 25 pg/m ouse of each toxoided PT/FHA 
m ixture, while the untreated mixture was used at 5 pg/m ouse only. Anti-FHA ELISA 
titres are shown with group g.m. in bold.
Preparation
Toxoiding treatment and dose (pg/mouse) 
Anti-FHA ELISA titre 
Untreated EDAC Formaldehyde 
5 5 25 5 25
Glutaraldehyde 
5 25
AP16 1 90 2850 50 675 75 375
30 135 2075 50 600 1 300
25 1 0 0 2475 50 900 60 3000
1 330 330 1 0 0 2250 30 1350
15 1 1500 150 550 300 4000
7 5 3 1487 72 8 5 2 33 1127
PF3 1 0 0 0 280 2520 50 1 2 0 0 2 0 0 0 2250
500 1800 1 2 0 0 300 6000 630 2500
375 300 5000 1 0 0 0 530 1 0 0 0 8000
700 1800 6300 150 380 550 900
850 1050 6000 250 4500 700 6400
645 789 3568 224 1455 865 3038
PF4 800 435 5130 1 1 0 1500 300 90
550 450 3200 90 600 1500 2600
1500 345 2 0 0 0 300 4900 1050 1500
325 1 0 0 0 2 0 0 0 250 3000 1 1 0 3050
460 900 7100 845 1450 745 2370
629 571 3417 229 1805 522 1205
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Table 37 : Effect of EDAC, formaldehyde and glutaraldehyde on the 
anti-PT response after im m unization with PT:FHA antigen mixtures.
Groups of five m ice were im munized with 5 and 25 pg/m ouse of each toxoided 
PT'.FHA m ixture, while the untreated mixture was used at 5 pg/m ouse only, Anti-PT 
ELISA titres are shown with group g.m. in bold.
Preparation
Toxoiding treatment and dose (pg/mouse) 
Anti-PT ELISA titre 
Untreated EDAC Formaldehyde 
5 5 25 ' 5 25
Glutaraldehyde 
5 25
AP16 690 950 5350 710 450 95 570
355 2 0 0 2300 2 0 0 2450 430 2580
180 1700 4500 125 3200 1800 90
150 750 1300 30 4000 980 5600
95 2 0 0 0 6450 70 500 145 5500
2 2 9 8 6 5 3 4 1 5 130 1 4 5 8 4 0 2 1 3 2 4
PF3 1 1 0 760 1 0 0 0 670 520 940 6600
540 60 7000 450 170 350 2400
2 0 0 950 5280 240 1850 1550 1700
90 440 4000 2 2 0 45 800 1040
600 1 2 0 0 6500 85 5000 1 2700
2 3 0 4 7 0 3 9 5 0 2 6 7 5 1 6 2 1 0 2376
PF4 1 2 0 0 550 1800 590 600 400 600
360 810 2300 230 4150 2 0 0 0 8500
2 1 0 1 1 0 0 6700 15 3200 1225 3530
800 2 0 0 0 7500 2150 2330 1 0 0 0 7200
760 300 8100 215 1 0 0 28 4350
5 6 0 7 8 3 4 4 2 0 2 4 8 1131 4 8 7 3 5 5 0
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Figure 33: Anti-FH A titres with PT:FHA antigen m ixtures after  
treatm ent with EDAC, form aldehyde and glutaraldehyde. T reated  
preparations were immunized at 5.0 (]□) and 25.0 (jÈ3 ) P-g/mouse into groups of five 
mice. Each bar represents the g.m. anti-FHA ELISA titre with the upper 95% CL,
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T ab le  38: O ne-w ay  analy s is  o f v a r ia n ce  to  d e te rm in e  th e  h e tero g en e ity  
o f the  an ti-F H A  titre s  a f te r  im m un iza tion  w ith  ED A C , fo rm ald eh y d e  an d  
g lu ta ra ld e h y d e - tre a te d  m ix tu res  of P T :F H A .
Group totals and F-valiies of logiQ anti-FHA ELISA titres at 5 or 25 p,g/mouse 
(PT:FHA) (PT:FHA)-E (PT:FHA)-F (PT:FHA)-G
Preparation 5 5 25 5 25 5 25
A P 1 6 4.051 8.603 15.861 9.273 14.653 7.607 15.260
P F 3 14.407 14.455 17.762 11.751 15.814 14.685 17.413
P F 4 13.994 13.783 17.668 11.797 16.282 13.587 15.404
1 5 .2 1 * * 5 ,2 2 * 2 .3 0 2 .9 5 0 .8 9 7 .8 0 * * 1 .0 6
Tabulated F value for 2 and 12 degrees of freedom at P = 5% is 3.89(*) and at the P 
1% is 6.93 (**).
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T ab le  39: t- tes t analy s is of an ti-F H A  E L ISA  t i tre s  to  d e te rm in e  w h e th e r 
to x o id in g  w ith  E D A C , fo rm a ld e h y d e  a n d  g lu ta ra ld e h y d e  a ffec ts  th e  
im m unogen ic ity  of FH A  in P T :F H A  m ix tu res . The tw o-tailed t-tests were 
done on the group means and SD from the 5 pg/mouse dose only.
Untreated PT:FHA 
(g.m .)
Treated PT:FHA 
(g.m .)
t-value Significance
AP16 (7) AP16-E (53) 2.324 *
AP16 (7) AP16-F (72) 4.234
AP16 (7) AP16-G (33) 1.891 NS
PF3 (645) PF3-E (789) 0.642 NS
PF3 (645) PF3-F (224) -2.885 $
PF3 (645) PF3-G (865) 1.422 NS
PF4 (629) PF4-E (571) -0.408 NS
PF4 (629) PF4-F (229) -2.996 *
PF4 (629) PF4-G (522) -0.491 NS
N=10 and D .f .= 8
175
T ab le  40: A nalysis of v a r ian ce  to  d e term in e  w h e th e r ED A C tre a tm e n t of 
P T :F H A  resu lts  in su p e r io r  im m unogenicity  of the FH A  com ponen t over 
fo rm ald eh y d e  an d  g lu ta ra ld e h y d e  toxoid ing . Four-point parallel line assays 
were performed on the anti-FHA ELISA titre group totals from the 5 and 25 pg/mouse 
doses.
PT'.H iA
preparation
F-values and source of variation 
Slope Preparation Parallelism
AP16-E and AP16-F 25.97** 0.05 0.57
AP16-E and AP16-G 19.89** 0.23 0 . 0 1
PF3-E and PF3-F 14.10** 5.62* 0.15
PF3-E and PF3-G 16.05** 0 . 0 1 0.15
PF4-E and PF4-F 37.46** 6.08* 0.19
PF4-E and PF4-G 8.99** 1.67 1.18
Tabulated F value for 1 and 16 degrees of freedom at P = 5% is 4.49(*) and at the P 
l% is  8.53 (**).
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A similar analysis of the anti-PT ELISA titres from the same set of sera was 
made. Bar charts of group g.m with 95% CL (Figure 34) showed that (a) anti-PT 
response increased with dose, (b) that all three PT:FHA preparations generated similar 
titres and (c) that two EDAC-treated PT;FHA mixtures showed the highest responses. 
These conclusions were confirmed by statistical analysis. Firstly, as with anti-FHA 
titres, the data was subjected to 1 -way analysis of variance to show up differences 
between the three PT;FH A  preparations. Table 41 shows that the data w ere 
hom ogeneous and that there were no significant differences between the three 
preparations after each toxoiding trea tm ent for each dose. Therefore, different 
procedures were adopted for the statistical analysis of anti-PT titres compared with anti- 
FHA titres. This was done by grouping all three preparations collectively as one 
PT.'FHA sample for each toxoiding treatment at each dose. Two-tailed t-tests on the 5 
pg/mouse dose (Table 42) with the untreated preparation as com parator showed that 
EDAC-treatment had a significant adjuvant effect but fonnaldehyde and glutaraldehyde- 
treatment did not. Results from the 4-point parallel-line assays (Table 43) all had a 
highly significant slope and there was no deviation from parallelism . A clear 
adjuvanting effect was demonstrated for anti-PT titres after EDAC treatment relative to 
formaldehyde toxoiding but not when compared with glutaraldehyde. Thus, EDAC 
induced the highest anti-PT responses followed by glutaraldehyde. Formaldehyde 
treatment appeared to have no adjuvant effect.
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F ig u re  34: A n ti-P T  t i tre s  w ith  P T :F H A  an tigen  m ix tu re s  a f te r  tre a tm e n t
w ith  ED A C , fo rm a ld eh y d e  an d  g lu ta ra ldehyde»  T rea ted p repara tions w ere
immunized at 5.0 ( Ü  )and 25.0 (,E3 )jig/mouse into groups of five m ice Each bar
represents the G.m. anti-PT ELISA titre w ith the upper 95% CL.
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T ab le  41: O ne-w ay  analy s is  of v a r ia n ce  to  d e te rm in e  th e  h e tero g en e ity  
o r  h o m o g e n e ity  o f a n ti-P T  t i t r e s  a f te r  im m u n iz a tio n  w ith  E D A C , 
fo rm ald eh y d e  an d  g lu ta ra ld e h y d e - tre a te d  m ix tu re s  of P T :F H A .
Group totals and F-values of log io  anti-FHA ELISA titres at 5 or 25 pg/mouse 
(PT:FHA) (PT:FHA)-E (PT:FHA)-F (PTrFHA)-G
Preparation 5 5 25 5 25 5 25
A P 16 11.798 14.686 17.667 10.571 15.819 13.019 15.610
P F 3 11.806 13.360 17.983 12.130 13.565 11.610 16.879
P F 4 13.741 14.468 18.227 11.973 15.268 13.468 17.751
2 .1 4 0 .5 7 0 .3 1 0 .4 4 0 .5 5 0 , 2 2 0 .7 8
Tabulated F value for 2 and 12 degrees of freedom at P = 5% is 3.89(*) and at the P 
1% is 6.93 (**).
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T ab le  42: t- te s t ana ly s is  of an ti-P T  E L IS A  t i tre s  to  d e te rm in e  w h e th e r  
to x o id in g  w ith  E D A C , fo rm a ld e h y d e  a n d  g lu ta ra ld e h y d e  a ffec ts  th e  
im m unogenicity  of P T  in PT :FH A  m ix tu res. The two-tailed t-tests were done 
on the group means and SD from the 5 pg/mouse dose only.
Untreated PT.'FHA 
(g.m .)
Treated PT:FHA 
(g.m .)
t-value Significance
PT:FHA (309) (PT'.FHA)-E (682) 3.434 **
PT:FHA (309) (PT;FHA)-F (205) -1.461 NS
PTiFHA (309) (PT:FHA)-G (347) 0.290 NS
N=30 and D.f.= 28
I
I:
I
.li
I
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Table 43: Analysis of variance to determine whether EDAC treatment of 
PT:FHA results in superior immunogenicity of the PT component over 
formaldehyde and glutaraldehyde toxoiding. Four-point parallel line assays 
were performed on the anti-PT ELISA titre group totals from the 5 and 25 pg/m ouse 
doses.
PT:FHA F-values and source of variation
preparation Slope Preparation Parallelism
(PT:FHA)-E and (PT:FHA)-F 30.93** 19.78** 0.13
(PT:FHA)-E and (PT:FHA)-G 28.39** 3.33 0 . 0 1
(PT;FHA)-F and (PT:FHA)-G 18.41** 3.06 0.18
Tabulated F value for 1 and 56 degrees of freedom at P = 5% is 4.00-4.08(*) and at the 
P = 1% is 7.08-7.31 (**).
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O R IG IN S O F T H E  W O R K
The impetus for the work described in this thesis was the report of Christodoulides et 
aL (1987), that pertussis toxin (PT) was not only detoxified by the carbodiimide, 
EDAC, but also had its immunogenicity enhanced. The immunogenicity of FHA was 
also enhanced when the EDAC treatment was applied to a mixture of the two antigens. 
In the ten years since this report there has been neither confirmation nor refutation of 
this finding, although the paper has been cited (Nencioni et aL, 1990). M eanwhile, 
preparations of PT and combinations of PT with other protective antigens including 
FHA, pertactin and the agglutinogens have been detoxified with formaldehyde (Sato et 
aL, 1984), glutaraldehyde (Quentin-Millet et aL, 1988), H2 O2  (Sekura et al,, 1988) and 
tetranitrom ethane (W inberry et aL, 1988). Also, PT has been modified by genetic 
manipulation to produce non-toxic recombinant PT (Nencioni et al., 1990). These 
experimental vaccine preparations have been subjected to clinical trials in Sweden and 
Italy and are summarized in Table 44. The acellular vaccines were found to be generally 
more efficacious than the Connaught whole-cell preparation and showed less 
reactogenicity.
A detailed search of the early literature on toxoiding has uncovered very few 
reports where toxoiding enhanced the immunogenicity of the treated protein compared 
to the native molecule. With diphtheria and tetanus toxoids it is not feasible, for toxicity 
reasons, to compare the im munogenicity o f the native protein with its non-toxic 
derivative. W ith non-toxic proteins, such as OA and BSA, the chem ical changes 
produced by toxoiding agents have been well documented (Habeeb and Hiramoto, 
1968; Habeeb, 1969) but no comparative immunogenicity studies were reported. O f 
particular interest therefore is the study of Nencioni et aL (1991) on the treatment of 
genetically-detoxified PT with formaldehyde. Here the formaldehyde treatment as 
normally applied to biologically-active PT had neither a beneficial nor a detrimental
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effect on immunogenicity although the specificity of the antibodies changed with the 
severity of formaldehyde treatment. However, the storage stability o f the preparation 
was improved by a mild formaldehyde ti’eatment without affecting antibody specificity.
In view of the above, the decision was taken at the start of this work to make 
parallel comparisons of the effects of treatment with formaldehyde, glutaraldehyde and 
EDAC both on PT and FHA and also on a model antigens lysozym e (LZ) and 
ovalbumin (OA), the latter being treated with EDAC only. However, before discussing 
the results so obtained, it was necessary to define appropriate methods for the statistical 
processing of mouse serum ELISA titres and this is presented next.
SERUM ELISA TITRES AND THEIR POPULATION DISTRIBUTION 
Determination of End-Points
ELISA titres throughout the study were calculated from the intersection of the A ^^m o  
= 0.5 on the ordinate with the titration curve followed by interpolation down to the 
abscissa. The reciprocal of the logjo antiserum dilution was converted to its arithmetic 
value. It was necessary to calculate an ELISA titre for each antiserum since the chosen 
statistical tests depended on a full set of five replicate values (four in one experiment). 
In certain cases therefore, where the serum titre was less than the starting dilution, an 
attempt was made to obtain a titre by extending the titration curve until it reached the 
A4 9 2 nm = 0.5 intersection point. Sometimes, even this was not possible therefore that 
serum was assigned an abitrary titre of 1. Since a good positive reference serum was 
not available, this method of obtaining serum titres was used throughout this 
investigation.
A brief survey of the current literature revealed a number of methods for the 
calculation of ELISA titres. These included: comparing the linear portions from plots of 
absorbance versus log serum dilutions for test and reference sera by the parallel-line
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assay (Huang et al , 1996); expressing titres as an absolute value in jitg/ml by 
extrapolation from a standard curve of a reference serum pool (Samore and Siber,
1996); expressing ELISA titres as the reciprocal of the highest dilution o f antiserum 
above background controls (Roberts et aL, 1995; D ertzbaugh and W est, 1996; 
Fernandez et a l , 1996); or simply as the reciprocal serum dilution giving an O.D. of 
0.5 (Ott et a l , 1995) or 0.3 (O'Dempsey et a l , 1996).
Generally, the ELISA procedures for the quantification of anti-LZ, anti-PT and 
anti-FHA performed satisfactorily. However, the ELISA methodology for quantitating 
anti-OA required further development. It was found that an OA concentration of 100 
p-g/ml was required to give complete saturation of binding sites.To obtain maximal 
binding of specific antibody an excess of antigen had to be present in the coating phase 
so that the equilibrium point could be reached where most of the binding sites on the 
plastic are occupied (Engvall and Perlman, 1972). Kemeny (1992) reported that too 
high a concentration of protein during the coating phase in an ELISA resulted in protein 
to protein interactions leading to dissociation of 'bound* protein during the assay. 
Typically, a protein concentration of 1 to 10 pg/ml resulted in maximal binding of the 
protein to the plastic without dissociation. Also, all ELISA assays were performed with 
the native untreated antigens used in the coating phase. ELISA tests with the toxoided 
antigens for the coating phase may have revealed the formation of new epitopes of the 
antigens after toxoiding.
Population Distributions
In this investigation, im m unogenicity experim ents were designed so that each 
preparation was tested at certain doses in groups of five m ice yielding a set of five 
replicate values that were required for the statistical analysis. The question arose on 
whether to analyse the data by parametric or non-parametric statistical tests and also 
whether to represent the average value for each group as the arithmetic or geometric
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mean (which is the appropriate measure of central tendency for a group of lognormally 
distributed data). A survey of the pertussis literature revealed that there seems to be no 
universally adopted method for the expression of mean antibody titres. For example, 
Ashworth et al (1982), Burstyn et al. (1983), Sato et al. (1984), Thomas et al. (1989) 
and Redhead et al. (1993) summarized ELISA titres as arithmetic means, whereas 
Robinson et al. (1989), Christodoulides et al. (1989), Podda et al. (1990), Podda et al. 
(1991), and Nencioni et a l  (1991) used the geometric mean.
Thus before choosing suitable statistical tests for the analysis of ELISA titres, 
the distribution of the population was investigated by rankit plots (Appendix 6 ). It was 
difficult to judge from the 278 rankit plots whether the data followed a normal 
distribution or that the data were normalizable by conversion to logio titres. By 
summarizing the rankit plots with each immunogenicity experiment for each of the four 
antigens, it was decided to continue with statistical tests used for normally distributed 
data by first converting to logarithm s.W eir (1967) stated that ELISA titre readings 
usually have a skewed distribution. In fact, anti-OA titres from mouse sera were cited 
as an example of normalizable data by transformation to logarithms. Thus, all statistical 
analysis was done on the logio of the serum ELISA titres.
Reid (1968) reported that antibody titres in animals show asymmetry of the 
normal distribution curve or skewing. Logarithmic transformation of this type of data 
results in the curve being converted to the bell shape typical of a normal distribution. 
The data are thus said to follow a lognormal distribution as they are normalizable by 
conversion to logarithms. Such converted data are then suited for the statistical tests 
which are appropriate for sampling from a normal distribution (Colquhoun, 1971). A 
number of recent studies on vaccines stated that logarithmic transformation of antibody 
titres was carried out before statistical analysis because of skewing (Huang et a l ,  1996; 
Mulholland ef a/., 1996; Fernandez e ra /., 1996; O'Dempsey etal.,  1996; M iller er a/.,
1997).
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C H A R A C T E R IS T IC S  O F 'T O X O ID E D ' P R O T E IN S
C hanges in SD S-PA G E P rofiles
The proteins LZ and FHA were exam ined by SDS-PAGE to investigate changes 
brought about by chem ical treatment with EDAC, formaldehyde and glutaraldehyde. 
Ovalbum in was similarly exam ined after treatment with EDAC only. The mobility of 
the 14.3 KDa monomeric LZ band decreased with the severity of EDAC treatment. 
Conversely, modification of OA with EDAC appeared to result in a slight increase in 
m obility suggesting the protein had become more electronegative. Since EDAC 
predominantly modifies negatively charged carboxyl gi'oups on glutamate and aspartate 
residues (Hoare and Koshland, 1967) and free sulfhydryl groups (Carraway and 
Triplett, 1970) when reactions are carried out at acidic pH , the increased positivity of 
ED AC-treated LZ observed in SDS-PAGE is probably not surprising. Also, the 
presence of dimers suggest cross-links introduced by chem ical treatment which may 
restrict the binding of sodium-dodecyl sulphate (SDS) and concomitantly lower the 
electrophoretic mobility (Weber and Osborne, 1985). The slightly faster mobility of 
EDAC-treated ovalbumin is either a concentration effect or due to a large decrease in 
SDS binding which sometimes decreases the frictional drag because of fewer SDS 
molecules, thereby increasing the mobility.
Habeeb (1969) and Pass and M arcus (1970) observed that formaldehyde- 
treatment of BSA and rabb it serum album in respectively resulted in the proteins 
becoming more electronegative in polyacrylamide disc gel electrophoresis and attributed 
this to the modification of positively charged amino groups. However, modification of 
LZ by formaldehyde and glutaraldehyde in this study did not show any changes in the 
mobility of the monomeric LZ band. Rather, these agents caused the formation of 
dimers and polymers. Formaldehyde and glutaraldehyde are w idely accepted cross- 
linking agents and the chem ical mechanisms of these effects have been documented by
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Fraenkel-Conrat and Olcott (1948a and 1948b) for formaldehyde, and Flardy et al. 
(1979) for glutaraldehyde. S tudies by Habeeb (1969) w ith BSA and OA-BSA 
conjugates, Onica et aL (1978) with rabbit serum album in and HayGlass and Strejan 
(1983) with ovalbumin reported polymerization o f these antigens after glutaraldehyde 
treatment and changes in mobility such that treated proteins cross-linked to such an 
extent that they were unable to enter the gel. In a study by Hopwood et al. (1988), 
where the effect of microwaves, heating and formaldehyde were exam ined on a number 
of proteins, LZ-F preparations were dimerized extensively and also formed polymers.
The major effect of treating FHA with the three chem ical agents also resulted in 
the formation of cross-linked polymeric material although, the polymerization effect 
was less after EDAC-treatment com pared with formaldehyde and glutaraldehyde. 
Polymerization after formaldehyde and glutaraldehyde treatment of bacterial toxins as 
assessed by SDS-PAGE has been reported by Murphy (1967), Warren et al. (1973), 
Bazaral et al. (1973), Saletti and Ricci (1974), W arren et al. (1975), Cryz et  
a/.(1981), Porro et al. (1980) and Pollack and Prescott (1982). In a recent report, the 
treatment of FHA with formaldehyde was reported by Di Tom maso et al. (1994). 
These workers also observed the presence of high MW material >200 KDa which only 
barely entered the gel. Thus, the generation of multimeric products after chem ical 
treatment of LZ, OA and FHA with toxoiding substances appears common.
Effects on Structure and Biological Activities
In order to assess the effect of chem ical treatment, lysozyme was tested for loss of lytic 
acitivity for M. lysodeiktlcus cells; FHA was assayed for changes in haemagglutinating 
(HA) activity; and pertussis toxin was tested for alteration in histamine-sensitizing 
activity (HSA). An attempt has been made to explain changes in biological activities in 
terms of the chem ical modification of reactive residues by each toxoiding reagent. In
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order to do so, the number of potentially reactive residues that may react with each 
toxoiding agent per molecule of LZ , OA, FHA and PT is shown in Table 45.
L ysozym e (LZ)
EDAC treatment o f lysozyme (LZ) resulted in between 33 to 43% loss of activity 
whereas formaldehyde and glutaraldehyde treatment abolished activity to >99%. 
Relatively low levels of inactivation were obtained with EDAC even when the reagent 
was used at 3, 30, 60 and 120 times molar excesses of the num ber of potentially 
reactive residues of LZ (i.e. eight aspartate , two glutamate, three tyrosine and ten 
serine residues). The am ino-acid sequence of hen egg-white LZ is shown in Fig. 35 
with residues that ai'e part o f the active site highlighted in bold print.
Studies by Blake et al. (1965), Blake et al. (1967) and Phillips (1967) on the 
crystallographic structure of LZ in the late 1960s deduced that all carboxyl groups 
appeared to be on the surface of the molecule and hypothesised that 4 out of the 10 
(Asp-52, Asp-6 6 , Asp-101 and Glu-35) were involved in the catalytic action or were 
important in substrate binding. Dickerson and Gels (1969) stated that charged polar 
residues appear on the surface and the great majority of non-polar hydrophobic groups 
are buried in the interior. These studies imply that the am ino-acids which are reactive 
with EDAC are probably accessible to the reagent. However, in practice, the treatment 
with carbodiimides is more complex and factors such as pH, addition of a nucleophile, 
addition of a dénaturent, and the conformation of the protein, all govern the reactivity. 
The modification of LZ by carbodiimides has been discussed by Hoare and Koshland 
(1966), Lin and Koshland (1969), Lin (1970), Hayashi et al, (1972), BCi*amer and 
Rupley (1973), Timkovich (1977) and Yamada et al., (1983).
Lin and Koshland (1969) and Lin (1970) showed that modification of the 
carboxyl group o f Asp-52 by two different carbodiim ides in the presence of a 
nucleophile abolished enzyme activity. Later, Kramer and Rupley (1973) found that the 
'exposed' carboxyl group of Asp-101 was modified most readily whereas the 'buried'
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Table 45: Potentially reactive residues of lysozym e, ovalbumin,
filamentous haemagglutinin and pertussis toxin with formaldehyde, 
glutaraldehyde and EDAC.
Ami no-acid Reactivity No. of residues/ molecule of^
with^ LZ OA FHA PT
Total - 129 385 3591 972
Lysine F, G 6 2 0 173 24
Tyrosine E, F, G 3 1 0 39 49
Tryptophan F 6 3 14 9
Histidine E, F, G 1 7 62 2 1
Asparagine F 13 17 47 26
Cysteine E, F, G 8 h 6 b 3h 2 b
Aspartate E 8 14 203 34
Glutamate E 2 33 153 41
Serine E 1 0 38 250 70
^ E, F and G denote the toxoiding reagents EDAC, formaldehyde and glutaraldehyde 
respectively.
h cysteine residues in LZ were present as 4 disulphide bonds. The presence of free 
sulfhydryl groups in OA, PT and FHA was not determined.
c The am ino-acid sequences were obtained from Canfield (1965) for LZ, McReynolds 
et al. (1978) for OA, Domenighini et al. (1990) for FHA and Locht and Keith (1986) 
for PT.
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carboxyl of A sp - 6 6  and also Glu-7, A sp-18 were least reactive. The carboxyl of Glu- 
35 which is also largely 'buried' was again readily modified however, the rate of this 
reaction was dependent on the concentration of the nucleophile. These workers found 
that three additions of EDAC at 0.05 M to LZ at 10 mg/ml, pH 4.9-5.0 for 6  h without 
the addition of a nucleophile produced no significant effect on lytic activity.
The modification of LZ in this study was done w ithout a nucleophile and also 
for 24 h compai'ed with the 6  h used in the above studies. Despite these differences, 
some modification of the carboxyl groups in the active site probably did take place to 
cause the 33-43% loss in activity. The longer period of the EDAC reaction may have 
increased the rate of side reactions with resultant changes in protein conformation 
leading to reduced efficiency of substrate binding. K ramer and Rupley (1973) found 
the side reactions N-acylurea formation, inter- or intramolecular cross-linking and 
modification o f tyrosine residues to be unimportant in their study. However, these 
reactions may have occured as evidenced by the formation of dimers and polymers of 
LZ which occur when activated carboxyls react with other protein groups as 
nucleophiles and form covalent cross-links as reported by Timkovich (1977).
Formaldehyde and glutaraldehyde predominantly react with the epsilon-amino 
groups of lysine (lys) residues (Fraenkel-Conrat et al., 1945). Since all 6  lys residues 
are on the surface of LZ they should be readily available for modification. There are no 
lysine residues involved in the binding of substrate in the active site, although Lys-33 is 
situated at the very bottom of the cleft. Imoto et al (1972) reviewed a number of studies 
which utilised various agents that modified the amino groups of LZ. Certain chem ical 
reagents like acetic anhydride (Fraenkel-Conrat, 1950) which modified all 6  lys 
residues could com pletely inactivate the enzym e, whereas others, such as O- 
methylisourea did not affect enzyme activity; neither did the introduction of cross-links 
by phenyl-2-4 disulphonyl chloride (Moore and Day, 1968). This work has shown that 
modification of LZ with formaldehyde and glutaraldehyde, but not EDAC, can abolish 
activity.
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Figure 35: The amino-acid sequence of hen's egg-white lysozyme.
Residues that are part of the active site are highlighted in bold. Based on Canfield and 
Liu (1965) and Phillips (1966).
;>s
Filamentous haemagglutinin (FHA)
Aside from the studies of Christodoulides et aL (1987, 1989), even after an extensive 
review of the pertussis literature, there have been no other reports on the treatment of a 
mixture of PT and FHA with EDAC. These authors used histamine-sensitising activity 
in mice as the marker for the detoxification of PT by EDAC. However, the effect of this 
agent on the haemagglu ti nating activity (HA) of FHA was not examined. While FHA in 
itself is not toxic (Irons and MacLennan, 1979b, Munoz et aL, 1981b, Sato and Sato, 
1984), a number of investigations have routinely 'detoxified' the antigen preparation to 
ensure com plete inactivation of trace amounts of PT left by the extraction and 
purification processes for vaccine manufacture (Sato et a l , 1984, Tan et a l , 1991, 
Ruuskanen et al , 1991). In none of these references was there any mention of 
inactivation of the HA by fonnaldehyde or glutaraldehyde treatment.
In the present study, the following parameters were investigated to provide 
more information on the effect o f toxoiding agents on the HA activity of FHA: 
formaldehyde concentration, time and temperature of foimaldehyde treatment, addition 
of lysine, time of glutaraldehyde treatment, EDAC concenti'ation and time of exposure 
to EDAC. A formaldehyde concentration of 6.25 mM was sufficient to abolish all 
detectable HA activity. However, it was found necessary to use a temperature of 37 °C 
with exposure for 48 h. Since fonnaldehyde can potentially react with lysine, tyrosine, 
tryptophan, histidine, asparagine and cysteine residues (French and Edsall, 1945), the 
effect of this agent on FHA is difficult to interpret.
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After an extensive literature search in BIDS, virtually no references were found 
for the inactivation of LZ w ith formaldehyde and glutaraldehyde. However, in an 
earlier study by Fraenkel-Conrat (1950), treatment with formaldehyde at neutral or 
acidic pH caused a 90% loss in activity in the presence of amines (e.g. alanine) and 
cross-linking between the amino groups and blocking of amide, guanidyl and aromatic 
groups was thought to occur.
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The reaction with the other aldehyde -glutaraldehyde was much faster in that all 
detectable activity was lost by 60 min either with or w ithout the addition of lysine. The 
faster reaction rate with glutaraldehyde has also been reported in the review by Relyveld 
(1977) for the detoxification of whole-cell pertussis vaccine, tetanus toxin, diphtheria 
toxin and other m icrobial antigens. This agent modifies lysine residues, the formation 
of methylene bridges causing cross-links. These effects may impose conformational 
constraints and thus, destroy the HA. Also, Habeeb and Hiramoto (1968) found that 
glutaraldehyde reacted with alpha-amino groups of ami no-acids, the N-term inal amino 
groups of some peptides, the sulphydryl group of cysteine, and were partially reactive 
w ith tyrosine and histidine residues. Again, as w ith form aldehyde, due to the 
corhplexity of the chem ical reactions, it is difficult to predict the effect of the reagent on 
FHA.
R ecently, M akhov et aL (1994) reported the structure of FHA based on 
electron microscopy, circular dichroism spectroscopy and computational analysis of its 
am ino-acid sequence. FHA has a globular head with a 35nm shaft which tapers slightly 
from the head end. W ith the toxoiding agents, both inter-molecular cross-links and 
intra-molecular cross-links could have occurred between FHA molecules, causing the 
formation of large aggregates which may have resulted in the concealment of binding 
sites for RBCs. In the report by Tan et al. (1991), detoxification of FHA was achieved 
with formaldehyde instead of glutaraldehyde because the former reagent produced less 
FHA precipitation.
%
With EDAC, despite increasing the concentration of the reagent to 50 mM, the
.maximum percent inactivation o f FHA was only 75%, and this was achieved in 24 h. 
Thus, under the conditions used in this study, there appears to be only a certain number 
of residues that are available for reaction with the reagent. Perhaps, cross-linking and 
m acrom olecular aggregation of ED A C-treated FHA caused the drop in HA. 
Modification of reactive residues may also disrupt the tertiary structure of the protein 
causing interference with receptor binding.
,.;5
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Pertussis toxin (PT)
The first acellular pertussis vaccine was produced in 1981 by Sato et aL (1984) and 
was a m ixture of PT and FHA detoxified with formaldehyde. Similar preparations were 
tested in large-scale clinical trials in Sweden (Ad Hoc group for the study of pertussis 
vaccines, 1988), but the PT component was found to show some reversal to toxicity 
(Storsaeter et al„ 1990). This prompted investigations into alternative methods of 
detoxification.
Numerous acellular vaccine prepai'ations have been formulated with the PT 
com ponent detoxified with a variety o f chem ical detoxification agents of which 
formaldehyde has been most commonly used. Thus, formaldehyde treatment has been 
appllied to crude extracts from B. pertussis culture supernates (Matsui and Kuwajima, 
1959, Munoz and Hestekin, 1966) and to purified PT preparations (Sato et al., 1974, 
Sato et al., 1984, Rutter et al., 1987). This present study found that formaldehyde 
treatment based on the method of Sato et al. (1984) of purified PT preparations and 
PT:FHA antigen m ixtures removed 97 to >99% of the original HSA. Therefore, 
formaldehyde is effective in reducing the HSA of PT. In the early studies of Matsui and 
Kuwajima (1959) and Munoz and Hestekin (1966), 0.5% formaldehyde ti’eatment fo r?  
days at 37 °C of culture supernates and saline extracts containing active PT was 
sufficient to destroy HSA completely. Sato et al. (1974), also reduced HSA to 0.1% of 
the original level before toxoiding by four days of formaldehyde treatment. Toxoiding 
conditions were generally similar to those used in this work. There were three to four 
additions of 0.2% formalin at pH 7.0 with 0.05 M lysine included in the reaction 
mixture. However, these workers found a reversal to toxicity, in that 3.3% of the 
original HSA was regained after storage at 37 ^C.
Detoxification o f PT alone w ith glutaraldehyde gave variable results. The 
inactivation of HSA was between 50 and 90%. In the present work, <50% inactivation 
were obtained for two o f the three PT;FHA m ixtures. Due to this very incomplete 
inactivation, the samples were retoxoided and then retested for HSA. Retoxoiding
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resulted in sucessful detoxification of PT in the PTiFHA mixtures w ith <1-2% residual 
HSA remaining. However, with PT alone, levels remained at 50-90% inactivation. 
This is in disagreement with the results of Ruuskanen et aL (1991) and Garcia-Sanz et 
al. (1992) who obtained 100 to 1000 fold, and 98.9%, reductions in HSA respectively. 
The former report used a combination of glutaraldehyde and formaldehyde treatment. 
PT was treated with glutaraldehyde for 2 h then incubated with formalin and amino- 
acids for 7 days at 40 °C. Further details of the toxoiding procedure were not provided, 
Garcia-Sanz et al. (1992), used a 6 -fold higher glutaraldehyde concentration and 
incubated for 4 rather than the 2 h used in our experiments. Interestingly, in an earlier 
report in which the toxoiding conditions were not specified, Garcia-Sanz et al. (1985), 
repbrted unsuccesful detoxification o f their PT acellular vaccine preparation with 
glutaraldehyde, formaldehyde and heat.
In my experiments, conditions for glutaraldehyde treatment were based on the 
detoxification procedure of Munoz et al. (1981b). These authors specified that the final 
HSA was <25% of the original value (the dose that sensitised 50% of mice tested was 
>16 ng/mouse) after detoxification o f a crystalline preparation of PT. Perhaps, these 
conditions need to be made more severe as in Garcia-Sanz et al. (1992) in order to 
obtain satisfactory destruction of HSA. In fact, the double toxoiding o f the PT:FHA 
mixtures resulted in a sucessful detoxification of PT by glutaraldehyde.
Detoxification studies with PT and EDAC gave disappointing results despite 
following the toxoiding procedure exactly as described by Christodoulides et al. 
(1987). EDAC at 21 mM, which is equivalent to a weight-weight agent-protein ratio of 
80; 1 for 24 h at 37 <^ C, pH 5.0 was reported to remove >99% of the original HSA of a 
mixture of PTiFHA. Under these toxoiding conditions, in my experiments, however, 
the inactivation o f HSA was generally between 50-90% except once when a PT 
preparation was 96% inactivated. As w ith glutaraldehyde, PT preparations were 
retoxoided with EDAC and retested for HSA. This time the residual HSA activity was
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<1-2%. Possibly, this discrepancy was due to an error in the concentration of EDAC, 
or its deterioration upon storage.
Cloning of the gene encoding PT by N icosia et ah (1986) and Locht and Keith 
(1986) revealed the absence of lysine residues in the SI subunit of the toxin molecule.
Therefore, since glutaraldehyde and formaldehyde react with lysine residues, A- 
protomer activity could be left intact. Nicosia et a l , (1986), noted that treatment of PT 
with glutaraldehyde led to cross-linking of the S2, S3, S4 and the S5 subunits (which 
make up the B oligomer), with the formation of multimeric aggregates, whilst the SI 
subunit retained its original size. Potentially reactive residues of PT w ith EDAC, 
form aldehyde and glutaraldehyde are listed in Table 44. Form aldehyde and 
glutaraldehyde can, in theory, react with a number of ami no-acids additional to lysine; 
therefore modification of A-protomer activity could occur. Also, these agents introduce 
cross-linking which may result in conformational changes, accounting for the drop in 
activity. Since the only activity monitored during the detoxification o f preparation in 
this study was HSA which is a function of the oligomeric B subunit (Nogimori et ah 
1984a, 1984b), it is difficult to ascertain how much the A-protomer was affected by 
these reagents.
Barbieri and Cortina (1988) mapped the catalytic region of the SI subunit which 
possessed ADP-ribosyltransferase activity and found substitution of Asp-11, Arg-13, 
and Trp-26 decreased enzyme activity to below detectable levels. Also, Glu-139 
substitution reduced activity by 15%. Since EDAC reacts with carboxyl groups and 
formaldehyde with tiyptophan, it is possible that A-promoter activity may be modified.
In fact, Christodoulides et ah (1987) observed that the EDAC-treated PT:FHA 
m ixtures did not significantly increase serum insulin levels, which is one of the 
biological activities of the A-promoter. Also, side reactions leading to the formation of 
N -acylurea adducts by reaction with EDAC (Timkovich, 1977) may also cause
V-
reduction in activity.
Î
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In conclusion, the complexity of the chem ical reactions upon treatment of the 
four antigens exam ined in this study makes evaluation of the reaction products difficult. 
A fuller investigation into the other biological activities of PT and a complete chem ical 
analyses of the four treated antigens is required to understand the effects of these 
toxoiding agents on these proteins.
IMMUNOGENICITY OF 'TOXGIDED' PROTEINS Sr.,
The effect of chem ical treatment on the immunogenicity of the four antigens ovalbumin 
(OA), lysozyme (LZ), filamentous haemagglutinin (FHA) and pertussis toxin (PT) was 
investigated in mice. The central questions addressed were, whether EDAC treatment 
caused an enhanced antibody response, whether this phenomenon occurred after EDAC 
trea tm ent of selected m odel prote ins and bacterial p rote ins, and w he ther 
im munogenicity obtained after immunization with the EDAC-treated antigen was 
superior to the conventional toxoiding agents formaldehyde and glutaraldehyde.
In the induction of an antibody response towards a foreign antigen, recognition
:by B-cells, T-cells and antigen presenting cells (APC) is involved (Unanue, 1984). B- 
cells can recognize some bacterial or parasitic antigens w ithout any intermediary by 
membrane associated surface immunoglobulin (Ig). Antigens which stimulate this type 
of response are termed T-independent (T-ind) antigens. B-cells are capable of 
recognizing free or soluble exogenous antigens. T-cells requ ire presentation of a 
pep tide sequence of the antigen associated with certain proteins called m ajor 
histocompatibility complex (MHC) molecules ultimately found on the surface of the 
APC. Antigens presented in this manner to T-cells are T-dependent (T-dep). T-cells 
possess the ability to recognize infected cells which contain foreign organisms and 
other antigens. Triggering of B-cells can be brought about by T-helper cells (Ty) which 
leads to the stimulation of a particular B-cell clone or clones and ultimately results with 
secretion of antibody directed towards T-cell epitopes.
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The antibody responses induced by untreated and 'toxoided' antigens are 
discussed separately fo r the four proteins used in this study. To sim plify the 
interpretation o f the effects the chem ical treatments had on the immunogenicities of 
these antigens, summary diagrams were prepared by com paring geometric means 
(g.m.) ELISA titres for each antigen at each dose before and after chem ical treatments 
by two-tailed t-tests. Each t-test was termed an experiment, A highly significant t-value 
(P < 1%) was scored as a +3 or -3 for an adju van ting or repressive effect respectively. 
Similarly, a score of +2 or -2 was applied for a significant t value (P>1<5%). When 
differences between the two g.m.'s were not significant, a score of 4-1 or -1  was given 
depending on whether the mean of the treated antigen was higher or lower than the 
meân of the untreated preparation. A value of 0 was applied when the two means were 
identical. These scores were plotted on the x-axis as the scale of adjuvanting.
Ovalbumin
The effect of EDAC treatment of OA on antibody responses is summarized in Figure 
36. An overall repressive effect is apparent with 15 'experiments' yielding negative 
values (7 of which were statistically significant) compared with 9 positive values (1 
being statistically significant). A dose of 0.1 mg/mouse best shows this repressive 
effect whilst immunization with 0 .0 1  or 1 .0  mg/mouse did not always give lower g.m. 
titres relative to the untreated control. Statistical analysis of variance also showed that 
EDAC treatment of OA could reverse the adjuvanting effect of Al(OH)]
A 1(0 H )3  is a commonly used adjuvant and licenced for use in humans. In these 
experiments, treatment with EDAC could nullify the adjuvanting effects of Al(OH)g. 
The OA preparations injected into mice with Al(OH )3  in a formulation which should 
have made it more resistant to dispersal. As such, it acts as a depot for prolonged 
antigenic stimulation and should have perpetuated the immune response.
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Figure 36: A summary of the effect of EDAC on the immunogenicity of 
ovalbumin
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However, in this study, addition of Al(OH )3  to OA-E preparations did not result in 
increased responses.
OA is a rela tively small globular protein therefore it is endocytosed or 
pinocytosed by APC. This is followed by proteolytic processing to yield 'sequential' T- 
cell epitopes (Shimonkevitz et al., 1983). These authors indicated that preparations of 
denatured ovalbum in, which were largely aggregated, did not stim ulate T-cell 
hybridoma tumour lines and suggested that this was due to insufficient exposure of 
critical sites. Allen (1987) reported that there was an absolute reqiurement for OA to be 
proteolytically cleaved before presentation could occur. Cleavage exposes epitopes 
which may be hidden by the tertiary conformation of the protein. In this study, the 
foifnation of polymers (visualized as faint high molecular w eight bands by SDS- 
PAGE) by the EDAC treatment may have hindered processing of the protein, reducing 
the effective presentation of T-cell epitopes and therefore lower antibody titi*es. Vidard 
et al. (1992), generated 9 peptides which were antigenic T-cell epitopes which could be 
obtained from OA by digestion with different pools of proteases. Chem ical 
modification by alkylation, dénaturation and reduction of OA could reduce stimulation 
o f certain T-cell hybridom as suggesting that these treatments were affecting OA 
processing. However, a large proportion o f the treated protein rem ains in the 
monomeric foim. Diment (1990) reported that cathepsin D, an aspartyl protease, had an 
important role in the processing of OA for antigen presentation. Treatment with OA 
primarily modifies aspartate and glutamate residues therefore perhaps the action of this 
enzyme is obstructed because of altered target residues. Formation of altered epitopes 
after EDAC treatment has been observed by Davis et al. (1984). Perhaps use of native 
OA as the coating agent in the ELISA was not appropriate for the detection of antibody 
against OA-E which may have altered epitopes. Thus, an ELISA developed with OA-E 
in the coating phase m ight detect antibodies to epitopes not present on the native 
molecule.
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L y so zy m e
A ntibody responses towards LZ and LZ treated with EDAC, form aldehyde and 
glutaraldehyde were quantified from mouse sera as described previously. Summary 
diagrams of the results from t-tests com paring the untreated with the chem ically 
modified preparations were constructed (Figure 37). It can be seen that with EDAC 
(Figure 37), 16 'experiments' had a positive adjuvanting effect, of which only 3 were 
statistically significant, whereas 8  statistically insignificant experiments had negative 
values. W ith formaldehyde and glutaraldehyde, no major effects on adjuvanticity could 
be demonstrated. This may have been due to the small number o f 'experiments' from 
which no definite conclusions could be made. N evertheless, a dem onstrable 
adjuvanting effect was obtained after treatment with EDAC (Figure 37). The analysis of 
variance also revealed statistically significant adjuvanting effects with EDAC from two 
separate experiments but none with either formaldehyde and glutaraldehyde. This 
adjuvanting effect of EDAC was obtained only after immunization of LZ-E treated with 
EDAC at 21 mM compared with untreated LZ.
Lysozyme is a T-dependent antigen (Harding et al. 1988), therefore B-cells 
must interact with T-cells in the induction of an antibody response. B-cells which can 
also act as APCs use surface immunoglobulin (Ig) to take up and concentrate specific 
antigen which is then processed and presented in association with MHC class II 
molecules to T-cells. Lanzavecchia (1985) estimated that B-cells accumulate specific 
antigen up to 10^-fold more efficiently then other antigen-presenting cells. Enhanced 
binding of LZ-E to membrane Ig on B-cells may result in enhanced uptake and 
processing. B-cells may preferentially present LZ-E to T-cells which may lead to the 
stimulation and proliferation of the respective B-cell clones (Chesnut and Grey, 1981 
and Lanzavecchia, 1985) resulting in the observed increase in immunogenicity. EDAC 
treatment of LZ may slightly alter the tertiary conformation of the protein exposing
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Figure 37: A summary of the effect of EDAC, formaldehyde and 
glutaraldehyde on the immunogenicity of lysozyme.
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binding sites or make binding sites more readily accesible to membrane bound or free 
Ig.
Polymerization or aggregation of foreign antigen can lead to increased uptake by 
macrophages (Harding et ah, 1988). EDAC treatment of LZ led to polymerization 
particularly dimerization but to a lesser extent than treatment with formaldehyde and 
glutaraldehyde. The increase in antibody response towards preparations of LZ-E could 
be due to the antigen being more readily "seen" and accessible to the APC system. 
Since increased immunogenicity did not result with formaldehyde and glutaraldehyde, 
excessive polym erization of the antigen may make it more resistant to proteolytic 
breakdown during antigen processing thereby reducing effective presentation. B-cell 
activation through cross-linking of B-cell antigen receptors can occur; however, 
excessive B-cell receptor cross-linking by antigen might decrease B-cell triggering. The 
LZ-F and LZ-G preparations may not have enhanced immunogenicity, but neither did 
they reduce it. Perhaps there is limited proteolytic degradation o f these preparations, 
with enough stimulation to generate responses similar to the untreated LZ, but not to 
enhance the responses.
Filamentous Haemagglutinin
Filamentous haemagglutinin (FHA) has been shown to protect mice against respiratory 
challenge with B. pertussis ( Sato et al. 1981b, Sato et al. 1982, Oda et al. 1984 and 
Sato and Sato 1984). Since these observations have been made, FHA is considered to 
be one of the protective antigens of this organism. Most o f the acellular vaccine 
preparations have FHA as a component (Sato et al. 1984, Rutter et al. 1987, Podda et 
al. 1991 and Edwards, 1993).
FHA is essentially non-toxic and important in bacterial adhesion (Reiman et al. 
1989). The rationale for its inclusion therefore was for the production of antibodies 
which would block attachment of the organism to the respiratory mucosa and thereby
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reduce the risk of infection (Edwards, 1993). Indeed, Swedish field trials with two 
Japanese acellular vaccine preparations showed that the two com ponent PT:FHA 
prepai’ation present in the ratio of 1:1 (JNIH-6 ) was more protective in infants (vaccine 
efficacy 69%) than the monocomponent PT (JNIH-7) for which vaccine efficacy was 
54% (Ad Hoc group for the study of pertussis vaccines, 1988).
FHA was subjected to a mild chemical treatment with toxoiding agents to 
inactivate trace amounts of contaminating toxic material such as PT present after the 
extraction and purification procedures or to stabilise the protein before incorporation 
into a vaccine preparation (Sato et al. 1984, Podda et al. 1991).
In my work, FHA was extracted from a Tn5 mutant B. pertussis strain BP357 
(Weiss et al, 1985) so that the preparation would be free of PT. Since PT is known to 
enhance antibody responses to antigens that are injected with it, it was important to 
ensure that the FHA preparation was free from the toxin in order to compare the effect 
of chemical toxoiding agents on the immunogenicity of FHA. The effect of injecting 
FHA with a quantified amount of PT after toxoiding the mixture was examined in 
separate experiments.
The summary diagi'ams depicted in Figure 38 show the positive or negative 
effects on immunogenicity of chemically-treated preparations of FHA, Overall, EDAC 
treatment had a negative adjuvanting effect, with three negative experiments (two of 
which were statistically significant) as opposed to three non-significantly positive 
experiments. Formaldehyde-treatment of FHA seemed to have a positive adjuvanting 
effect on immunogenicity as shown by three positive ( 2  significant) compared with 
three insignificant negative experiments. Glutaraldehyde treatment had similar effects 
with two out o f three significant positive experiments and one out of three significant 
negative experiments.
A number of relatively recent publications detail the production of acellular 
pertussis vaccines in which FHA was treated with formaldehyde or a combination of 
formaldehyde and glutaraldehyde (Watanabe et a l ,  1991; Ruuskanen et a i ,  1991; Tan
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Figure 38: A summary of the effect of EDAC, formaldehyde and 
glutaraldehyde treatm ent on the im m unogenicity of filam entous  
haemagglutinin (FHA).
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et a /.,1991; Podda et al., 1991). In none of these studies was a direct comparison of the 
treated preparation made with native FHA. Furthermore, since the FHA was made for 
vaccine purposes, all the preparations were injected as m ixtures w ith PT and/or 69 
KDa. It is therefore difficult to assess from the published literature exactly how the 
immunogenicity of FHA was affected by toxoiding. Certainly, the immunogenicity 
after chem ical treatment as regards protective activity was not impaired since treated 
FHA gave satisfactory ELISA titres and aided protection from i.e. challenge of mice 
against virulent B. pertussis (Tan et al. 1991). These workers also reported that 
immunization with mixtures of treated-FHA and pertussis toxoid resulted in higher 
FHA titres than im m unization with a prepara tion o f W CPV. In all o f the 
aforementioned publications, there were satisfactory increases in ELISA titres towards 
the treated FHA in the various ACPV preparations probably as a result of immunisation 
with the known adjuvants PT and aluminium hydroxide or aluminium phosphate.
The sligh t enhanced anti-FH A  responses tow ards fo rm aldehyde and 
glutaraldehyde-treated FHA observed in this study, may be a result o f polymerization 
of the protein and therefore continuous stimulation of the immune response or increased 
accessibility to APCs. Indeed, as observed by SDS-PAGE, FHA-F and FHA-G 
preparations were polymerized to a greater extent than FHA-E.
In 1991, Di Tom m aso et al. found that proteolytic fragm ents of FHA 
stimulated certain T-cell clones which were mainly from the carboxy term inal and 
amino term inal regions of the protein. In a later report (Di Tommaso et al. 1994), T- 
cell responses were investigated towards formaldehyde-treated B. pertussis antigens, 
FHA being one of them. They reported that formaldehyde-treatment o f the protein 
resulted in the inhibition of certain T-cell clones and suggested a number of causes for 
this inhibition. Firstly, that formaldehyde-treated FHA was either more resistant to 
antigen processing with interference in proteolytic breakdown into peptides; or that 
there was reduced peptide binding to MHC molecules; or lastly, that there was impaired 
recognition by T-cell receptors of the peptide-MHC complex. The slight negative effect
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of EDAC on the immunogenicity of FHA could be due to any o f the above reasons. 
However, the conflicting results obtained with FFÏA-F and FHA-G preparations 
suggests that treatment with the two aldehydes modified the FHA in a manner different 
to EDAC. Perhaps treatment with the two aldehydes which results in cross-linking of 
the molecules changes the status of FHA as a T-dependent antigen to a T-independent 
antigen due to the increased aggregation of the treated FHA.
Pertussis Toxin and Mixed Antigen Preparations of Pertussis Toxin and 
Filamentous Haemagglutinin
Fears over the safety of WCPV preparations due to a high concentration of endotoxin 
and the possibility of active PT led to the development of acellular vaccines (Griffiths, 
1988). Although high levels of anti-PT and anti-FHA were found in the serum of 
vaccinated individuals, the vaccines were not deem ed satisfactory due to some 
reversion of the activity of the formaldehyde-detoxified PT component (Storsaeter et 
al., 1988). Following this observation, a number of workers attempted alternative 
chem ical detoxification procedures with formaldehyde (Sato et ta/. 1984, Watanabe et 
al., 1991), glutaraldehyde (Quentin-Millet a l ,  1988), hydrogen peroxide (Sekura, 
1988), tetranitromethane (W inberry et al., 1988) and EDAC (Christodoulides et al., 
1987) as some alternatives. The latter authors observed that EDAC-treatment of PT not 
only reduced toxicity to below detectable levels but actually enhanced immunogenicity. 
This observation formed the basis of the present investigation.
The immunization of mice with chem ically-detoxified PT only, or detoxified in 
conjuction with FHA, was exam ined. Summaiy diagrams of the effects of the three 
toxoiding agents on the immunogenicity of the preparations are shown in Figure 39. 
Figure 39a revealed that immunization with PT-E, PT-F or PT-G without FHA showed 
no significant adjuvanting effects in comparison with untreated PT (by t-tests carried 
out with ELISA titres from sera raised against 1 or 5 pg/mouse dose of PT or its
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Figure 39; A summary of the effect of EDAC, formaldehyde and 
glutaraldehyde on the immunogenicity of pertussis toxin (PT) alone and 
antigen mixtures of PT and FHA.
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toxoids). Statistical analysis by 4-point parallel line assays however, indicated that the 
PT-E and PT-G preparations were just significantly adju van ted at the P= 5% level. 
W hen the three toxoids were compared relative to each other by one-tailed t-tests for 
each dose at 1, 5 and 25 pg/mouse, formaldehyde detoxified PT induced significantly 
lower responses when compared with EDAC-treated PT at the 25pg dose. Thus, it can 
be concluded that detoxification of PT alone with EDAC and glutaraldehyde does result 
in the production of a higher response relative to the native toxin but this adjuvanting 
only just achieves statistical significance. An important point is that the PT-E and PT-G 
preparations used to immunize the mice were incompletely detoxified (only between 50 
to 90%). The PT-F preparation was more acceptably inactivated with HSA >99% 
inactivated. The incomplete detoxification of PT-E and PT-G were only subsequently 
realised as mice had already been immunized. Also, the incomplete detoxification of 
PT-E and PT-G preparations was unexpected since the detoxification conditions chosen 
from the existing literature were standard methods. Three separate preparations of 
PT.-FHA present in the ratio's of 1:2.25 for AP16, 2:3 for PF3 and 1:5 for PF4 were 
tested for HSA and immunogenicity after treatment with the three toxoiding agents. 
W hilst form aldehyde trea tm ent inactivated HSA by between 98 to 99%, the 
glutaraldehyde trea tm ent was unsuccesful in reducing toxicity (<50% HSA 
inactivation). Treatment with EDAC was marginally more effective in reducing the 
activity of A P I6  and PF3 (between 50 to 90% inactivation) and PF4 (90 to 90% 
inactivation). The concomitant effects on the immunogenicity were also exam ined and 
the results are summarized for anti-FHA and anti-PT titres in Figures 39b and 39c 
respectively. There were no major enhancing effects found with anti-FHA responses 
although form aldehyde-treated PF3 and PF4 were significantly low er than the 
respective untreated preparations. Significantly higher anti-FHA responses were 
obtained with A P I 6  trea ted with fo rm aldehyde and ED A C how ever, the 
immunogenicity of the untreated preparation itself was very low. Since this preparation 
had been extracted previously and stored frozen for a number of years before use, it
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was thought that the FHA had probably degraded, but toxoiding which results in 
aggregation may have restored immunogenicity. Due to the low immunogenicity of the 
native A P I 6 , results from the analysis were interpreted with caution. A nti-PT 
responses were similar for all three toxoids therefore they were analysed collectively. A 
definite adjuvanting effect was noted for EDAC, w hereas form aldehyde and 
glutaraldehyde treatments did not significantly enhance or reduce immunogenicity 
relative to the untreated preparations.
The inherent toxicity of bacterial toxins have made parallel comparisons of the 
immunogenicity of the untreated toxin and the detoxified counterpart impractical. In the 
few cases where the toxin could be compared with the corresponding toxoid it was 
found that the effect of toxoiding agents varied with the toxin being treated. 
Enhancem ent o f im m unogenicity was found after form aldehyde trea tm ent o f 
staphylococcal 9-haemolysin (Steame and Birkbeck, 1980), staphylococcal enterotoxin 
B (Warren et al., 1973) m\d B . pertussis heat-labile toxin (Livey and Wardlaw, 1984). 
However, these toxins were poorly immunogenic before detoxification. Polymerization 
o f the toxin molecules were suggested to be the cause of the enhanced responses. Also, 
the presence of free molecules of circulating toxoid (which had less efficient binding to 
host cell receptors as a result of the formaldehyde treatment) may have resulted in 
continued stimulation of the immune response. Conflictingly, formaldehyde treatment 
of cholera toxin (Holmgren et al., 1972) and Pseudomonas aeruginosa  exotoxin A 
(Pavlovskis et al. 1981; Cryz et al., 1981; Cryz et al., 1983) were reported to reduce 
immunogenicity. This was attributed to storage and handling of the materials used for 
im munization, the age of immunized animals, different aggregation states of the 
immunogen and an altered antigenic status of the toxoided molecules.
Results from this study also indicated that immunisation with PT-F alone 
repressed immunogenicity relative to the native toxin. However, the anti-PT response 
was not affected when mixtures of PT and FHA detoxified with formaldehyde were 
injected. The anti-FHA response was significantly lower for two out of the three
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formaldehyde-detoxified mixtures of PT and FHA. Formaldehyde toxoiding of PT was 
routinely used in the manufacture of Japanese ACPV preparations. Sato et a l  (1984) 
detoxified a mixture of PT and FHA with formaldehyde and stated that their preparation 
was one-tenth as toxic as conventional WCPV but just as effective in the production of 
anti-FHA and anti-PT in children. Similarly, Watanabe et al. (1991) also detoxified 
antigen mixtures of PT and FHA with formaldehyde in the production of Kitasato 
ACPV preparations and found anti-PT and anti-FHA responses in mice to be 
comparable with WCPV. In a report by Sato and Sato (1988), formaldehyde-detoxified 
PT:FHA mixtures induced comparable anti-PT responses to W CPV in mice but the 
anti-FHA responses were higher. In my study, PT:FHA mixtures treated with the three 
toxbiding agents were also compared to a heat-killed sonicated suspension o f B, 
pertussis cells although only one-quarter of the human dose (5 OU) was injected into 
each mouse. A nti-PT and anti-FHA responses were lower than with the purifed 
detoxified antigens. This was probably a result of the lower quantity of antigen present 
in the sonicated preparation.
It is difficult to assess the effect of formaldehyde on the immunogenicity of PT 
and PT;FHA mixtures from these studies since firstly, no direct comparison was made 
with the native toxin and secondly being ACPV preparations, the detoxified PT was 
usually injected with other antigens apart from FHA. Comparisons were usually made 
with WCPV preparations and equivalent immunogenicity was reported. In 1989, Pizza 
et al., constructed a non-toxic mutant of PT using molecular genetic techniques and 
termed it PT-9K/129G. This mutant protein contained an Arg^ to Lys and a Glu^^^ to 
Gly substitution in the SI subunit which made it devoid of any activity. This genetically 
engineered protein was not only devoid of toxicity, but also did not revert to its active 
form, which is a problem with formaldehyde-detoxified PT (Sato and Sato, 1988). 
Nencioni e ta l. (1990), showed that PT-9K/129G did not change its biological and 
immunological properties; therefore it was possible to explore the effect of chemical 
treatment on immunogenicity, on a molecule which was practically identical to the
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native toxin without the associated toxicity. In a later report, Nencioni et aL (1991), 
showed that after form aldehyde trea tm ent of PT-9K/129G the total am ount of 
antibodies was not affected. Nor did the specificity and quality of the antibodies change 
w ith the severity o f the formaldehyde treatment. However, they found that the 
formaldehyde treatment affected the natural B-cell epitopes present on the molecule and 
postulated that the immune system may produce antibodies directed against non­
protec tive epitopes, or lower affinity antibodies for protective epitopes. It is possible 
therefore that the lower responses obtained upon injection of my PT-F or (PT:FHA)-F 
may be due to altered antigenicity o f the resulting toxoids. Also, aggregation or 
alterations in the conformation of the toxin after the formaldehyde treatment may mask 
imfriunodominant epitopes. In the review by Rappuoli et al. (1994), treatment of PT 
w ith formaldehyde was reported to eliminate some B-cell epitopes. Di Tommaso et al. 
(1994) reported that formaldehyde treatment of B. pertussis  antigens im paired 
proteolytic processing, consquently with fewer T-cell epitopes being generated. Thus, 
the reduced immunogenicity of formaldehyde-detoxified antigens can be explained by 
these observations.
G lu taraldehyde-treatm ent o f PT and PT:FHA m ixtures did not have as 
deleterious effects on the immunogenicity as formaldehyde treatment. In view o f the 
fact that glutaraldehyde modifies proteins in a similar manner to formaldehyde but with 
bifunctional reactivity, the antigenicity of the molecules would be expected to be 
modified accordingly. However, unlike formaldehyde, the glutaraldehyde treatment 
used in these experiments did not inactivate the HSA of PT effectively. As mentioned 
previously, the HSA of PT-G was inactivated only to levels of between 10 to 50% of 
the original. The PT:FHA m ixtures treated with glutaraldehyde were only <50% 
inactivated. Thus, the PT molecule appears to have been minimally affected by the 
glutaraldehyde treatment as regards toxicity, suggesting that antigenic epitopes were 
probably also unchanged.
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D etoxification o f PT w ith glutaraldehyde in my experim ents was done 
according to the conditions specified by Munoz et al. (1981a, 1981b). These workers 
reported inactivation of HSA activity >75%. I found that a double toxoiding treatment 
with glutaraldehyde was requ ired before HSA could be inactivated to >98%. 
Unfortunately however, the immunogenicity of these retoxoided preparations was not 
determ ined. In a report by Garcia-Sainz et al. (1985), a B. pertussis  cell supernate 
which contained PT am ongst other antigens was detoxified by a more severe 
glutaraldehyde treatment. The antibody response towards the toxoided preparation was 
investigated by W estern blotting (Garcia-Sainz et a l ,  1992) and the response was 
mainly directed towards the A-protomer. These authors suggested that the A-protomer 
waê associated with or cross-linked to other subunits making the A-protomer a better 
immunogen in the toxoided preparation compared with the untreated preparation which 
contained the isolated subunits. Since the HSA is a property associated with the B- 
oligomer (Nogimori et al., 1984a, 1984b) it can be concluded that the glutaraldehyde 
treatment applied in this study did not affect the B-oligomer.
Ruuskanen et al. (1991), detoxified PT with glutaraldehyde followed by a 
longer incubation with formalin. Their PT toxoid was devoid of HSA at 25 qg/mouse 
and a good correlation was found between anti-PT m easured by ELISA and 
neutralizing antibody measured by the CHO assay, suggesting the toxoid was still 
antigenic. In the study by Tan et al. (1991), glutaraldehyde treatment was done in a 
buffer containing glycerol as an anti-aggregating agent. Imm unogenicity of the 
preparation was similar to the WCPV control. Again, no direct comparison was made 
with the untreated preparations. Results from these studies did not reveal any major 
differences between the toxin and toxoid with or w ithout the presence of FHA. This 
may have due to the little change in the PT molecules as evidenced by the lack of HSA 
inactivation. Relyveld (1977) compared the immunogenicity of diphtheria and tetanus 
toxoids detoxified with formaldehyde and glutaraldehyde. Both glutaraldehyde-treated 
toxins had superior immunogenicity over formaldehyde toxoids. The same observation
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was made in this study with PT but again, due to the incomplete inactivation of HSA it 
was difficult to say how much the PT was modified and therefore, the superior 
immunogenicity of glutaraldehyde-treated B. pertussis antigens is questionable.
The observation of the enhancing effect on the im munogenicity by EDAC 
treatment of a mixture of PT and FHA made by Christodoulides et ah (1987) was 
further investigated. A clear adjuvanting effect was demonstrated after EDAC-treatment 
of PT injected either alone or with FHA but not for FHA alone or as a m ixture with PT. 
These workers reported that a much higher ELISA reading (A4 9 2 ) was obtained with 
sera raised against 5 p.g of toxoid compared with the same dose of toxin (per mouse). 
They also reported that a dose of 5 qg was not sufficient to induce a detectable anti-PT 
or dnti-FHA response. Since their antigen mixtures had been adjusted to PT:FHA ratios 
of approx. 1:1, it is assumed that the PT content of a typical 5 jig dose would be 2.5 
P-g. The content of PT in 5 pg of samples used in this study (assum ing that the total 
protein in the preparations were jus t PT or FHA), would be 1.5, 2 and 0.83 pg in 
A P I6 , PF3 and PF4 respectively. Similarly, FHA content would be approx. 3.5, 3 and 
4.15 pg. The differences in the better responses could not be satisfactorily explained 
since the two immunization schedules, and mouse strains were identical.
The use of EDAC as a toxoiding agent has been reported by Lonnroth and 
Holmgren (1975) for cholera toxin and Klipstein et ah (1982) for E. coli heat-labile 
enterotoxin. EDAC was not succesful in reducing the toxicity and in neither case was 
an enhanced response reported. On the conti-ary, Klipstein et ah (1982) found that 
treatment with EDAC actually reduced both antigenicity and immunogenicity. Thus, to 
my knowledge the only instances of an enhanced response from EDAC treatment o f a 
protein antigen was by Christodoulides et ah (1987) and partially confirmed in my 
studies. These latter demonstrate that treatment of PT does result in enhanced antibody 
responses. However, what proportion of these antibodies were neutralizing and thus 
protective was not investigated. Stimulation of protective antibodies was demonstrated 
by i.e. and i.n. challenge of immunized mice by Christodoulides et ah (1987). Thus, it
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can be concluded that EDAC-treated PT does produce protective antibody. Again 
however, as with glutaraldehyde, the toxicity of PT was not effectively reduced by 
treatment with EDAC at the concentrations used and therefore, the quantity of antibody 
generated towards modified epitopes would also be reduced. The report by Nencioni et 
al, (1991) stated that the total amount of antibodies did not change after injection with 
formaldehyde-detoxified PT-9K/129G. Further investigation into the specificity and 
protective capacity of these antibodies generated by EDAC-treated PT is required.
The enhanced response towards PT may reflect a change in antigen clearance so 
that the antigen remains localised in the lymph nodes providing a constant source of 
stimulation, coupled with increased resistance to antigen degradation. Cross-linking of 
PT m olecules may change the size and conform ation o f the protein so that 
immunodominant epitopes become more accessible and more effectively presented. 
Antigen processing of the treated protein may yield sequential T-cell epitopes which 
stimulate a greater population of T-lymphocytes. An altered conformation may present 
non-protective epitopes which are more antigenic. EDAC-treatment may alternatively 
increase susceptibility o f the m olecules to APC proteases w ith generation of an 
increased number of T-cell epitopes. Thus, the interaction o f the immune system with 
toxin and toxoid is complicated, and further experiments would be required to study 
these facets.
IM PL IC A T IO N S  O F T H IS  STUDY FO R  FU T U R E A C E L L U L A R
V A C C IN E S
As noted above (p. 187) various formulations of ACPV provided protection against 
pertussis and some of them were more effective than the Connaught WCPV. The most 
efficacious ACPVs appeared to be the 5-component Connaught product, the 3-
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component Smith-Kline Beecham vaccine, and the three-component Biocine vaccine 
which contained the components in the quantities shown below.
Connaught product: Glutaraldehyde-inactivated PT (10 p,g)
(5-component) FHA (5 qg)
Fimbriae 2 and 3 combined (5 pg)
Pertactin (3 pg)
Smith-Kline Beecham product: Formalin and glutaraldehyde inactivated PT (25 pg)
(3-component) FHA (25 pg)
Pertactin (8  pg)
Biocine product: Genetically-inactivated PT (5 pg)
(3-component) FHA (2.5 pg)
Pertactin (2.5 pg)
The clinical trial conducted in Italy by Greco et al. (1996), revealed that 5 pg 
genetically-inactivated PT stimulated greater anti-PT IgG both in ELISA and by CHO- 
cell clustering assay for neutralizing antibody than 25 pg chem ically-detoxified PT, 
even though both preparations were of similar protective efficacy. According to 
Rappuoli et al. (1995), the superior immunogenicity of the genetically-detoxified 
pertussis toxoid was due to the structural integrity of the molecule with retention of T  
and B-cell epitopes. The induction of a satisfactory neutralizing antibody response with 
only one fifth of the dose norm ally required to elicit protective antibody with 
chemically-detoxified PT also resulted in fewer adverse reactions.
Marsili et al. (1992) investigated the suitability of a strain of pertussis producing 
the genetically detoxified PT molecule for production of a WCPV preparation. They 
found that seological responses towards pertussis antigens did not differ from 
conventional WCPV. However, responses towards the diphtheria and tetanus toxoids
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were reduced, suggesting that the genetically-inactivated pertussis toxoid had not 
retained its adjuvanting activity. A mild chem ical treatment with formaldehyde was 
applied to stabilize genetically-inactivated PT (Nencioni et a l ,  1990) and preparations 
of FHA and pertactin (Podda et aZ., 1991), The use of EDAC instead of formaldehyde 
to stabilize the genetically detoxified PT should therefore be investigated. EDAC 
treatment might result in further stimulation of protective antibody towards the PT itself 
and also to other antigens injected with it. The serological responses towards the other 
pertussis vaccine components, namely pertactin and fimbriae could be evaluated after a 
mild EDAC treatment and also whether their shelf life m ight benefit from the treatment. 
The immune responses towards EDAC-modified PT and LZ could be studied further to 
analyze how changes in structural conformation could lead to the stimulation of 
enhancement of antibody production.
219
R E F E R E N C E S
I
:c
■|
220
Abita, J.P., Maroux, S., Delaage, M. and Lazdunski, M. (1969). The reactivity of 
carboxyl groups in chymotrypsinogen, FEES Lett., 4, 203-206.
Ad Hoc group for the study of pertussis vaccines, (1988). Placebo-controlled trial of 
two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. 
L a n c e t, i, 955-960 .
Allen, P.M. (1987). Antigen processing at the molecular level. Immunol. Today , 8 , 
270-273,
Andersen, E.K, (1953). Serological studies on H, pertussis, H. parapertussis, and H. 
bronchisepticus. Acta. Path. Microbiol. Scand., 33, 202-224.
Arai, H. and M unoz, J.J. (1981). Crystallization of pertussigen from B ordete lla  
pertussis . Infect. Immun., 31, 495-499.
A rai, H. and Sato, Y. (1976). Separation and characterization o f two distinct 
haemagglutinins contained in purified leukocytosis-promoting factor from Bordetella  
pertussis . Biochim. Biophys. Acta., 444, 765-782.
Arai, H .,and Munoz, J.J. (1979). Fimbrial haemagglutinin in stationary and shake 
cultures of Bordetella pertussis. Infect. Immun., 25, 764-767.
Arico, B., Miller, J.F., Roy, C., Stibitz, S., Monack, D., Falkow, S., Gross, R. and 
Rappuoli, R. (1989). Sequences required for expression o f B ordetella  pertussis  
virulence factors share homology with prokaryotic signal transduction proteins. Proc. 
Natl. Acad. Sci. USA, 8 6 , 6671-6675.
Arnon, R. and Sela, M. (1969). Antibodies to a unique region in lysozyme provoked 
by a synthetic antigen conjugate. Proc. Nat. A cad .Sci. USA, 62, 163-170.
Arya, S.C., Ashraf, S.J. and Pathak, V.P. (1989). G lutaraldehyde in w hole-cell 
Bordetella pertussis vaccine. Vaccine , 1, 486.
Ashworth, L.A.E., Dowsett, A.B., Irons, L.I, and Robinson, A. (1985). The location 
o f surface antigens o f Bordetella  pertussis  by im m unoelectron microscopy. In
221
Proceedings o f  the Fourth International Symposium on Pertussis. D evelop. Biol. 
S ta n d .,^ 1 , 143-152.
A shworth, L.A.E., F itzgeorge, R.B., Irons, L.L, M organ, C.P. and Robinson, A, 
(1982). Rabbit nasopharangeal colonization by Bordetella pertussis : the effects of 
immunization on clearance and on serum and nasal antibody levels. J. Hyg. Camb., 
8 8 , 475-486.
Askelof, P., and G illenius, P. (1982). Effect of lymphocytosis-promoting factor from 
Bordetella pertussis on cerebellar cyclic GMP levels. Infect. Immun., 36, 958-961.
Banks, T .E., B lossey, B.K. and Shafer, J.A. (1969). Inactivation o f alpha- 
chymotrypsin by a water-soluble carbodiimide J. Biol. Chem., 244, 6323-6333
Barbieri, J.T. and Cortina, G. (1988). A D P-ribosyltransferase m utations in the 
catalytic S-1 subunit of pertussis toxin. Infect. Immun., 56, 1934-1941.
Barkin, R.M. and Pichichero, M.E. (1979). DTP vaccine: reactogenicity of commercial 
products. Paedriatics, 63, 256-260.
Bassili, W.R. and Stewart, G.T. (1976). Epidemiological evaluation of immunisation 
and other factors in the control of whooping cough. Lancet, 1, 471-474.
Bauminger, S. and Wilcheck, M (1980). The use of carbodiimides in the preparation of 
immunizing conjugates. Methods in Enzymology , 70, 151-159.
Bazaral, M., Goscienski, P.J. and Hamburger, R.N. (1973). Characteristics o f human 
antibody to diphtheria toxin. Infect .Immun .,7 , 130-136.
Bergman, R.K. and Munoz, J. (1964). Histaming-sensitivity in mice of different ages 
after Bordetella pertussis treatment or adrenalectomy. Proc. Soc. Exptl. Biol. Med., 
117, 400-403.
Beuvery, E.C., M iedema, F., Van Delft, R., Haverkamp, J. (1983). Preparation and 
immunochemical characterization of meningococcal group C polysaccharide-tetanus 
toxoid conjugates as a new generation of vaccines. Infect. Im m un . , 40, 39-45.
222
Blake, C.C., Johnson, L.N., Mair, G.A., North, A.C.T., Phillips, D.C., and Sarma, 
D.R. (1967). On the conformation o f the hen egg-white lysozyme molecule. Proc. 
Roy. Soc., Ser. B. Biol. Sci., 167, 365-377.
Blake, C.C.F., Koenig, D.F., Mair, G.A., North, A.C.T., Phillips, D.C. and Sarma, 
V.R. (1965). Sructure of hen egg-white lysozyme. Nature, 206, 757-761.
Blom , J., H ansen, G.A. and Poulsen, F.N., (1983). M orphology o f cells and 
haemagglutinins of Bordetella species : resolution of substructural units in fimbriae of 
Bordetella pertussis . Infect. Immun., 42, 308-317.
Blumberg, D.A., Lewis, K., Mink, C M., Christenson, P.D., Chatfield, P., Cherry, 
J.D. (1993). Severe reactions associated with diphtheria-tetanus-pertussis vaccine: 
detailed study of children with seizures, hypotonic-hyporesponsive episodes, high 
fevers and persistent crying. Paediatrics, 91, 1158-1165.
Bokosh, G.M., and Gilman, A.G. (1984). Inhibition o f receptor-mediated release o f 
arachidonic acid by pertusis toxin. Cell, 39, 301-308.
Bordet J. and Gengou O. (1906). Le microbe de la coqueluche. Ann. Inst. Pasteur, 
Paris, 20, 731-741.
Bordet, J. and Gengou, O. (1909). L'endotoxine coquelucheuse. Ann. Inst. Pasteur, 
23, 415-419.
Brennan, M .J., Zhong, M.L., Cowell, J.L., Bisher, M .E., Steven, A C., Novotny, 
P. and M anclark, C.R. (1988). Identification of a 69-kDa nonfimbrial protein as an 
agglutinogen of Bordetella pertussis. Infect. Immun., 56, 3189-3195.
Bunney, W.E. (1931). The action of formaldehyde on diphtheria toxin. J. Immunol., 
20, 47-59.
Burstyn, D .G., Baraff, L.J., Peppier, M.S., Leake, R.D., S.T. Geme (Jr), J. and 
M anclark, C.R. (1983). Serological response to filam entous haem agglutinin and 
lym phocytosis-promoting toxin of Bordetella pertussis. Infect. Immun., 41, 1115- 
1156.
■I
Carraway, K.L. and Koshland, D.E. (1968). Reaction of tyrosine residues in proteins 
with carbodiimide reagents. Biochim. Biophys. Acta  , 160, 272-274.
Carraway, K.L. and Koshland, D.E. (1972). Carbodiimide modification o f proteins. 
M ethods in Enzymology , 25B, 616-623.
Casey, P.J., and Gilman, A.G. (1988). G-protein involvem ent in receptor-effector 
coupling. J. Biol. Chem., 263, 2577-2580.
Cherry, J.D., Brunell, P.A., G olden, G.S. (1988). Report o f the task force on 
pertussis and pertussis immunisation-1988. Paediatrics, 81 (Suppl), 939-984.
223
Canfield, R.E. and Liu, A.K. (1965). The disulphide bonds o f egg-white lysozyme 
(muramidase). J. Biol Chem. , 240, 1997-2002.
Capiau, C., Carr, S.A., Hemling, M .E., Plainchamp, D., Conrath, K., Hauser, P., 
Simoen, E., Comberbach, M., Roelant, S.P., Desmans, P., Permanne, P., and Petre, 
J.O. (1990). Purification, characterisation and immunological evaluation of the 69-kDa 
outer m em brane protein of Bordetella  pertussis  . In Proceedings o f  The Sixth  
International Symposium on Pertussis.. DHSS, Publication No. (FDA) 90-1164. (Eds 
C.R. Manclark) pp 75-86.
Carraway, K.L. and Triplett, R.B. (1970). Reaction o f carbodiimides with protein 
sulfhydryl groups. Biochim. Biophys. Acta, 200, 564-566.
Carter, E.J. and Preston, N.W. (1984). Assocation between B ordetella  pertussis  
agglutinogen 2 and fimbriae. J. M ed Microbiol. , 18, 87-94.
Chestnut, R.W. and Grey, H.M. (1981). Studies on the capacity of B-cells to serve as 
antigen-presenting cells. J. Immunol., 126, 1075-1079.
Cheung, D.T. and Nimni, M.E. (1982). M echanism o f cross-linking o f proteins by 
glutaraldehyde. I. reaction with model compounds. Connective Tissue Research, 10, 
187-199.
224
Christodoulides, M., Parton, R. and Stewart-Tull, D.E.S. (1989). Optimal conditions 
fo r the toxoiding o f pertuss is toxin w ith l-e thy l-3 (3-d im e thy lam inop ropyl) 
carbodiimide. HCl. FEMS Micro. Immunol., 47, 425-436.
Christodoulides, M., S idey, P.M ., Parton, R. and Stew art-Tull, D .E.S. (1987). 
Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure. 
Vaccine , 5, 199-207.
Cody, C.L., Baraff, L.J., Cherry, J.D., Marcy, S.M. and M anclark, C.R. (1981). 
Nature and rates of adverse reactions associated with DTP and DT immunizations in 
infants and children. Paedriatics, 6 8 , 650-660.
Colquhoun, D. (1971), Lectures on Bio statistics: an Introduction to Statisitics with 
Application in Biology and Medicine, pp. 78-80, Clarendon Press, Oxford.
Confer, D.L., and Eaton, J.W. (1982). Phagocyte impotence caused by an invasive 
bacterial adenylate cyclase. Science, 217,948-950.
Coote, J.G. and Brownlie, R.M. (1988). Genetics of virulence of Bordetella pertussis. 
In; Pathogenesis and Immunity in Pertussis. Chp 3, 39-74, Eds. A.C. W ardlaw, and 
R. Parton. John W iley and Sons.
Cowell, J.L., Hewlett, E.L., and Manclark, C.A. (1979). Intracellular localization o f 
the dermonecrotic toxin of Bordetella pertussis. Infect. Immun., 25, 896-890.
Cowell, J.L., Zhang, J.M., Urisu, A., Suzuki, A., Steven, A .C., Liu, T., Liu, T-Y., 
and Manclark, C.R. (1987). Purification and characterisation of serotype 6  fimbriae 
from Bordetella pertussis and comparison of their properties with serotype 2 fimbriae. 
Infect. Immun., 55, 916-922.
Cryz, S.J. (Jr.) and Iglewski, B.H. (1983). Toxoids of Pseudom onas aeruginosa  
toxin A: production by chemical and genetic means. Rev. In f  Dis , 5, S992-S997.
Cryz, S.J., Cross, A .S., Sadoff, J.C. and Purer, E. (1990). Synthesis and 
characterization of Escherichia coli 0 -18  O-polysaccharide conjugate vaccines. Infect. 
Im m un., 58, 373-377.
225
Cryz, S.J., Friedman, R.L., Pavlovskis, O R. and Iglewski, B.H. (1981). Effect o f 
formalin toxoiding on Pseudomonas aeruginosa  toxin A; biological, chemical and 
immunochemical studies. Infect. Immun., 32, 759-768.
Davis, L.E., Roth, S.A. and Anderson, B. (1984). Antisera specificities to 1-ethyl-3- 
(3-dim ethylam inopropyl)carbodiim ide adducts of proteins. Im m unology , 53, 435- 
441.
Dawson, D.J. and Mauritzen, C.M. (1969).Studies on tetanus toxin and toxoid. Aust. 
J .B io l. Sci. ,2 2 ,  1217-1227.
Dertzbaugh, M.T. and West, M.W. (1996). Mapping o f protective and cross-reactive 
domains of the type A neurotoxin o f Clostridium  botulinum  . Vaccine , 14, 1538- 
1544.
Di Tommaso, A., De M agistris, M .T., Bugnoli, M., M arsili, I., Rappuoli, R. and 
Abrignani, S. (1994). Formaldehyde treatment of proteins can constrain presentation to 
T  cells by limiting antigen processing. Infect. Immun., 62, 1830-1834.
Di Tommaso, A., Domenighini, M., Bugnoli, M., Tagliabue, A., Rappuoli, R. and De 
M agistris, M.T. (1991). Identification o f subregions o f B ord e te lla  p er tu ss is  
filamentous haemagglutinin that stimulate human T-cell responses. Infect. Im m u n ., 
59, 3313-3315.
Dickerson, R., E. and Gels, I. (1969). The structure and action of proteins, pp. 69-78. 
(Ed. W.A., Benjamin), Canada.
Diment, S. and Shinde, S. (1995). Selective processing of exogenous antigens by 
antigen presenting cells with deleted MHC genes. J. Im m uno l., 154, 530-535.
Domenighini, M., Reiman, D., Capiau, C., Falkow, S., Prugnola, E., Scarlato, E and 
Rappuoli, R. (1990). Genetic characterization of Bordetella pertussis  filam entous 
haem agglutinin: a protein processed from  an unusually large precursor. M ol. 
Microbiol, 4, 787-800.
Dubos, R.J. and Geiger, J.W. (1946). Preparation and properties of shiga toxin and 
toxoid. J. Exp. Med. , 84, 143-156.
I1:
226
Eaton, M.D. (1937). Chem ical modification of purified diphtheria toxin. J. Immunol., 
33, 419-436.
Edwards, K.M. (1993). A cellular pertussis vaccines- a solution to the pertussis 
problem ? / .  Infect. Dis., 168, 15-20.
■1
Edwards, K.M., Bradley, R.B., Decker, M.D., Palmer, P.S., Van Savage, J., Taylor, 
J.C., Dupont, W .D., Hager, C.C., and W right, P.P. (1989), Evaluation o f a new 
highly purified pertussis vaccine in infants and children. J. Inf. Dis., 160, 832-837.
Eldering, G., Hornbeck, C., and Baker, J, (1957). Serological study o f Bordetella  
pertussis and related species. J. Bacterial., 74, 133-136.
Engvall, E. and Perl man n P. (1972). Enzyme-linked immunosorbent assay, ELISA. 
III. Quantitation o f specific antibodies by enzyme-labeled anti-im munoglobulin in 
antigen-coated tubes. J. Immunol., 109, 129-135.
Evans, D.G. and M aitland, H.B. (1939). The failure o f whooping cough sera to 
neutralize pertussis toxin. J. Path. Bacterial., 465, 465-467.
Evans, D.G. and Perkins, F.T, (1955). Tests for agglutinin production of pertussis 
protective antigen, SPA. J. Path. Bact., 69, 329-331.
Farizo, K.M., Cochi, S.L., Zell, E.R., Brink, E.W., W assilak, S.G. and Patriarca, 
P.A. (1992). Epidemiological features o f pertussis in the United States, 1980-1989. 
Clin. Infect. Dis., 14, 708-719.
Fernandez, P.M ., Conner, M .E., Parwani, A.V., Todhunter, D ., Smith, K .L., 
Crawford, S.E., Estes, M .K., and Saif, L.J. (1996). Isotype-specific antibody 
responses to rotavirus and virus proteins in cows inoculated with subunit vaccines 
com posed of recom binant SA II rotavirus core-like particles (CLP) or virus-like 
particles (VLP). Vaccine , 14, 1303-1312,
Fernandez, R.C. and Weiss, A.A. (1994). Cloning and sequencing o f a Bordetella  
pertussis serum resistance locus. Infect. Immun., 62, 4727-4738.
227
Fine, P.E.M. and Chen, R.T. (1992). Confounding in the studies o f adverse reactions 
to vaccines. Amer. J. Epid. , 136, 121-135.
F ine, P.E .M ., and Clarkson, J.A. (1987). Reflections on the efficacy o f pertussis 
vaccines. Rev. Inf. Dis., 9, 866-883.
Finger, H. and W irsing von K oenig, C.H. (1985). Serological diagnosis o f 
Whooping cough. In Proceedings o f the Fourth International Symposium on Pertussis, 
Develop. Biol. Stand., 61, 331-340.
Finn, T.M. and Stevens, L.A. (1995). Tracheal colonization factor: a B ordete lla  
pertussis secreted determinant. Molec. Microbiol., 16, 625-643.
Fish, F., Cowell, J.L., M anclark, C.R. (1984). Proliferative response o f immune 
mouse T-lymphocytes to the lymphocytosis-promoting factor o f Bordetella pertussis . 
Infect. Immun., 44, 1-6.
Fraenkel-Conrat, H. (1950). The essential groups o f lysozym e, with particular 
reference to its reaction with iodine. Arch. Biochem., 27, 109-124.
Fraenkel-Conrat, H. and Mecham, D.K. (1949). The reaction o f formaldehyde with 
proteins. VII. Demonstration of intermolecular cross-linking by means o f osmotic 
pressure measurements. J. Biol. Chem. , 177, 477-486.
Fraenkel-Conrat, H., Cooper, M., Olcott, H.S. (1945). The reaction of formaldehyde 
with proteins. J. Amer. Chem. Soc., 67, 950-954.
Fraenkel-Conrat, H. and Olcott, H.S (1948a). The reaction of form aldehyde with 
proteins. V. Cross-linking between amino and primary amide or guanidyl groups. J. 
Amer. Chem. Soc., 70, 2673-2684.
Fraenkel-Conrat, H ., O lcott, H.S (1948b). The reaction of form aldehyde with 
proteins. VI. Cross-linking of amino groups with phenol, imidazole, or indole groups. 
J. Biol. Chem., 174, 827-843.
228
Garcia-Sainz, J.A., Romero-Avila, M.T., Ruiz-Arriaga, A,, Ruiz-Puente, J., Agundis, 
C., Ortiz, V. and Isibasi, A. (1992). Characterization and detoxification of an easily 
prepared acellular pertussis vaccine. Antigenic role of the A protom er of pertussis 
toxin. Vaccine , 10, 341-344.
Garcia-Sainz, J.A., Ruiz-Puente, J., Jimenez-Paredes, J., Gonzalez-Pacheco, M, and 
Villalva-Posada, H. (1985). Comparitive biological activities of whole-cell pertussis 
vaccine and a new acellular preparation. Vaccine , 3, 23-26.
Glenny, A.T. and Hopkins, B.E. (1923). Diphtheria toxoid as an immunizing agent. 
Br. J. Exp. Path., 4, 283-288.
Goldman, W.E., Klapper, D.G. and Baseman, J.B. (1982). Detection, isolation and 
analysis of a released Bordetella pertussis  product toxic to cultured tracheal cells. 
Infect. Immun., 36, 782-794.
G oodm an, Y .E., W ort, A .J. and Jackson , F.L . (1981). E nzym e-linked  
immunosorbent assay for detection of pertussis immunoglobulin A in nasopharangeal 
secretions as an indicator of recent infection. J, Clin. Microbiol., 13, 286-292.
Gordon, J.E., Hood, R.I. (1951). Whooping cough and its epidemiological anomalies. 
Amer. J. Med. Sci., 222, 333-361.
Gorringe, A.R., Ashworth, L.A.E., Irons, L.I., and Robinson, A. (1985). Effect of 
monoclonal antibodies on the adherence of Bordetella pertussis to Vero cells. FEMS 
Microbiol. Lett., 26, 5-9.
Gran Strom, M., Lindberg,A.A., Askelof, P., and Hederstedt, B. (1982). Detection of 
antibodies in human serum against the fimbrial haemagglutinin of Bordetella pertussis 
by enzyme-linked immunosorbent assay. / .  Med. Microbiol., 15, 85-96.
Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A.E., Anemona, A,, 
Ciofi Degli Atti, M.L., Giammanco, A., Panel, P., Blackwelder, W.C., Klein, D.L., 
Wassilak, S.G.F. and the Progetto Pertosse Working Group (1996). A controlled trial 
of two acellular vaccines and one whole-cell vaccine against pertussis. New. Engl. J. 
M ed. ,3 3 4 , 341-347.
229
Griffiths, E. (1988). Efficacy of whole-cell pertussis vaccine. In; Pathogenesis and 
Immunity in Pertussis, ed. Wardlaw A.C. and Parton R. Chapter 17, 353-374. John 
Wiley and Sons Ltd.
Grist, N.R. (1977). Vaccination against whooping cough. L a n c e t , 1, 358.
Guiso, N., Rocancourt, M., Szatanik, M. and Alonso, J-M. (1989). B o rd e te lla  
adenylate cyclase is a virulence associated factor and im m unoprotective antigen. 
Microbial Pathogen., 7, 373-380.
Gulbenkian, A., Schobert, L., Nixon, C., and Tabachnik, I.I.A. (1968). Metabolic 
effects of pertussis sensitization in mice and rats. Endocrinology, 83, 885-892.
Gupta, R.K., Saxena, S.N., S harm a, S.B. and Ahuja, S. (1988). Studies on the 
optim al conditions for inactivation o f B ordetella  p er tu ss is  organism s with 
glutaraldehyde for preparation of a safe and potent pertussis vaccine. Vaccine , 6 ,491- 
496.
Gupta, R.K., Saxena, S.N., Sharma, S.B., and Ahuja, S. (1990). Protection of mice 
inoculated with purified pertussis toxin and filamentous haemagglutinin against imtra- 
cerebral challenge with Wvt Bordetella pertussis . Vaccine,S, 289-291.
Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. (1987a). The effects of 
different inactivating agents on the potency, toxicity and stability of pertussis vaccine. 
J. Biol. Stand., 15, 87-98.
Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N, (1987b). G lutaraldehyde 
inactivated pertussis vaccine: a less histamine sensitizing vaccine. J. Biol. Stand., 15, 
159-164.
Gustafsson, L., Hallander, H.O., Clin, P., Reizenstein, E. and Storsaeter, J. (1996). 
A controlled trial of a two-component acellular, a five component acellular and a whole­
cell pertussis vaccine. New. Engl. J. M e d ., 334, 349-355.
H abeeb, A .F.S.A. (1969). A study of the antigenicity o f form aldehyde- and 
glutaraldehyde-treated bovine serum albumin and ovalbumin-bovine serum albumin 
conjugate. J. Immunol ; 102; 457-465.
230
Habeeb, A.F.S.A. and Hiramoto, R. (1968). Reaction of proteins with glutaraldehyde. 
Arch. Biochem Biophys , 126, 16-26.
Harding, C.V., Leyva-Cobian, F. and Unanue, E.R. (1988). Mechanisms of antigen 
processing. Immunological Reviews , 106, 77-91.
Hardy, P.M., Hughes, G.J.and Rydon, H.N. (1979). The nature o f cross-linking of 
proteins by glutaraldehyde. II. The formation of quaternery pyridinium compounds. J.
Chem. Soc., P erk in  I, 2282-2286.
Harrari, I., Donohue-Rolfe, A., Keusch, G. and Arnon, R. (1988). Synthetic peptides 
of shiga toxin B subunit induce antibodies which neutralize its biological activity.
Infect. Immun. ,5 6 , 1618-1624.
Hattori, Y. (1970). Stabilisation of proteins with a water-soluble carbodiimide reagent.
Chemical Abstracts ,7 3 , 69,850.
Hayashi, K., Kugimaya, M., Shimoda, T., M atsumoto, N. and Funatsu, M. (1972).
The modification of carboxyl group of lysozyme. J. Fac. Agr. Kyushu Univ. , 17, 1 - 
11 .
%
.Hayglass, K.T. and Strejan G.H. (1983). Antigen and IgE class-specific suppression 
m ediated by T supressor cells of mice treated with glutaraldehyde-polym erized 
ovalbumin. Int. Archs. Allerg. Appl. Immun., 71, 23-31
H ewlett, E.L., Manclark, C.R., and W olff, J. (1977). Adenyl cyclase in Bordetella  
pertussis vaccines. J.Inf. Dis, 136, S216-S219.
Hewlett, E.L., Sauer, K.T., Myers, G.A., Cowell, J.L, and Guerrant, R.L. (1983).
Induction of a novel m orphological response in Chinese ham ster ovary cells by 
pertussis toxin. Infect. Immun., 40, 1198-1203.
H oare, D.,G. and Koshland, D., E., Jr. (1966). A procedure for the selective 
modification of carboxyl groups in proteins. J. Am. Chem. Soc., 8 8 , 2057-2058.
,___
231
H oare, D.G. and K oshland, D .E ., Jr (1967). A m ethod for the quantitative 
modification and estimation of carboxylic acid groups in proteins. / .  Biol. Chem., 
242, 2447-2453.
H odder, S.L. and M ortim er, E.A. (Jr.) (1992). Epidem iology o f pertussis and 
reactions to pertussis vaccine. Epidemiologic Reviews , 14, 243-267.
H olm gren, J., A ndersson, A, W allerstrom , G. and O uchterlony, O. (1972). 
Experimental studies on cholera immunization. II. Evidence for protective antitoxic 
immunity mediated by serum antibodies as well as local antibodies. Infect. Immun . , 5, 
662-667.
H op wood, D., Yeaman, G. and M ilne, G. (1988). D ifferentiating the effects o f 
microwave and heat on tissue proteins and their cross-linking by formaldehyde. 
Histochem. A , 20, 341-346.
Huang, L-M., Lee, C-Y., Lin, T-Y., Chen, J-M,, Lee, P-I. and Hsu, C-Y (1996). 
Responses to prim ary and booster dose of acellular, com ponent, and whole-cell 
pertussis vaccines initiated at 2 months of age. Vaccine , 14,916-922.
lida, T. and Horiuchi, Y. (1987). The detoxification o f Bordetella pertussis  with 
glutaraldehyde. J. Biol. Stand. , 15, 17-26.
Imaizumi, A., Suzuki, Y., Ono, S., Sato, H., Sato, Y. (1983). Effect o f heptakis 
(2,6-0-dimethyl)-beta-cyclodextrin on the production of pertussis toxin by Bordetella 
pertussis . Infect. Immun., 41, 1138-1143.
Imoto, T., Johnson, L.N., North, A.C.T., Phillips, D.C. and Rupley, J.A. (1972). 
Enzymes , 3rd Edition, 7, 665-868.
Irons, L.I. and MacLennan, A.P. (1979a). Isolation of LPF-HA of Bordetella pertussis 
by affinity chromatography. Biochim. Biophys. Acta, 580, 175-185.
Irons, L.I. and MacLennan, A.P. (1979b). Substrate specificity and the purification by 
affinity com bination methods of two Bordetella pertussis  haem agglutinins. In 
International Symposium o f  Pertussis, p. 338-349, (Ed.s C.R. M anclark and J.C. 
Hill). USDHEW  Publication no. (NIH), 79-1830, Washington DC.
232
Irons, L.I., Ashworth, L.A.E. and W ilton-Smith, P. (1983). H eterogeneity of the 
filam entous haem agglutinin o f Bordetella pertussis  studied w ith m onoclonal 
antibodies. J. Gen. M icrobiol, 129, 2769-2778.
Iwasi, S., Ishida, S., A sakawa, S. and Akama, K. (1985). A curious histam ine- 
sensitising activity shown by the newly-developed Japanese acellular pertussis vaccine. 
In Proceedings o f  the Fourth International Symposium on Pertussis. Dev. Biol. Stand., 
61, 453-460.
Jacob, C.O., Harari, I, Arnon, R. and Sela, M. (1986). Antibodies to cholera toxin 
synthetic peptides of increasing size and their reactivity with related toxins. Vaccine , 4, 
95-98.
Joo, I. and, Putszai, Z. (1960). Interconnexion between the protective antigen and the 
histamine-sensitizing factor o f Bordetella pertussis . Nature, 188, 331-322.
K atada, T  and Ui, M. (1980). Slow interaction o f islet-activating protein with 
pancreatic islets during primary culture to cause reversal of alpha-adrenergic inhibition 
of insulin secretion. J. Biol. Chem., 255, 9580-9588.
Katada, T. and Ui, M. (1981). In vitro effects of islets-activating protein on cultured 
rat pancreatic islets. Enhancement o f insulin secretion, adenosine 3: 5 '-monophosphate 
accumulation and 45Ca phophate flux. / .  Biochem  ., 89, 979-990.
Katada, T. and Ui, M. (1982a). Direct modification o f the membrane adenylate cyclase 
system by islet-activating protein due to ADP-ribosylation.of a membrane protein. 
Proc. Natl. Acad. Sci., USA., 79, 3129-3133.
Katada, T., and Ui, M. (1982b). ADP-ribosylation of the specific membrane protein of 
C 6  cells by islet-activating protein associated with modification o f adenylate-cyclase 
activity. / .  Biol. Chem., 257, 7210-7216.
Kawai, Y., M oribayashi, A. and Yano I. (1982). O rnithine-containing lipid of 
Bordetella pertussis that carries hemagglutinating activity. J. Bact., 152, 907-910.
233
Kendrick, P.L., and Eldering, G. (1939). A study in active im m unisation against 
pertussis. Amer. J. Hyg., 29, 133-153.
Kendrick, P.L., Eldering, G., Dixon, M.K., and Misner, J. (1947). Mouse protection 
tests in the study of pertussis vacine : a comparative series using the intracerebral route 
o f challenge. Amer. J. Publ. Hlth., 37, 803-810.
Keogh, E.V., North, E.A. and W arburton, M.E. (1947). H aem agglutinins o f the 
Haemophilus group. Nature, 160, 63-64.
Khorana, H.G. (1953). The chemistry of carbodiimides. Chemical Reviews , 53, 145- 
166.
Kimura, A., Mountzouros, K.T., Reiman, D.A., Falkow, S. and Cowell, J.L. (1990). 
Bordetella pertussis filamentous haemagglutinin : Evaluation as a protective antigen 
and colonization factor in a mouse respiratory infection model. Infect. Immun., 58, 7- 
16.
Kim ura, M. and Kunosakai, H. (1988). A cellular pertussis vaccines and fatal 
infections. Lancet, 1, 881-882.
Klipstein, A. (1985). Escherichia coli enterotoxins and cross-linked toxoid vaccines. 
J. Med. M icrob io l, 19, i-ii.
K lipstein, F.A ., Engert, R.F. and Clem ents, J.D. (1982). A rousal of m ucosal 
secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat- 
labile enterotoxin. Infect. Immun., 37, 1086-1092.
Klipstein, F.A., Engert, R.F., Clements, I.D. (1981). Protection in rats immunized 
with Escherichia coli heat-stable enterotoxin. Infect. Im m u n ., 34, 637-639.
Koch, Y., W ilchek, M., Fridkin, M., Chobsieng, P., Zor, U., Lindner, H.R. (1973). 
Production and characterization of an antiserum to synthetic gonadotropin-releasing 
hormone. Biochem. Biophys. Res. Comm., 55, 616-622,
234
Kong, A.S. and Morse, S.I. (1977a). The in vitro effects of Bordetella pertussis  
lymphocytosis-promoting factor on murine lymphocytes. I. Proliferative response. / .
Exp. Med., 145, 151-162.
Kong, A.S. and M orse, S.I. (1977b). The in vitro effects on Bordetella pertussis  i
lymphocytosis-promoting factor on murine lymphocytes. II. Nature of the responding 
cells. J. Exp. Med., 145, 163-174.
Korn, A.H., Feairheller, S.H., F ilachione, E.M. (1972). Glutaraldehyde: nature of the 
reagent. J. Mol. Biol. , 65, 525-529.
Lacey, B.W. (1960). Antigenic modulation of Bordetella pertussis. J. Hyg.Camb., 
58, 57-93.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4. Nature , 227, 680-685.
Lanzavecchia, A. (1985). Antigen specific interaction between T and B cells. Nature , 
314, 537-539.
Lapin, J.H. (1943). In ' W hooping Cough’, C. C. Thomas, Illinois.
Kramer, K.J. and Rupley, J.A. (1973). Sulfanilation o f lysozyme by carbodiimide 
reaction. Reactivities of individual carboxyl groups. Arch. Biochem. Biophys. , 156, 
414-425. ':k:l
K ulenkam pff, M., Schw artzm an, J.B. and W ilson, J. (1974). N eurological 
complications of pertussis inoculation. Arch. Dis. Child., 49, 46-49.
K urzer, F. and D ouraghi-Zadeh, K. (1967). A dvances in the chem istry o f 
carbodiimides. Chemical Reviews , 67, 107-152.
Kwantes, W,, Joynson, D. H. M. and Williams, W. O. (1983). B. pertussis isolation 
in general practice during the 1977-79 whooping cough epidemic in West Glamorgan. 
J. Hyg. Cam^., 90, 149-158.
235
Lan trop, H. (1960). Labora tory diagnosis of w hooping-cough or B o rd e te lla  
infections. Bull, W.H.O., 23, 15-35.
Le ininger, E., K enim er, J.G. and Brennan, M.J. (1990). Surface proteins o f 
B ordetella  pertussis  in adherence. In Proceedings o f  the Sixth  In ternational 
Sym posium  on Pertussis. D HSS, Publication No. (FDA) 90-1164. (Eds C.R. 
Manclark), pp. 100-104.
Leslie, P.H. and Gardner, A.D. (1931). The phases o f H aem ophilus pertussis. J. 
Hyg. Camb., 31, 423-434.
Levine, L. and Pieroni, R.E. (1966). A Unitarian hypothesis o f altered reactivity to 
stress mediated by Bordetella pertussis. Experientia, 22, 797-800.
Levine, S., W enk, E .J., D evlin, H .B ., P ieroni, R.E. and Levine, L. (1966). 
H yperacute allergic encephalom yelitis: adjuvant effect o f pertussis vaccines and 
extracts. / .  Immunol., 97, 363-369.
Lichtinghagen R. and Glaubitz R. (1995). A competitive polym erase chain reaction 
assay for reliable identification of Bordetella pertussis in nasopharyngeal swabs. Eur. 
J. Clin. Biochem., 33, 87-93.
Lin, T-Y. and Koshland, D.E. (1969). Carboxyl group modification and the activity of 
lysozyme. J. Biol. Chem. , 244, 505-508.
Lin, Y-T (1970). Lactose synthetase. M odification of carboxyl groups in alpha- 
lactalbumin. Biochem. , 9, 984-995.
Linggood, F.V., Stevens, M.F., Fulthorpe, A.J., W oiwod, A .J., Pope, C.G. (1963). 
The toxoiding of purified diphtheria toxin. B r i t . J. Exp. Path., 44, 177-188.
Linneman, C.C. (Jr). (1979). Host-parasite interactions in pertussis. In International 
Symposium on Pertussis. (Eds. C.R. M anclark and J.C. Hill), pp. 3-18. DHEW  Publ. 
No. (NIH) 79-1830, Washington, DC.
236
Livey, I. and Wardlaw, A.C. (1984). Production and properties of Bordetella pertussis 
heat-labile toxin. / .  Med. M icro . , 17, 91-103.
Locht, C. and Keith, J. (1986). Pertussis toxin gene : nucleotide sequence and genetic 
organization. Science, 232, 1258-1264.
Lonnroth, I. and Holmgren, J. (1975). Protein reagent modification of cholera toxin: 
characterization of effects on antigenic, receptor-binding and toxic properties. J. Gen. 
M icrobiol , 91, 263-277.
Low ry, O.H., Rosebrough, N.J., Fair, A.L., and Randall, R.J. (1951). Protein 
measurement with the Folin reagent. J. B io l Chem. , 193, 265-275.
MacLennan, A.P. (1960). Specific lipopolysaccharides of Bordetella. Biochem., 74, 
398-409.
M adsen, T. (1933). Vaccination against whooping cough. J. Amer. Med. Assoc., 
101, 187-188.
M aitland, H.B., Kohn, R. and Macdonald, A.D. (1955). The histamine-sensitizing 
property of Haemophilus pertussis. J. Hyg., 53, 196-211.
M akhov, A .M ., Hannah, J.H., Brennan, M.J., Trus, B.L., K ocsis, E., Conway, 
J.F ., W ingfield, P .T ., Sim on, M .N. and Steven, A .C. (1994). F ilam entous 
haem agglutinin of Bordetella pertussis  . A bacterial adhesin formed as a 50-nm 
monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns. 
J. M o l B io l.,2 4 1 , 110-124.
M arsili, I., Pizza, M., G iovannoni, F., Voipini, G., Bartolini, M., O livieri, R., 
Rappuoli, R. and N encioni, L. (1992). Cellular pertussis vaccine containing a 
Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule. Infect. 
Im m un., 66, 1150-1155.
Masry, F.L.G. (1952). Production, extraction and purification of the haemagglutinin of 
Haemophilus pertussis. J.Gen. M icrobiol, 1, 201-210.
237
Matsui, T. and Kuwajima, Y. (1959). Formation of the toxoid of histamine sensitizing 
factor in Bordetella pertussis . Nature, 184, 199-200.
McFarlan, A.M., Topley, E., and Fisher, M. (1945). Trial of whooping cough vaccine 
in city and residential nursing groups. Brit. Med. J., 2, 205-208.
M cReynolds, L., O 'M alley, B.W., N isbet, A.D., Fothergill, J.E., Givol, D., Fields,
S., Robertson, M. and Brownlee, G.G. (1978). Sequence o f chicken ovalbum in 
mRNA. Nature  , 273, 723-728.
Meade, B.D., Kind, P.D., and Manclark, C.R. (1984b). Lymphocytosis- promoting 
factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to 
inflammation. Infect. Immun., 46, 733-739.
Meade, B.D., Kind, P.D., Ewell, J.B., McGrath, P.P., and M anclark, C.R. (1984a). 
In  vitro  inhibition of m urine m acophage migration by B o rd e te lla  p e r tu s s is  
lymphocytosis-promoting factor. Infect. Immun., 45, 718-725.
Miller, D.L., Alderslade, R. and Ross, E.M. (1982). Whooping cough and whooping 
cough vaccine: the risks and benefits debate. Epidemiologic Reviews , 4, 1-24.
M iller, E., Ashw orth, L.A .E., Redhead, K., Thornton, C., W aight, P.A. and 
Coleman, T. (1997). Effect of schedule on reactogenicity and antibody persistence of 
acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of 
clinical performance. Vaccine, 15, 51-60.
M ink, C.A.M., Cherry, J.D., Christenson, P., Lewis, K., Pineda, E., Shlian, D., 
Dawson, J.A. and Blumberg, D.A. (1992). A search for Bordetella pertussis infection 
in university students. Clin. Infect. Dis., 14, 464-471.
M ontecucco, C., Tom asi, M., Schavo, G. and Rappuoli, R. (1986). Hydrophobic 
photolabelling of pertussis toxin subunits interacting with lipids. FEBS Lett., 194, 
301-304.
Moore, G.L. and Day, R.A. (1968). Protein conformation in solution: cross-linking of 
lysozyme. Science, 159, 210-211.
238
Moreno-Lopez, M. (1952). El genero Bordetella . Microbiol. Espanola., 5, 177-181.
Morse, S.I. and Morse, J.H. (1976). Isolation and properties of the leukocytosis and 
lym phocytosis-prom oting factor of Bordetella pertussis. J. Exp. Med., 143, 1483- 
1502.
Morse, S.I. and Riester, S.K. (1967a). Studies on the leukocytosis and lymphocytosis 
induced by Bordetella pertussis. I. Radioautographic analysis of the circulating cells in 
mice undergoing pertussis-induced hyperleukocytosis. J. Exp. Med., 125, 401-408.
Morse, S.I. and Riester, S.K. (1967b). Studies on the leukocytosis and lymphocytosis 
induced by Bordetella pertussis. II. The effect of pertussis vaccine on the thoracic duct 
lymph and lymphocytes of mice. J. Exp. Med., 125, 619-628.
Morse, S.I., and Bray, K.K. (1969). The occurence and properties of luekocytosis- 
stimulating material in the supernatant fluids of Bordetella pertussis cultures. J. Exp. 
M ed., 129, S23-S50.
M orse, S.L, M orse, S.H. (1976). Isolation and properties o f leukocyte and 
lymphocyte promoting factor of Bordetella pertussis . J, Exp. Med., 143, 1483-1502.
Mortimor, E.A. (Jr.) (1988). 'Pertussis vaccine'. In Vaccines (Eds Plotkin, S.A. and 
Mortimor, E.A.), pp.74-97, Saunders Company, Philadelphia, USA.
Mota, I. (1958). Mast cell and histamine in rat anaphylaxis: the effect of Haemophilus 
pertussis. Nature, 182, 1021-1022.
MRC (1956). Vaccination against whooping cough : Relation between protection in 
children and results o f laboratory tests. Brit. Med. J., 11, 454-462.
MRC. (1951). The prevention of whooping cough by vaccination : a Medical Research 
Council investigation. B r i t . Med. J., 1, 1463-1471.
MRC.(1959). Vaccination against whooping cough : The Final Report to the Whooping 
Cough Immunisation Committee of the Medical Research Council and to the Medical 
Officers of Health for Bethesda and Wandsworth, Bradford, Liverpool and Newcastle. 
Brit. Med. 1, 994-1000.
239
M ulholland, E.K., H oesterm ann, A., W ard, J.L, Maine, N., Ethevenaux, C ,  and 
Greenwood, B.M. (1996). The use of Haemophilus influenzae type b-tetanus toxoid 
conjugate vaccine mixed with diphtheria-tetanus pertussis vaccine in Gambian infants. 
Vaccine , 14, 905-909.
M uller, A.S., Leenuwenburg, L, Pratt, D.S., (1986). Pertussis: epidemiology and 
control. Bull World Health Organiz,, 64, 321-331.
M unoz, J. (1963), Imm unological and other biological properties of B ordete lla  
pertussis antigens. BacterioL Rev., 27, 325-340.
Munoz, J. (1964). J. Adv. Immunol ., 4 , 397-400.
Munoz, J. (1988), Action o f pertussigen (pertussis toxin) on the host immune system. 
In Pathogenesis and Immunity in Pertussis . Chp 8, p p .173192 (Eds. A.C. Wardlaw, 
R. Parton.). John W iley and Sons, Chichester.
M unoz, J. and Bergman, R.K. (1966). Some histamine sensitizing properties o f 
soluble preparations o f the histam ine-sensitizing factor (HSF) from B ord e te lla  
pertussis. J. Immunol., 97, 120-125.
Munoz, J. and Bergman, R.K. (1968). Histamine-sensitizing factors from microbial 
agents, with special reference to Bordetella pertussis . Bact. Rev. 32, 103-126.
Munoz, J. and Hestekin, B.M. (1966). Antigens of Bordetella pertussis . IV. Effect of 
heat, m erthiolate and formaldehyde on histamine-sensitizing factor and protective 
activity of soluble extracts from Bordetella pertussis. J. Bact., 91, 2175-2179.
Munoz, J.J. (1971). Protein toxins from Bordetella Pertussis . Vol. IIA -B acterial 
Protein Toxins (Eds. S. Kadis, T.C. Montie, S.J.Ajil) pp 271-300, Academic Press 
Inc. Ltd (London).
Munoz, J.J. and Bergman, R.K. (1977). Bordetella pertussis. Im m unological and 
other biological activities. In Immunology Series ( Ed. N. Rose), 4, p p .l. M arcel 
Dekker, Inc. New York.
240
M unoz, J.J., Arai, H., Bergm an, R.K. and Sadowski, P.L. (1981a), Biological 
activities of crystalline pertussigen from Bordetella pertussis. Infect. Immun., 33, 820- 
826.
Nelson, J.D. (1978). The changing epidemiology of pertussis in young infants: the role 
of adults as resevoirs o f infection. Am. J. Dis. Child., 132, 1-373.
N encioni, L., Pizza, M., Bugnoli, M „ De M agistris, T., Di Tom m aso, A., 
Giovannoni, F., Manetti, R., Marsili, I., Matteucci, G„ Nucci, D., Olivieri, R„ Pileri, 
P., Presentini, R., V illa, L., Kreeftenberg, J.G., Silvestri, S., Tagliabue, A. and 
Rappuoli, R. (1990). Characterization of genetically inactivated pertussis toxin mutants: 
candidates for a new vaccine against whooping cough. Infect. Immun. , 58, 1308- 
1315.
4
M unoz, J.J., Arai, H. and Cole, R.L. (1981b). M ouse-protecting and histam ine 
sensitizing activities of pertussisigen and fimbrial haemagglutinin from Bordetella  
pertussis . Infect. Immun  ., 32, 243-250.
Murphy, S.G. (1967). Tetanus toxin and antigenic derivatives. II. Effect of protein and 
formaldehyde concentration on toxoid formation. J. B a d , 94, 586-589.
M use, K.E., Findley, D., Allen, L. and Collier, A.M. (1978). In vitro  model of 
Bordetella pertussis infection: pathogenic and microbicidal interactions. In Third Int.
Symp on Pertussis. (Eds. C.R. M anclark and J.C. Hill), p41-50, US DHEW  Publ.
No. (NIH) 79-1830, W ashington, DC.
?
1Nagel, J., Degragg, S., and Schiff-Evers, D. (1985). Im proved serodiagnosis o f whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF 
antibody levels. In Proceedings o f  the Fourth International Symposium on Pertussis , 
Develop. Biol. Stand., 61, 325-330.
Nakase, Y. and Endoh, M. (1988). Heat-labile toxin of Bordetella pertussis . In 
Pathogenesis and Immunity in Pertussis. (Eds. A.C. W ardlaw, R. Parton). pp. 211-
229., John Wiley and Sons, New York,
241
Noble, G.R., Bernier, R.H., Es ber, E.C., Hardegree, C ,  H inman, A.R., Klein, D., 
Saab, E J , (1987). Acellular and whole-cell pertussis vaccines in Japan: report of a visit 
by US scientisits. J  A m er .M ed A ssoc, , 257, 1351-1356.
Nogimori, K., Ito, K., Tamura, M., Satoh, S., Ishii, S., Ui, M. (1984b). Chemical 
modification o f islet-activating protein, pertussis toxin. Essential role o f free amino 
groups in its lymphocytosis-promoting activity. Biochim. Biophys. Acta  , 801, 220- 
231.
Nogimori, K., Tam ura, M., Yajima, M., Ito, K., N akam ura, T., Kajikawa, N., 
M aruyama, Y., Ui, M. (1984a). Dual mechanisms involved in the development of 
diverse biological activities of islet-activating protein, pertussis toxin, as revealed by 
chemical modification of lysine residues in the toxin molecule. Biochim . Biophys. 
Acta, 801, 232-243.
Northrup, R.S, and Chisari, F.V. (1972). Response of monkeys to immunization with 
cholera toxoid, toxin and vaccine; reversion of cholera toxoid. J . Inf. Dis., 125, 471- 
479.
Novotny, P., Chubb, A.P., Cownley, K., Montaraz, J.A. and Beesley, J.E. (1985). 
Bordetella adenylate cyclase: a genus specific protective antigen and viielence factor. In 
Proceedings o f  the Fourth International Symposium on Pertussis. Develop. Biol. 
Standard. , 61, 27-41.
O D em psey, T.J.D., McArdle, T., Ceesay, S.J., Banya, W .A.S., Demba, E., Secka, 
O ., Leinonen, M ., K ayhty, FI., Francis, N., and G reenw ood, B.M . (1996). 
Immunization with a Pneumococcal capsular polysaccharide vaccine during pregnancy. 
Vaccine , 14, 963-970.
Nencioni, L., Volpini, G., Peppoloni, S., Bugnoli, M., De M agisitris, T., M arsili, I., 
and Rappuoli, R. (1991) Properties of pertussis toxin m utant PT-9K/129G after 
formaldehyde treatment. Infect. Immun , 59, 625-630.
N icosia, A., Perugini, M., Franzini, C., Casagli, M., B on i, M .G., A ntoni, G., 
Almoni, M., Neri, P., Ratti, G. and Rappuoli, R. (1986). Cloning and sequencing o f 
the pertussis toxin genes: operon structure and gene duplication. Proc, Natl. Acad. ScL 
USA, 83, 4631-4635.
242
Oda. M., Cowell, J.L., Burstyn, D.G. and M anclark, C.R. (1984). Protective 
activities of the filamentous haemagglutinin and the lymphocytosis promoting factor of 
Bordetella pertussis in mice. / .  Infect. Dis., 150, 823-833.
Olander, R-M, M uotiala, A., Karvonen, M., Kuronen, T  and Runeberg-Nyman, K. 
(1990). Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA 
in two different mouse strains and passive protection in the murine intranasal infection 
model. Micro. P a thogen ., 8, 37-45.
Onica, D., Lenkei, R., and Ghetie V. (1978). Im m unogenicity o f glutaraldehyde- 
treated homologous albumin in rabbits. Immunochemistry , 15, 687-693.
Onorato, I.M., Wassilak, S.G. and Meade, B. (1992). Efficacy o f whole cell pertussis 
vaccine in preschool children in the United States. J.Amer.M ed.Assoc., 267 , 2745- 
2749.
Ott, G., Barchfield, G .L., and Nest, G.V. (1995). Enhancem ent of the humoral 
response against human influenza vaccine with the simple submicron oil/w ater 
emulsion adjuvant ME 59. Vaccine , 13, 1557-1562.
Parfentjev, I.A. and Goodline, M.A. (1948). Histamine shock in mice sensitized with 
Haemophilus pertussis vaccine. / .  Pharmacol. Exp. Ther., 92, 411-413.
Parish, H.J. (1958). Antisera, toxoids, vaccines and tuberculins in phrophylaxis and 
treatment. 4th Edition, Wellcome Foundation, E. and S. Livingstone.
Parsonage, D., Wilkemounts, S. and Senior, A.E. (1988). Directed mutagenesis of the 
dicyclohexylcarbodiimide-reactive carboxyl residues in beta-subunit of Fl-ATPa.se of 
Escherichia c o l i . Arch. Biochem. Biophys., 261, 222-225.
Parton, R. (1996). New perspectives on Bordetella pathogenicity. J. Med. M icrobiol, 
44, 233-235.
Pass, F.and Marcus, D M. (1970). Specificity of rabbit antibody to formaldehyde- 
treated rabbit serum albumin. J. Invest. Dermat., 54, 32-36.
243
Pavlovskis., O.R., Edman, D.C., Leppla, S.H., W retlind, B., Lew is, L.R., M artin, 
K.E. (1981). Protection against experimental Pseudomonas aeruginosa  infection in 
mice by active immunisation with exotoxin A toxoids. Infect. Im m u n ., 32, 681-689.
Pedemonte, C.H. and Kaplan, I.H. (1985). Carbodiimides inhibit Na, K-ATPase by 
form ing intramolecular cross-links. Biophysic. J . , 47, 342a.
Perkins, F.T. (1969). Vaccination against whooping cough. Brit. Med. J., 2, 429- 
430.
Phillips, D.C. (1966). The three dimensional structure of an enzym e molecule, Sci. 
Am er. ,2 1 5 , 78-90.
Phillips, D.C. (1967). The hen-egg white lysozyme molecule. Proc. Natl. Acad. Sci. , 
USA, 57, 484-495.
PHLS. (1973). Public Health Laboratory Service W hooping Cough Committee and 
W orking Party. Efficacy of whooping cough vaccines used in the U.K. before 1968. 
Brit. Med. J., 1, 259-262.
P illemer, L., Blum, L., and Lepow, I.H. (1954). Protective antigens of Bordetella  
Pertussis Haemophilus pertussis , Lancet, 1, 1257 -1260.
P ittman, M. (1952). Influence of preseiwatives, of heat, and o f irradiation on mouse 
protective activity and detoxification of pertussis vaccine. J. Im m uno l, 69, 201-216.
P ittm an, M. (1979). Pertussis toxin : the cause of harm ful effects and prolonged 
immunity o f whooping cough. Rev. Inf. Dis., 1, 401-412.
Pittman, M. (1984). The concept o f pertusiss as a toxin-mediated disease. Pediatric  
Infect. Dis., 3, 467-486.
Pizza, M., Bartoloni, A., Prugnola, A., Silvestri, S., Rappuoli, R. (1988). Subunit SI 
of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. 
Proc. Natl. Acad. Sci. USA, 85, 7521-7525.
244
P izza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De M agistris, 
M.T., V illa, L., Nucci, D., M anetti, R., Bugnoli, M., G iovannoni, F., Olivieri, R., 
Barbieri, J.T., Sato, H. and Rappuoli, R. (1989). Mutants o f pertussis toxin suitable 
for vaccine development. Science , 497-500.
Podda, A., Nencioni, L., De Magistris, M.T., Di Tommaso, A., Bossu, P., Nuti, S., 
Pileri, P., Peppoloni, S., Bugnoli, M., Ruggiero, P., M arsili, L., D 'Errico, A., 
Tagliabue, A. and Rappuoli, R. (1990). Metabolic, humoral and cellular responses in 
adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT- 
9K/129G. / .  Exp. Med., 172, 861-868.
Podda, A,, Nencioni, L., M arsili, I., Peppoloni, S., Volpini, G., Donati, D., Di 
Tommaso, A., De Magistris, M.T. and Rappuoli, R. (1991). Phase 1 clinical trial of an 
acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined 
with FFIA and 69 kDA. Vaccine, 9, 741-745,
Pollack, M.and Prescott, R.K. (1982). Toxoid from exotoxin A o f P seudom onas  
aeruginosa: Preparation and characterization. J. Inf. Dis., 145, 688-697.
Pollard, R. (1980). Relation between vaccination and notification rates for whooping 
cough in England and Wales. L a n ce t, 2, 1180-1182.
Pon'o, M., Saletti, M., N encioni, L., Tagliaferri, L. and M arsili, I. (1980). 
Immunogenic correlation between cross-reacting material (CRM 197) produced by a 
mutant of Corynebacterium diphtheriae and diphtheria toxoid. J. Inf. Dis., 142, 716- 
724.
Preston, N.W. and Stanbridge, T.N. (1976). Mouse or man? W hich are pertussis 
vaccines to protect? J. Hyg. Camb., 76, 249-256.
Q uentin-M illet, M .J., Arminjon, F., Danve, B., Cadoz, M., Armand, J. (1988). 
Acellular pertussis vaccines: Evaluation o f reversion in a nude mouse model. / .  Biol. 
Stand,, 16, 99-108.
Ramon, G, (1923). Sur le pouvoir flocculant et sur les propriétés immunisantes d'une 
toxin diphtherique rendue anatoxique (anatoxine), Compt. Rend. Acad. Sci. , 177, 
1338-1340.
245
R appaport, R,S., Bonde, G., M cCann, T., Rubin, B.A. and Tint, H. (1974). 
Development o f a purified cholera toxoid. II. Preparation of a stable antigenic toxoid by 
reaction of purified toxin with gluteraldehyde. Infect. Immun., 9, 304-317.
Rappuoli, R. (1994). Toxin inactivation and antigen stabilization: two different uses of 
formaldehyde. Vaccine , 12, 579-581.
Rappuoli, R. and Silvestri, S. (1987). Pertussis toxin. Estratto da Chim icaoggi- 
maggio, 46-48.
Rappuoli, R., Douce, G., Doug an, G. and Pizza, M, (1995). Genetic detoxification o f 
bacterial toxins: a new approach to vaccine development. Int. Arch. Allergy Im m unol,, 
108, 327-333.
Rappuoli, R., Pizza, M., Podda, A., De Magistris, M.T. and Nencioni, L. (1991). 
Towards third-generation whooping cough vaccines. Tibtech ., 9, 232-238.
Redhead, K. (1985). An assay of Bordetella pertussis adhesion to tissue culture cells, 
J. Med. Microbiol., 19, 99-108.
Redhead, K., Hill, T., and Clark, H. (1987). Interaction of lactoferrin and transferrin 
with the outer membrane of Bordetella pertussis. J. Gen. Microbiol, 133, 891-
Redhead, K., W atkins, J., Barnard, A. and M ills, K .H .G . (1993). E ffective 
immunization against Bordetella pertussis respiratory infection in mice is dependent on 
induction of cell-mediated immunity. Infect. Immun . , 61, 3190-3198.
Regan, J.C. and Tolstoouhov, A. (1936). Relations of acid base equilibrium to the 
pathogenesis and treatment of whooping cough. N Y State J. Med., 36, 1075-1087.
Reid, D.B.W. (1968). 'Statistical methods in virology', pp. 104-124 in Textbook o f 
Virology (Eds. A.J. Rhodes and C.E. van Rooyen), 5th edn., W illiams and W ilkins, 
Baltimore.
Reiman, D.A., Dom enighini, A.M ., Tuomanen, E., Rappuoli, R. and Falkow, S.
(1989). Filamentous haemagglutinin of Bordetella pertussis : nucleotide sequence and 
crucial adherence. Proc. Natl. Acad. Sci., USA, 8 6 , 2637-2641.
246
Relyveld, E.H. (1973). Preparation des vaccins antitoxiques et antimicrobiens a L’aide 
du glutaraldehyde. CR Acad. Sci. Paris , Ser D, 277, 613-616.
Relyveld, E.H. (1978). Detoxification of microbial toxins with glutaraldehyde and their 
use in the preparation of vaccines. In Toxins: Animal, Plant and M icrobial (Ed. 
Rosenberg, P.), Pergamon Press, Oxford, pp. 1049-1065.
Relyveld, E.H. and Ben-Efraim, S. (1983). Preparation o f vaccines by the action of 
glutaraldehyde on toxins, bacteria, viruses, allergens and cells. M ethods Enzymol. , 
93, 24-60.
R ich, D.H. and Singh, J. (1979). The carbodiimide method. In The Peptides , I, 241- 
261, Academic Press Inc.Ltd., London.
Richards, P.M. and K now les,, J.R. (1968). Glutaraldehyde as a protein cross-linking 
agent. J. Mol. Biol. , 37, 231-233.
Riehm, J.P. and Scheraga, H.A. (1966). Structural studies of ribonuclease. XXL The 
reaction between ribonuclease and a water soluble carbodiimide. Biochemistry , 5, 99- 
115.
Roberts, J.A., Kaack, M.B., Baskin, G. and Svenson, S.B. (1995). Vaccination with 
formalin-killed P-fimbriated E. coli whole-cell vaccine prevents renal scarring from 
pyelonephritis in the non-human primate. Vaccine , 13, 11-16.
Roberts, M., Cropley, I., Chatfield, S. and Dougan, G. (1993). Protection of mice 
against respiratory Bordetella pertussis infection by intranasal immunization with P.69 
and FHA. Vaccine , 11, 866-872.
Roberts, M., Tite, J.P., Fairweather, N.F., Dougan, G., and Charles, LG. (1992). 
Recombinant P.69/pertactin : immunogenicity and protection of mice against Bordetella 
pertussis infection. Vaccine, 10, 43-48.
Robinson, A. and Funnell, S.G.P. (1992). Potency testing of acellular pertussis 
vaccines. Vaccine , 10, 139-141.
____
247
Robinson, A. and Hawkins, D.C. (1983). Structure and biological properties of 
solubilized envelope proteins o i Bordetella pertussis. Infect. Immun., 39, 590-598,
Robinson, A. and Irons, L.I. (1983). Synergistic effect o f B ordetella  pertussis  
lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens 
in mice. Infect. Immun., 40, 523-528.
Robinson, A., Ashworth, L.A.E., Baskerville, A., and Irons, L.I. (1985). Protection 
against intranasal infection of mice with Bordetella pertussis . In Proceedings o f  the 
Fourth International Symposium on Pertussis. Develop. Biol. Stand., 61, 165-172.
Robinson, A., Irons, L.I., Seabrook, R.W., Pearce, A., M atheson, M. and Funnel,
5.G.P. (1990). S tructure-function studies of B ordetella  pertussis  fimbriae. In 
Proceedings fo  the Sixth International Symposium on pertussis . DHSS, Publication 
No. (FDA) 90-1164. (Eds C.R. Manclark), pp 126-134.
Robinson, A.J. (1981), The whooping cough immunization controversy. Arch. Dis. 
Child. , 56, 577-580.
Robinson, A.L., Ashworth, A.E. and Irons, L.I. (1989). Serotyping B ord e te lla  
pertussis strains. Vaccine, 7, 491-491.
Rom anos, M .A., C lare, J.J., Beesley, K .M ., Raym ent, F .B ., B allantine, S.P., 
M akoff, A .J., D ougan, G., Fairw eather, N .F., and C harles, LG. (1991). 
Recombinant Bordetella pertussis pertactin (P69) from the yeast Pichia pastoris : high- 
level production and immunological properties. Vaccine, 9, 901-906.
Rutter, D.A., Ashworth, L.A.E., Day, A., Funnel, S., Lovell, F. and Robinson, A. 
(1987). Trial of a new acellular pertussis vaccine in healthy adult voluntoovs.Vac ci ne,
6 , 29-32.
Ruuskanen, O., Noel, A., Putto-Laurila, A., Petre, J., Capiau, C., Delem, A., 
Vandevoorde, D., Simoen, E., Teuwen, D.E., Bogaerts, H. and Andre, F.E. (1991). 
Development o f an acellular pertussis vaccine and its administration as a booster in 
healthy adults. Vaccine , 9, 117-121.
248
Ruuskanen, O., Viljanen, M.K., Salmi, T.T., Lehtonen, O. P., Kouvaleinen, K., and 
Peltonen, Y.T. (1980). DTP and DTP-inactivated polio vaccines : comparison of 
adverse reactions and IgG, IgM and IgA antibody response to DTP. Acta Paediatr. 
Scand., 69, 177-180.
Saletti, M. and Ricci, A. (1974). Experim ents with cholera toxin detoxified with 
glutaraldehyde. Bull. World Health Organ., 51, 633-638.
Samore, M.H. and Siber, G.R. (1996). Pertussis toxin enhanced IgG l and IgE 
responses to primary tetanus immunization are mediated by interleukin-4 and persist 
during secondary responses to tetanus alone. Vaccine , 14, 290-297.
Sato Y., Sato, H., Izum iya, K., Cowell, J.L., M anclark, C.R. (1982) Role o f 
antibody to filam entous hem agglutinin and to leukocytosis-prom oting factor- 
hemagglutinin in immunity to pertussis. Sem. Infect. D is . , 4, 380-385.
Sato, H. and Sato, Y. (1984). Bordetella pertussis infection o f mice: correlation of 
specific antibodies against two antigens, pertussis toxin and filamentous hemagglutinin 
with mouse protectivity in an intra-cerebral or aerosol challenge system. Infect. 
Im m un., 46, 415-421.
Sato, Y. and Arai, H. (1972). Leukocytosis-promoting factor of Bordetella pertussis.
I. Purification and characterization. Infect.and Immun., 6 , 899-904.
Sato, Y. and Sato, H. (1988). Further characterization of Japanese acellular pertussis 
vaccine prepared in 1988 by 6  Japanese manufacturers. Tokai J. Exp. Clin. M e d ., 13, 
suppl 79-88.
Sato, Y., Arai, H. and Suzuki, K. (1974). Leukocytosis-prom oting factor o f 
Bordetella pertussis , 9, 801-810.
Sato, Y., Arai, H., and Suzuki, K. (1973). Leukocytosis-prom oting factor o f 
Bordetella pertussis. II. Biological properties. Infect. Immun., 7, 992-999.
Sato, Y., Cowell, J.L ., Sato, H., Burstyn, D.G. and M anclark, C.R. (1983). 
Separation and purification of the hemagglutinins from Bordetella pertussis. Infect. 
Im m un., 41, 313-320.
249
Sato, Y., Izumiya, K., Oda, M. and Sato, H. (1979). Biological significance of 
Bordetella pertussis  fim briae or hemagglutinin: a possible role of fim briae or 
hemagglutinin for pathogenesis and antibacterial immunity. In International Symposium  
on Pertussis (Eds. C.R.M anclark and J.C. Hill), pp. 51-57. US DHEW  Pub. No. 
NIH 79-1830, Washington, DC.
Sato, Y., Izumiya, K., Sato, Cowell, J.L. and M anclark, C.R. (1981a). Role of 
antibody to leukocyosis-prom oting  factor, haem agglutin in  and filam entous 
haemagglutinin in immunity to pertussis. Infect. Immun. , 31, 1223-1231.
Sato, Y., Izumiya, K., Sato, H., Cowell, J.L., and M anclark, C.R. (1980). Aerosol 
infection of mice with Bordetella pertussis . Infect. Immun. , 29, 261-266.
Sato, Y., Kimura, M. and Fukumi, H. (1984). Development of a pertussis component 
vaccine in Japan. L a n ce t, i, 122-126.
Sato, Y., Sato, H., Izumiya, K., Cowell, J.L., and Manclark, C.R. (1981b). Role o f 
antibody to filam entous haem agglutinin and to leukocytosis-prom oting factor 
haemagglutinin in immunity to pertussis. In Seminars in Infectious Diseases, Vol IV. 
Bacterial Vaccines. (Eds. J.B. Robbins and J.C. Hill), pp. 380-385. Thieme-Stratton, 
New York.
Sauer, L.W., (1937). Municipal control of whooping cough. J. Amer. Med. Assoc., 
109, 487-488.
Sekura, R.D., Fish, F., Manclark, C.R., Meade, B., Zhang, Y-L. (1983). Pertussis 
toxin: affinity purification of a new ADP-ribosyltransferase. J. Biol. Chem., 258, 647- 
651.
Sekura, R.D., Schneerson, R. and Robbins, J.B. (1986). Safety and antigenicity o f a 
pertussis toxoid vaccine evaluated in adult volunteers. In W orkshop on Acellular 
Pertussis Vaccines ; US Department of Health and Human Services and US Public 
Health Service, Bethesda, Sept. 1986, pp. 135-138.
Sekura, R.R.D. (1988). C linical, m etabolic, and antibody responses o f adult 
volunteers to an investigational vaccine composed of pertussis toxin inactivated by 
hydrogen peroxide. J. Pedriatr., 113, 806-813.
250
Shahin, R.D., Amsbaugh, D.F. and Leef, M.F. (1992). Mucosal immunisation with 
filamentous haemagglutinin protects against Bordetella pertussis respiratory infection. 
Infect. Immun., 60, 1482-1488.
Shahin, R.D., Brennan, M.J., Li, Z.M., Meade, B.D., and M anclark, C.R. (1990). 
Characterization of the protective capacity and immunogenicity of the 69kD outer 
membrane of Bordetella pertussis . J.Exp.M ed., 171, 63-73.
Sheehan, J.C. and Hess, G.P. (1955). A new method of forming peptide bonds. J . 
Am. Chem. Soc. , 77, 1067-1068.
Shim onkevitz, R., K appler, J.W ., M arrack, P. and Grey, H.M. (1983). Antigen 
recognition by H-2 restricted T cells. I. Cell-free antigen processing. J. Exp. Med., 
158, 303-316.
Sm ith, P .K ., K rohn, R.L, H erm anson, G .T., M allia, A .K ., G artner, F .H ., 
Provenzano, M.D., Fujim oto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C. 
(1985). Measurement of protein using bicinchoninic acid. Analytical Biochem. , 150, 
76-85.
Stainer, D.W. (1988). Growth of B.pertussis . In Pathogenesis and Immunity in 
Pertussis. Chp 2, 19-37. Eds. A.C. W ardlaw, and R. Parton. John W iley and Sons, 
Chichester.
Stainer, D.W., and Sholte, M.J. (1970). A simple chemically defined medium for the 
production of phase 1 Bordetella pertussis . J. Gen. Microbiol., 63, 211-220.
Stearne, L.E.T. and B irkbeck, T.H. (1980). The action o f  form aldehyde on 
staphylococcal 3-haemolysin. J. Med. Microbiol., 13, 223-230.
Stewart, G.T. (1977). Vaccination against whooping cough: efficacy versus risk. 
L a n c e t, 1, 234-237.
Stocks S.P. (1933). Some epidemiological features of whooping cough. A statistical 
investigation. Part 1. Lancet , 1, 213-216.
251
Storsaeter, J, and Olin, P. (1992). Relative efficacy of two acellular pertussis vaccines 
during three years of passive surveillance. Vaccine, 10, 142-144.
Storsaeter, J., Hallander, H., Farrington, C.P., Olin, P., Molby, R. and M iller, E.
(1990). Secondary analyses of the efficacy of two acellular pertussis vaccines in a 
Swedish phase III trial. Vaccine , 8 , 457-461.
Storsaeter, J., Olin, P., Renemar, B., Lagergard, T., Norberg, R., Romanus, V. and 
Tiru, T. (1988). M ortality and morbidity from invasive bacterial infections during a 
clinical trial of acellular pertussis vaccines in Sweden. Pedriatr. Infect, Dis. J., 7, 637- 
645.
Strom, J. (1960). Is universal vaccination against pertussis always justified?. Br. Med. 
J . , 2 ,  1184-1186.
Tamura, M., Nogimori, K„ Mural, S., Yajima, M., Ito, K., Katada, T., Ui, M. and 
Ishii, S. (1982). Subunit structure of the islet-activating protein, pertussis toxin, in 
conformity with the A-B model. Biochemistry, 21, 5516-5522.
Tamura, M., Nogimori, Yajima, M., Ase, K., and Ui, M. (1983). The role of the B- 
oligom er moiety of islet-activating protein, pertussis toxin in the development of 
biological effects on intact cells. J. Biol. Chem., 258, 6756-6761.
Tan, L.U., Fahim, R.E.F., Jackson, G., Phillips, P., Wah, P., Alkema, D., Zobrist, 
G., Herbert, A., Boux, L., Chong, P., Harjee, N., Klein, M. and Vose, J. (1991). A 
novel process for preparing an acellular pertussis vaccine composed o f non-pyrogenic 
toxoids of pertussis toxin and filamentous hemagglutinin. Molec. Immunol., 28, 251- 
255.
Thomas, M.G. (1989). Epidemiology of pertussis. Rev. Inf. Dis., 2, 255-262.
Thomas, M.G., Ashworth, L.A., Miller, E., and Lambert, H.P. (1989). Serum IgG, 
IgA and IgM responses to pertussis toxin, filam entous haem agglutinin, and 
agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with 
whole-cell pertussis vaccine. J. Inf. Dis., 160, 838-845.
252
Timkovich, R. (1977). Polymerization side reactions during protein modifications with 
carbodiimide. Biochem. Biophys. Res. Comm., 74, 1463-1468.
Tonerwebb, J. and Taylor, S.S. (1987). Inhibition of the catalytic subunit of cAMP- 
dependent protein kinase by dicyclohexylcarbodiimide. Biochemistry , 26, 7371-7378.
Trollfors, B., Taranger, J., Lagergard, T., Lind, L., Sundh, V., Zackrisson, G., 
Lowe, C.U., Blackwelder, W., Robbins, J.B. (1995). A placebo-controlled trial of a 
pertussis-toxoid vaccine. New Engl. J. Med,, 333, 1045-1050.
Tuomanen, E. and W eiss, A. (1985). Characterization of two adhesins of Bordetella  
pertussis for human respiratory ciliated epithelial cells. J. Inf. Dis., 152, 118-125.
Tuom anen, E., W eiss, A., Rich, R., Zak, F. and Zak, O. (1985). Filam entous 
haemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. 
In Proceedings o f the Fourth International Symposium on Pertussis. Develop. Biol. 
Stand., 61, 197-204.
Unanue, E.R. (1984). Antigen presenting function of the macrophage. Ann. Rev. 
Im m u n o l , 2, 395-428.
Urisu, A., Cowell, J.L. and Manclark. C.R. (1985). Filamentous haemagglutinin has a 
major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect. 
Im m un., S I ,  695-701.
Urisu, A., Cowell, J.L., and Manclark, C.R. (1986). Involvement of haemagglutinin 
in the adherence of Bordetella pertussis to human WiDr cultures. In Proceedings o f  
the Fourth International Symposium on Pertussis. Develop. Biol. Stand., 61, 205- 
214.
Vandamme, P., Hommez, J., Vancanneyt, M., Monsieurs, M., Hoste, B., Cookson, 
B., Vonkonig, C.H.W ., Kersters, K., Blackall, P.J. (1995). Bordetella hinzii sp.- 
nov, isolated from poultry and humans. Int. J. System. Bacterial., 45, 37-45.
Vidard, L., Rock, K.L. and Benacerraf, B. (1992). D iversity in MHC class II 
ovalbumin T cell epitopes generated by distinct proteases. J. Immunol., 149, 498-504.
253
Viljanen, M.K., Mertsola, J., Kuronen, T., and Ruuskanen, O. (1985). Class-specific 
antibody response to lymphocytosis promoting factor (LPF) and fim briae (F) in 
pertussis. In Proceedings o f  the Fourth International Sym posium  on Pertussis, 
Develop. Biol. Stand., 61 (Eds. C.R. Manclark and W. Hennessen), pp. 337-340.. S. 
Karger, Basel.
Viljanen, M.K., Ruuskanen, O., Granberg, C,, and Salmi, T.T. (1982). Serological 
diagnosis of pertussis : IgM, IgA and IgG antibodies against Bordetella pertussis  
measured by enzyme-linked immunosorbent assay (ELISA). Scand. J. Inf. Dis., 14, 
117-122.
W adsworth, A., Quigley, J.J., and Sickles, G. (1938). Preparation o f diphtheria 
toxoid, the action of formaldehyde: precipitation by calcium. J. Inf. Dis., 61, 237-250.
W ardlaw, A.C. (1985). "Practical Statistics fo r  Experimental Biologists". John Wiley 
and Sons, Chichester.
W ardlaw, A.C. (1988). Virulence factors and species specificity in Bordetella . Soc. 
Gen. Micro., 24, 41-56. Ed. Donachie, Griffiths and Stephen.
W ardlaw , A.C. (1992). M ultiple discontinuity as a rem arkable feature o f the 
development of acellular pertussis vaccines. Vaccine , 10, 643-651.
W ardlaw, A.C. and Parton, R. (1983). Bordetella pertussis toxins. Pharmac. Ther., 
19, 1-53.
W ardlaw, A.C. and Parton, R. (1983). Pertussis vaccine. 'Im m unization against 
Bacterial Disease'. In Medical Microbiology, 2, 207-253.(Ed. C.S.F. Easmon and J. 
Jeljaszewicz), Academic Press, London and New York.
Wardlaw, A.C. and Parton, R. (1988). Pathogenesis and Immunity in Pertussis. John 
Wiley and Sons Ltd, Chichester,
W arren, J.R., Spero, L., and Metzger, J.F. (1973). Antigenicity of formaldehyde- 
inactivated staphylococcal enterotoxin B . ./ . Immunol., I l l ,  885-892.
254
W arren, J.R., Spero, L., Metzger, J.F. and McGann, V.G. (1975). Immunogenicity 
of formaldehyde-inactivated enterotoxins A and Ci of Staphylococcus aureus. J. Inf. 
D is., 131, 535-542.
W atanabe, M., Izumiya, K,, Sato, T., Yoshino, K., Nakagawa, N., Ohoishi, M. and 
Hoshina, M. (1991). Comparative biological activities of acellular pertussis vaccines 
produced by Kitasato. Kitasato Arch. Exp. Med. , 64, 31-42.
W eihl, C., Riley, H.D. and Lapin, J.H. (1963). Extracted pertussis antigen. Amer. J. 
Dis. Child. , 106, 210-215.
Weir, D.M. (1967). 'Handbook o f  Experimental Immunology'. Blackwell Scientific 
Publications, pp. 1174-1176.
W eiss, A. A., Falkow, S. (1984). Genetic analysis of phase change in B ordetella  
pertussis Infect. Immun., 43, 263-269.
W eiss, A.A. and Hewlett, E.L. (1986). Virulence factors of B. pertussis. Ann. Rev. 
M icrobiol., 40, 661-686.
W eiss, A.A., Hewlett, E.L., Myers, G.A. and Falkow, S. (1985). Genetic studies of 
the molecular basis of whooping cough. Develop. Biol. Stand. , 61, 11-19.
W eiss, A.A., M yers, G .A., Crane, J.K. and Hew lett, E.L. (1986). B o rd e te lla  
pertussis adenylate cyclase toxin: structure and possible function in whooping cough 
and the pertussis vaccine. In Microbioology 1986 (Ed. L. Leive), pp. 70-74. American 
Society for Microbiology, Washington DC.
W entz, K.R. and Marcuse, E.K. (1991). D iphtheria-tetanus-pertussis vaccine and 
serious neurological illness: an updated review of the epidem iologic evidence. 
Paediatircs , 87, 287-400.
W eyant, R.S., H ollis, D .G ., W eaver, R.E., Amin, M .F.M ., Steigerw alt, A .G., 
O 'Conner, S.P., W hitney, A.M ., Daneshvar, M.I., Moss, C.W., and Brenner, D.J. 
(1995). Bordetella holmesii sp.-nov, a new Gram-negative species associated with 
septicemia. J. Clin. Micro., 33, 1-7.
255
WHO. (1979). Report o f Expert Committee on Biological S tanda rdization .W //0  
Technical Report Series , 638, 60-80.
W illiam s, A. and Ibrahim, I.T. (1981). Carbodiimide chem istry: recent advances. 
Chemical Reviews , 81, 589-636.
W inberry, L., W alker, R., Cohen, N., Todd, C., Sentissi, A., Siber, G. (1988). 
Evaluation of a new method for inactivating pertussis toxin with tetranitromethane. In 
Abstr International Workshop on Bordetella. pertussis. Rocky M ountains Laboratory, 
Ham ilton, Montana.
W insnes, R., Lonnes, T., Mogster, B. and Berdal, B.P. (1985). Antibody responses 
after vaccination and disease against leukocytosis-prom oting factor, filam entous 
haem agglutinin, lipopolysaccharide and a protein binding to com plem ent-fixing 
antibodies.In Proceedings o f the Fourth International Sym posium  on Pertussis, 
Develop. Biol. Stand., 61 (Eds. C.R. Manclark and W. Hennessen), pp. 353-365.S. 
Karger, Basel.
Wolff, J. and Cook, G.H. (1973). Activation of thyroid membrane adenylate cyclase 
by purine nucleotide. J. Biol. Chem., 248, 350-355.
Yajima, M., Hosoda, K., Kanbayashi, Y., Nakamura, T., Takayashi, I., and Ui, M. 
(1978). Biological properties of islets-activating protien (TAP) purified from the culture 
madium of Bordetella pertussis . J. Biochem., 83, 305-312.
Yamada, H., Kuroki, R., Hirata, M. and Imoto, T. (1983). Intram olecular cross- 
linkage of lysozyme. Imidazole catalysis o f the formation of the cross-link between 
lysine-13 (epsilon-amino) and leucine-129 (alpha-carboxyl) by carbodiimide reaction. 
Biochem istry, 22, 4551-4556.
Y oshida, M., Allison, W.S., Esch, F.S. and Futai, M. (1982). The specificity of 
carboxyl group modification during the inactivation of the Escherichia coli Fl-ATPase 
with dicyclohexyl (C-14) carbodiimide. / .  Biol. Chem. , 257, 33-37.
256
Zhang, J.M., Cowell, J.L., Steven, A.C. and Manclark, C.R. (1985), Purification of 
serotype 2  fimbriae o f Bordetella pertussis  and their identification as a mouse 
protective antigen. In Proceedings o f  the Fourth International Symposium on Pertussis. 
Develop. Biol. Stand., 173-185.
XXI
A P P E N D I C E S
XXll
Appendix 1 
1% (w/v) Casamino acids solution.
Casam ino acids (Difco Technical) 10.0 g
M gCl2 .6 H2 0  0 .1  g
CaCl2  0.015 g
NaCl 5.0 g
The ingredients were dissolved in 980 ml o f DW and the pH adjusted to 7.1 with IN 
NaOH and the volume made up to IL. Aliquots were dispensed and autoclaved at 121 
15 psi for 15 min. For preservation of stock cultures, glycerol (10% v/v) was 
added before autoclaving.
Bordet Gengou agar plates
The BG agar base (9 g) was dissolved in 250 ml DW containing glycerol (4% v/v), 
autoclaved at 121 °C, 15 psi for 15 m in., and cooled to 56 °C. D efribinated horse 
blood (50 ml) was added aseptically to give a final concentration o f 17% (v/v), mixed 
gently with the agar and poured into plastic petri dishes. These were stored at 4 
and used within two weeks.
C y c lo d e x tr in  l iq u id  (C L ) m e d iu m  (Imaizumi etal . ,  1983)
1. L-glutamate (monosodium salt; BDH) 10.72 g
2. L-proline (Sigma) 0 .24  g
3. NaCl 2.5 g
4. KH2 PO4  0.5 g
5. KCl 0.2  g
6.M gCl2.6H 20 0.1 g
7. CaCl2  0.02 g
8 . Tris (hydroxymethyl-methylamine) 1.52 g
9. L-cysteine 0 .04  g
10. FeS04.7H 20 0.01 g
11. Ascorbic acid 0.4  g
12. Nictotinic acid 0 .004  g
13. Glutathione 0 .15  g
14. Casam ino acids 1.0 g
15. Methylbeta cyclodextrin 1.0 g
Ingredients 1-8 , 14 and 15 were dissolved in 800 ml of DW and the pH adjusted to |
7.6  with 2.5 N HCl. The volume was made up to 990 ml and autoclaved at 121 °C, 15
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psi for 15 m in. Ingredients 9-13 were dissolved in DW , filter sterilized and added 
aseptically to the autoclaved medium.
Appendix 2
Buffer recipes used in the extraction of antigens of B, pertussis antigens 
0.05M Tris -HCl buffer, pH 8.0
Tris 6.055 g
The Tris was dissolved in 900ml of DW  and the pH was adjusted to 8.0 with 5N HCl. 
The volume was made up to IL with DW.
0.05M Tris-HCl, pH 8.0 + l.OM NaCl
Tris 6.055 g
NaCl 58.44 g
The Tris was dissolved in 800ml of DW  and the pH was adjusted to 8.0 with 5N HCl.
The NaCl was dissolved and the volume made up to IL.
O.IM Tris-HCL, pH8.0 + 0.5M NaCl + 6M urea
Tris 12.11 g
NaCL 29.22 g
urea 360.36 g
The Tris was dissolved in 200ml of DW  and the pH was adjusted to 8.0 with 5N HCl. 
The NaCl and urea were added and allowed to dissolve over a moderately heated 
magnetic stirrer. The volume was made up to IL  with DW.
O.IM Tris-HCl, pH 8.5 + 0.5M NaCl
Tris 12.11 g
NaCl 29.22 g
The Tris was dissolved in 900ml of DW  and the pH was adjusted to 8.5 with 5N HCl.
The NaCl was dissolved and the buffer volume was made up to IL  with DW.
O.IM sodium acetate, pH 4.5 + 0.5M NaCl
sodium acetate 8.203
NaCl 29.22 g
The sodium acetate was dissolved in 900ml of DW and the pH was adjusted to 8.5. 
The NaCl was dissolved and the volume made up to IL with DW.
XXIV
A ppendix 3
L ayout of a Typical Im m unization E xperim ent
Animal
Identification
Preparation Dose (mg)
Blue head 1 10.0
Blue rump 1 1.0
Blue back 1 0.1
Blue head and rump 2 10.0
Blue head and back 2 1.0
Blue back and rump 2 0.1
Red head 3 10.0
Red rump 3 1.0
Red back 3 0.1
Red head and rump 4 10.0
Red head and back 4 1.0
Red back and rump 4 0.1
A total of 60 mice was divided into groups of 12 per cage and injected with the four 
preparations at the three doses. Each animal was identified as listed in the table.
Appendix 4
Enzym e-linked im m unoso rbent assay : bu ffer recipes 
C oating buffer, pH 9.6
0.05M Carbonate buffer, pH 9.6
N aiCO s
NaHCO]
Dissolved in DW and made up to IL 
W ashing buffer
Phosphate buffered saline, pH 7.4
NaCl
KH2 PO4
Na2HP0 4 .1 2 H 2O
1.59
2.93
8.0 g 
0.2 g 
2.8 g
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KCl 0.2 g
Salts were dissolved in 900 ml DW  and the pH was adjusted to 7.4. Tween 20 and 
thimerosal were added to 0.05% (v/v) and 0.01% (v/v) respectively and the buffer 
volume was made up to 1 L.
Incubation buffer
Prepared as wash buffer except the thimerosal was omitted.
Substrate buffer: O-phenylenediamine in citrate/phosphate buffer, pH 5.0
Sunbstrate solutions were prepared as below
0.1 M citric acid 21.01 g
Dissolved in 1 L of DW
0.2 M phosphate (Na2HPO4.2H20) 35.6 g
49.0 ml citrate buffer + 51.0 ml phosphate buffer were m ixed and the pH checked as 
5,0. O -phene^& diam ine (34 mg) and 20 pi of hydrogen peroxide was added to the 
100 ml of citrate/phosphate buffer and stored in the dark. The solution was prepared 
just before use and used on the day only.
Appendix 5
Buffers used in SDS-PAGE:
-Acrylamide/ bisacrylamide
Acrylam ide 30 g
N,N' methylene bisacrylam ide 0.8 g
dissolved in 100 ml o f DW, filtered and stored at 4 ^C.
Lower gel buffer: 1.5 M Tris-HCl, pH 8.8
Tris/HCl 18.1 g
SDS 0.4 g
Dissolve salts in 80 ml o f DW and adjust pH to 8.8 with 5N HCl. The volume was 
made up to 100 ml with DW and store at 4°C. I
Upper gel buffer: 0.5M Tris-HCl, pH 6.8
Tris/HCl 6.06 g
SDS 0.4 g
A'
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Dissolve salts in 50 ml of DW  and adjust pH to 6.8 with 5N HCL The volume was 
made up to 100 ml with DW and store at 4°C.
Ammonium persulphate; a 10% (w/v) solution was prepared fresh before use in 
DW.
Running buffer: Tris-glycine buffer, pH 8.3
Tris 6.06 g
Glycine 28.8 g
SDS 2.0 g
D issolved in 1.8 L of DW  and pH checked and adjusted to 8.3 with 5N HCL The 
volume was made up to 2 L with DW.
Solubilising buffer:
Upper gel buffer 25 ml
Glycerol 10 ml
B-mercaptoethanol 5 ml
SDS 3 g
DW 60 ml
Bromophenol blue 0.01 g
Separating gel; 12% acrylamide concentration 10% acrylamide
Lower gel buffer 10 ml 10 ml
DW 13.4 ml 16.6 ml
Acrylam ide solution 16,6 ml 13.4 ml
Degas above solution then add
10% ammonium persulphate 200 pi 200 pi
TEMED 20 pi 20 pi
Stacking gel (4.5% acrylamide):
Upper gel buffer 2.5 ml
DW 6.0 ml
Acrylam ide solution 1.5 ml
Degas then add
10% ammonium persulphate 30 p i
TEMED 20 pi
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Fixing/Staining solution:
Coomassie blue R250
Methanol
DW
Glacial acetic acid
1.25 g
227 ml 
227 ml 
46 ml
Destaining solution:
Methanol 
Glacial acetic acid 
DW
50 ml 
75 ml
875 ml
Western blotting:
Transfer buffer
Tris
Glycine
Methanol
pH was adjusted to 8.3 and the volume was made up to 2.5L
7.5 g 
36.0 g
500.0 ml
CHO cell clustering assay: 
Coomassie blue staining solution
Coomassie blue R250
Methanol
DW
Glacial acetic acid
0.5 g
250 ml 
250 ml 
35 ml
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A ppendix^ a: Summary plots of rankit analysis on anti-OA ELISA titres from 
immunization with OA in experiment A and B. The mean vertical deviation from 
the theoretical line, w ith  95% CL, is plotted against serum rank no. fo r each 
preparation.
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Appendix 6fc: Summary plots of rankit analysis on anti LZ ELISA titres from 
immunization with LZ in experiment A and B. The mean vertical deviation from 
the theoretical line, with 95% CL, is plotted against serum rank no, for each 
preparation,
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Appendix 6 c: Summary plots of rankit analysis on anti LZ ELISA titres from 
immunization with LZ in a preliminary experiment. T h e  m ean  ver tica l dev ia tion  
fro m  th e  th eo re tica l lin e , w ith  95 %  C L , is p lo tted  ag a in s t  seru m  ra n k  no. fo r  each  
p repara tion .
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Appendix 6d; Summnry plots of rankit analysis on anti-FHA ELISA titres from
immunization with FHA in experiment A. The mean vertical deviation from the
theoretical Une, with 95% CL, is plotted against serum rank no, for each preparation.
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Appendix 6e: Summary plots of rankit analysis on anti-FHA ELISA titres from
immunization with PT:FHA mixtures. The mean vertical deviation from the
theoretical line, with 95% CL, is plotted against serum rank no. for each preparation.
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Appendix 6f: Summary plots of rankit analysis on anti PT ELISA titres from
immunization with PT:FHA mixtures. The mean vertical deviation from the
theoretical line, with 95% CL, is plotted against serum rank no. for each preparation.
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